var title_f32_38_33376="Large plaque parapsoriasis 1";
var content_f32_38_33376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large plaque parapsoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 498px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHyAW0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6fEm4AYKnNO3hcIRyRxxVFpFDld3OPyqCe9JXETEk+3Ss27I0sXWdiCWIyewqGOVC7ByCFORz3qiLkIp837uBj2qFpoxLuOCcc47fWs+cqxrPeoisGHzZ4Gaihu/MlJO7eOeM4HtWc0nmruYDA9afHNtYx4IAHLfyqea7CxoyXkm6RQwVwMqf4ce9WLeRZ8EsG6d+KxN6q7x4Y5xglasxM0UcfQncMewpxk7g1obrMOVBw30o+6AWbOBzVKKYkkkruz/Ce1PeQAnnj26Vve5nYsllbgHqOKYSqgjPPvWbc3Hyjy2I54xTYZW2tk5zzk98UXKUS/Lgg4B+lVN7x5UDI+nSqzXBXO6UEnpSGeUkDK7T1z1pXAtnDnjAx09qqPpnmSbwwUdee9TrI28dAPSpTdhojgDHTNO4rtFTb5XTkg4NZt5etGT5JC47kf54q3dOCpALEN+dZV1HHE5dyMZ6k0jSC1K8l86lCGGTySp6H1qvJcfPuDMQSN24fyqC5kZGBJBXJ9M9eKpTGaWNwP3efujpmg7IpGhNqLRKbZm/dyqAAqbmz2/+vVSW6ygjVBHKp2srd/5VReB/mEhznqVP9akUSMkjGZXkQbWUuRhRgdemKnU0skTW2ImY4LMwwdpXavsB/Op4ZpXKIsoySQfkwVrPQ75N5IdR1bGVx2UAc54qxuUvmOTjOOBgL+nFMNi/CoVcljIAcltxHP40wz7pCymQY/vfnx2/nVRiQWO7aBwP9rvU9pLEymSa6RFXIAxk9Pr09aZJYiudhKOqK5Hy7c7j9avJenyCSMOPlI3fyFc/NcRpIXXD8clMg4/HpT4b5ZWV9gx0CnOQKVxuN9To1uImHFyyE/KyE/p/KnhxGASXlDAkc/zrnyVaQZAKg/Lzg/ietWbe6gjkk2wO7kjBY5A9j+tO5LRsi4x1KoSM+xzViylZCZN2Mk56Y/CspFR8Evt9c81YE5VQVUOq9RjBIoM2bS3GGJdlAA4XNTicFiGGWHGVNYbToxPyDPVfSnJclEAGQ55+Y0XM2jV8/D5PTpx3+tLBcMBtI+U557isyOZslgc5p/mtn0B75ouI1BcogBBG4HHrTxMW5DLnsB2rJEobjG0n0qVHkDN/cHQ0rkmylw27jOAelWI50ZcF13emeaxEJb92xODnn19Kq3mnyNJHLExVkPJzwR/jRd9Bcie50kz8A96qblZOFzxj0xTEklZV3qRjjOetDSOXBXaqZwR3P41SdxR0GSyiRIxyTuAYr+uakZ0Qbo2BK9MLUc7IFIHBPfHQ1AcJJGu3zHbnOeg9qexdky6tyfK6bXxnGcZqXzscjdg+hrLXb5hWRSjDoT6VaikULgMjY7mpuS0kD4OcZ5OagkA8qTGRk84606RhGxOMoOuKYzggbuQKlkIqxW7Ff3rZwT71I0abJCmWYY4qwGQAlj15NVt0WCV4DfqahpBdjmQPHs+7jHFEcSRkMxB7k1RuGmadSpbYeCc8U5ZWfei7htHJ7GpWnQepMLpVcB4zsPG49SaszSDb8jbj6ZqmSnmxxkgbhwD1NTjCE7SC30q43tqDJhIwUDaAR71DJOSOegOfSmSz/IFxlu+OlVpB5mQGwenPSrEtSaS4xls5A9Oary3DZLKwAxj9aiZdjgljuHYdBSSZ8s8kH0pFD1uMtkk5xyelS/aGAA43f3vSsyOGcucptGMmroJCDkbvU0WAtLdbioZvnHYd6d5uHwO/NVYN2CzHH1Oae2CC2ffNVYl2JWbep+Ynt9Ky9RJLN3GehHSrLsvTBAPUk9az7qRmZgCcAHHPzZoKhuZF6TvJwNh46e3NVoL9IAd8HnEfLszz+farNwdrK20F14ycE/j61QlhjkZwwKsffipa7HbG1tRUu4Zg7CeWKUHbGFQtg453foKrK+87GLLs5+boO3XrUUiyROg8xWAO3ePl4z61Lvgl2hQ6TKCdzc5PpSWu5o9C2YVhaJjLuEhICiQHjvkD/PFT25iD5+0xH0BfkD16cisVY/KdpCP3p5yeQfwqwZJHw8yRo7dSBgfh6etMRrNcRYxIcErnapUkd+cf/WqpdJG5VthY9OTVRnaFMxxxSE4ZuhA/x7VL57u2WcBAvC5Ax7e9O4+W2qLcalVQnbGBx1qyu3ywxXBz9RjiqnnblMjfOVHTBp8s0bR7vMaPgFY8Hk/yH50CsycyREkMpyeSykHFTJJGMYYhlGQo6tWfGrFS7BiQfmbP+TUqgEgMu4n7pHUUyWXfNkLqPOYZByOKtxyMGRjkAZ781Q3qUEYQjBxu96Vm2k8jcD69qRmakUx3E5IJ4A29acJpWJQjAB9eax0uAuSy5PTOOpq3bTh924ng8CkZs14m8r7pJ5/OrKuCu49xnFZAmXJB3DFSpMrvu2Hp37+9Mmxoj5yQrE88e1WN24HaFA7gf4VnJK2d+7b6YqZZnVsYVs9TUk2NKDPy5BYZJ46irch3gDk4OcdDWSsjF0CPjBx+FW2lblmBOeuMc00JllGYDBOSOnPrSyvIqkkEkjoOKrpKjk7cqw7GkldncpkhD3xyaEC3K9xezEYjjXyRkc54P0qOG42qzSRky54GOKc8rK+5V3qOwHP1pJ5w8XyLhzwD/hTNLiK5JEmNij5skfqBU4aLH3iOf4hWO6mI/vcso5GSaIbgx7tqIwJ6SDJA/OgbV1dGujsQxdtyg+lOYq6se49KiRwzMBk460/eMgKMMexqWYCsVdMvwo7U1rfchBY7c5GOppZWyg3Z+brjtSgqYggJI9SancT02ISGL4G7Kegp8KtjJHQd6eCFzk844qETsrtHy3GRxTWgrtjWjVW3nDuBj3odsFTnqecdKRzlstnGMYqsX+cpk7RzzTGmTzsQCVAx9agkmMa7iTimsx4GeMZqBjmReMkd6Y0WPOdhuVRjHIPWkQlypfC+lRNIF+Ug+/vTHYhhwSOffAoA1llVkYYUKcdaZJImOAD6GstbgINqjJx3prznA39BwfSi4NXLjvtOQOvWk3oyjBUEcYqmbhRjcpIP5UjSIzHGN3UdsUXJsTSJukB38jt2zUDjD8nLdwKQM7fLjjp7U4vgYPrg4pjvYzNRYYAUMhzlun51has0scLsn8A4PrXR3zbVDrnHuaw7iMy5wDg8fSkzrozMWwnuJt0lzvAbnOODitBfIdRznByPQelRLa+WxLklT7nNQyAgBR8iDr2yKnY6W+ZlpnKq3Csh9OntmlW4nnKQuIvJiJZR5Oc5PUnqaoJL5MjjAkRuCCCPxFWVukiCsr+aAwOzHFNMLdi23npNGZUjmZiF2spUjuB9famMYzO55iiY7hEG3Bar3TzyOHkm3Z+Y7hypPGB/KkRoVmEKl3ZcBjt289x3/Ogdiy8ojIVF+UjBx0NSeYCRukjO0gBSuCPf3ppwFUKwBPPHUVHLGULcnGODTJbNDYXKDgMegDZbj1AoNyirjLhVPPHOPrWPawSQymR5HbceAR0NWizY3AEf7vf607iaV9C6tyZcrGDg+o6U5pScKEIYZBwODWb5sylPs7GJgfvjirKSsqgHLL785pXE0aEJ3gAKME8fWrSqAAN20Z5Has2CbcWLfLzxirSSp5eCMjrmk2YSWpaLPgjcKsRtwNwOemKppJuOWIZcZJ/u1OjgsQcjb1PXimQ0XAytwSRU8UiAZHRuCaqZEbANs+b3psA8qZjzjnjNJkpGvbsq55znsDVpM5GTnnjmsyFwQdw46gmnJO6NkED+lArXNjzVzt4B75PNQzz5bCsRVQy7uR1zyaRpSy5BUnpSGokk+CwZwCCMUzz4oSUy3PIyuM0123KCxIx0qq0nLtIhJAwCDn9KaY12ZJfvlW8v5h1544rP+1M6jYjEjOccCphLmLGQSenXmsmeJ4ZD5blQ3PFUVBpbnW3E3lQkgFhnGAOtPI43hfnIxz6VEsoQKAeO/tU5Ytg461Bg9BzA7c9/QU2JdoJY9egqNjlzzzmnlwAOQKA1HyvhBlScciot/wB44J9PWmNJmRucDtTWlxwOcUiWMcnHOCvWoWYBi3c9cUkzZ4DVXkKkcg8HPFNDQ/zQGIzx65qJ5vm+TBHfmhjkYAwD3qlPEVA2jLA5Hen0GtS1LMVAP8R4HtUL3GxctJzjn2qrj+J2Ix3qdArDkr78daCmKZijHGMD2pFuxMvLDAxgGopcI44PPaoYzsPzICTnBosFkXXQMSAeOpFQLPsZlkwGHeniQYxu5xn3xSeWZBmQDIHBND8hXfUtQTKynZlscVKWUgbSwPvVEBkQiNF9etToxYqXGDjimvMTQ9yHBJBIx0Hesu9gAIA+UDsvU1qvIpOBlWGM+lQyIsgw4OTnGetA4ScTnMIsm7IPPQkgCq1yN5zgbvzrWurIvIzR/dx0A71Rmi2NiX5AQcAnAoOuE0zLlIVhkFgRSKFIJBwnT0qabAf5uccCkePdC2YyUAwAf8KRsnfQgkgzIQj5C9M/rSKm0lgMtwSwPpSFCr5Jz6gn0NTsqkgNnBPP1oKvYSFpGmDIzs3pnr+P+NWbcBlLHbknO1qbbuISR9kWUf3ZCygj2xVwL5aE7ACxIx2Xv+NCJk9bDH3uvUhBzgHio3kMT5dCMjnA6D2qQSSOriNyrA5IB5P19qheNzFkKDznpxVEoc7IQHT7pGeetClcZ3ZHoT09jUUYLKcqAfYjP5f4URpuOSvTikJlqHeDheQanSRlQK2ck9hVZTjbg8E8Z4qxGjSSb34GOCPTNT1IbLEEhKbSASvUEZzVnzMhfMDDpyvOKhVkaMbZQWHYHJApjXCEqpYBkPO44H4UyLa2NK3cPJ5bOoGQNzck+3vVwjYhBbocf/Xrm1uR5jKM5Ix61pRSPGvmbvc4AHFCFKFjWTAAIY+1S+YeNmM9eRnNUBKlwi+U+Q3PB6ml3iPIfr6Y6UEJFyORsFioGeSAeDQC3mcYGarwXC5IbIPrT90bFTuHXgUnqMsPKpUgnpVaZ8MrsM49OtKwJ+VgRg9xUEpyp5BxzgUiCtPLLCw3DPfb6e9PEgkG9nAB6cVF8xBLMdvQZ5OPSq6yquVbgg+1Umar3kdXFw25hz29qlMvYYxnmqxcBRUck6iNunSkc+5NJMd3ylQMcY60zzOmTk1nNdHdlT3qZZA3Xk+ppDehZ8wM2MnioncJsRCWPXn0qN5CI2Ct83bio1YkFn6ikIlLcg5+Y9aYGbJHWmbkJBJGTyKRpFxuWqRI8M3JYfh61DI5ZvlqQv368dfSmeYrHAxkDvTGiCUEtxwe9IcIoJ49zUzhDhmHI6VA4JIZcEUmihk5GM7m6c0oTcvyZ7ZzSkZPPPtTgFJOCQO9AXIUjUTF8nco5NSyFgg2Zf26VKNvOeQfSmONy7QcHk0ACsEXaSetSfeUKGBYciqrMc7RjipBOFUZzjFUDLKsAoDdfUDpTXl25LAbc8cc1WScMMhSjDpmneZnIIIzzkDigVtdRzSlUYkKxHpWVqNubiMhTjkexrRk2tkAHJ4zUK5LhGyfLTk/3qLlRfK7oxAs+9hMpYg9fWmtJuk2mJywP0rpFVSTlV9s1B5SMx+RQo6n1+lFjZVurRgT2pUglvz7motykDBDEnGMHj0NdE1ukgCvhuew71WNlFgsMgkdu+KLFKvpqZiRFQSWJXptzUM97FbtsZTnoADmtSWPBIA6d6pTW6swL4DdyVoZcJq+ozzFUBgdvvjrSmYqMgLg8ZA5qIoo6ncoppbdKCY1A9qVyyxEXMi84UdfarZmTgAJtDddvH59apJu3HGc+tSrHkbiC2Tj8KZLaJZZGHDAbT8w44I9qYgG0/KqkZOTnmpfJYuNrFRxUotvMHUbf5UrGbmkQ6VbyK7ysMFvyqy0IJZWUBicirsQUAL0xUjoC/I4p2MHVbdygkSLywHHtVwSL9nLbSwxjFNdSMBeAP0p8MiqSuM+uKLA5XKtrKZIWkiDKDwVPGavJMCm5u36UYXPyqAKhlhVxnoKmxSmmWvMSSPn5HxxnvVaSfEilJDHt7hsVneY6gqCeCSPb6e9J5pwC55zggihI1S7Gr9oPkhQ5kPox4/Cn78JkHIzyAeR7VnxMGOBkDOQKBIFLAjOeM+1DRLRZZ9oyM4bsaoyiJArSqp3ZwT3xUsk6Zxk9OM9M1TlPmSMzLjJ6+tC0COh10knbPXiqFzOEXIBPOBxVvdHt5571WmCy8MMijcwizP83NygyecVcjcuWU8AHP4etNWBA4JBPv6VZMIAxjjuab1RcmgUkyEnhe1D55AwF9RUT7i4CtwBxTZ2KoSvzHuKgkAxHXt0pyMduWAz3x0pNxKDPeiY/JtHb0poB6nJ4FMcj5gDj1x61EzeXDtH3v1qMyOVxxnvj1psm1iRGY53Dgd6fGQq4A6CoXLbcDvSo3ykk4AoGP8ANCk5PSq1yXlVtrlBjggVIWyCRjA4pMhU5Gc0NAlYWA/Igcndjr6055iHPftzTFkwfl+771XfMjgdRnOKEVa5aHzHODzUUrYymT049qfGwwQ2eOaik56jnFUiSJJdsgyecfn7VOJiSQSfrVBQTKdwwG6VKjMZBuQgjnrSWhTXUsbjlVUkNt61KrbFAJIxjr3quw5HGf603JRiT1PWmJFwylFIBBxnr3qs1wA4GNrHgCokuCwIwCMAkY596QuJOdoznGRQFi35pVdwO4+g9ai+0B2G7G7GStQBwCFZec9aZKgJG3rmgehO7g5BXtxUE0O+MDJBPrSqcqeoPPamKx/iJJJoKTKv2ZPugg9zTvs5344wOOKmiljldjlSoP61OCu4c8tQinNpldoGVeF3fT0q0sY2AHuOopu9iSMjrTg4YbRyOuaCeZtEqQFVAyM56mnYALEE9McVGGctwPlPGPWh+Wxgj3FBA5WZJBxlPWpEmDjZnB96haXy0IPU1CkpDEBcHPWgLGgJPlO5en8XrSLIgYADOarl8jG7kjjNJjo2OnpQKxdLcYHr3poftVTzBnrz6VIXA60Baw25x5nHHvVacKqnvk9KlmcN0JyKg3FVZnPyrzSuaxZYh/1Q4x6g024jVYy4zwMgCkhl3hXQjy274qXkcAfL70Cbsyg7/u8hueKeuSTuPHbNDxiJ844Jqwihh82OKCpS0NkthCR6YpNxMeOST3FQAEgHOB3oY+uTSMCZpQgHBPtQ85KHJ56f/qqkj7nKjPynrSoWLDPOKQ2WTMwIAwaZnapOePSqlwHyvlnknnNN2kswkc47AGkMuBvm5PIHamFyzZ3Zx0qGP5ThT09aAdhznvkZqhEpO7k/nSoArZHc1E0mw/ORk9BQ0uOuDQBM0mSelRuyhdpP4Ux2AUt2xTGdAFByCTyTQIf0Pqo9aeHVgMnntURIIAXgd6Zk9eQc4FMdiUhfU/nQHRN2eD2z3qMZYH17Y7U3cx25AJAwfakMnDZx8uCaA4Kgk98dOtQSTcgE4FKX3IFx06ZPencCyQMFQAT/AEqCVggwuPTnvR5wJIQ4ZeDVW8geZFwQCGzk0XGPQAyeYWPTAp27I9cc5pMhUyPw+lRbscgMWI6elMRKZMAjAPvj9KYrdx35FMZ8YXljxSM3y46UDsObnvyfT9Kjkzhdp69SKQEISc56HB/pSmZCV9SeBigY9WYrk8GkkIOcH6Ypr8rwQPpTGLKq5OMUDRDb2qxSuyk5bnmre/5eRj0qIvkYXH40g3FcHG0dSTRaw3d6ss7gOAee+aRWO4YxgVASNwLDHFPI6FTjHUUCLIYA9fpzQZ0d2TncByKqqNp+U4zT1T5twP8AjQKxZJL9simv1Bzg+gqPfsOc98Uo5wGOM96YrBIDwVbB65oErZUOcHvSOCvAPB6UOdx5zkfpSAbKcHKnB71Ksg2jPWoMgMFJ5xxTSz/LxwfSgbJ0AD8ED3oMYKlWJPeo8Ybv+FTK+W55oJJIECpt7VNtwuOtV88gdzViE5+Vu3rQJsbJGDywPFRqCMgDIq2TntgVE6hTyT+FOwubQsFzgY700/N9DVTkP1OBUu8hSQDnHT0qRkcg2AqCxJ5pylgvynk96buLH0pTKAcL1FFgHMxxluSPSollGScZHelkkAXnvUIKhc4pWBEyv354FKrBuo/OoWwV549aQuNuAcL7UMB7NGTgkF+vNPzt9MVBEA53DG7GM+1PLbsKR0oBkm/sCOe9JLgsvUt2wKiOQ5YnjHSkZgM4bk+9AExOHIGCKQANzk9+9MAyOuQahLlCMDA9B0ouNItquOM1CWKy4OSDkfjTQ53Dngdac0mct1PanuASfKM4GR0pT85BxwDyahLF+ScE+tDHGAWJpFWHsyMwK8tnt602SVg6AMME8g+lR/xAr94dRUioM/P17UIAWTeQACMHgUyT5JAPmJPGfSnKPm3L+lLtBBCg9KYmRbSXJc/TFMmOAApOc5NSZUKdwOO9NdAeR0PTNAyPqQxPPb604tsQ9PUijeF4wN4ppYBjxweuaBiI43nkjIzSvIT3xULybFLdT7U3cqjOCQaAJNw4HFAYkoR0zyKYo5JA4PQ0rHB7AE9aZRJdOWi+Q89qbBLIygzH5ulHJAweO9KAQSdvB5zQ0K+hPH6HOc8VOBgYUnn1qsoOMkjjmpQwyBnnqKYmOUbh0PJzzUciF0xuYYqXJHJNCkBT3PJGaQrjFTaFBYsB6mnNgJktu7fhTXLZU5AUikd9uBj8aBbiKoZy2ST0p6OO4z2qAkgZHApnnYYZ57UDtctOVLDbUi9Qe5qBFPJx1qRep5oIZYQ9d3XtSxyhhxng1XRirAZBFSqcscDBoJLitleaCVqASHb1waZ5gYnNMQ4NxnvTVdiDnOajeTBODg03cwXrUljRK25hjj1pBKcfIBnjrUTyIgcscAcmo0J3txkEUii3uYjDHp1pjuS3Aye1QBmD4pc9SMk0CsTM+FznJ6YozuXpjFQg46/WkyygDPFFh2LIYxgiPv1p4Py8nkVXDHgDt7U4EgfNQKxKXX7vfrj3pMKeTw1V3YhgVPSpFbH3utILWJzkEDdhe5qMkfmetMZgWwT7imOx2kZ5pgg3KSTzj2qRSCM5wPWoYmB4Pfih8MpUGn0KHu2T2OKVOc+9RouB1PAxTmBBGakLk/YgnpzUJk56kYzSMxAGSKgOCdwJ3E9adgRZMucADt09RSDBY4JGO1QqxUZOSM05ZDkE8fWnYQ7gjGOPQ0mOBk//AFqjYMWJAx64obJXG7J7UDFkcA54GenrUbb2QnHPbNKygAkjLfyqONjnA55wKYyFz5CZPTvn1p6YI3DJ3flVh4EuIXjkypIwCKIoFgiVO+OxoHcgSTYyrg4PQ1IGJPtmmyJg8DnPWn7hgNmkFxBlSQAeTT95yRjNMY4YcEg0u4huMnPf2piHhxkbhzUikKvGTz+VQvyF205dw9KAJ4yrA9vXNIh2k7qYDjvzTlwQdx59aCWODq2Rg46UOgZRhsCo84zk9OtOY9CPTpQIjflgoIxTGxn3FIT82TxUZI654oKJopmxk81OjhjkH2qouB165qRTgHjFBLLQJ3fWrAIAFUVchwMDH1qbdleppkNE0jkOOPlNKCDx6VCOcZ5FP34OBQgfYi8wgj1NITu6Z/Omt056+1Mkb5SBUFoYgDTFtwZehHapiyHIB5qFE/unA60keWyR09e9MZMAc5IOaYeHxSAtwx7013+Q0XEgyWzzUh6DJw3aqcRZAASWB6E1YUnIbrQhssKTtOetIzA4JNRu4wM5561G5JIOaQrEryiPaACxJ6+lJvJJB6etV97PIV7A4ye9TcAr1xQMc5JYMo4FKvOW70wnBBxwaCST060AJkoxyTlucgU4csMd+9NCcDJ681LkAYAwfakgGu4XHJ+WlLZUnoKpTXBWYLkbT941LG5cZycZ7ihSvoNqxOCMHJ596TIKnI49KafnGSvNOKgA9zjmmIPMwuCuR2pmd57lc5poCk7jk+1KCxYAD5fbpQA8soYYbIFM3bZTuOF68USZXBwAP6Uw7WODyM5psELJlwGUbc+v1oXKjPvzTmYLkZ+X2psj7sDj2oHceHOPlyRSMWY/Nk46U1cDJJPtSqQR7frQFxSeTg9qjhV8nz8E5ONtMk+/u7ipA+QcnntmjcdiTGc9hRsGcjrUYYK2Bmn7ieORimApO3B9KdnjOSTTMjbkkY7Uqj160xEgccjnHvT+SOSMVGAQqg/jTgACDmkIeSpU9qiRy+RgjHQ+tOfBHXHpTUIAwRQA0gsD70bBnHG0VIzc4zwaRsbaCb2GnHQCkJ4AHX3prZbFIB3zxTGSjjr25qToMA9aiVvlz3pQS3FIgnQ84pryFWO0VGpKnnrTgwJNABI23nHXio3OV+XHPrTi2Rk8DvTGZSepwPypFIcVI98fypowpJHHrSB8sMUSBW6ZwaVhil9+famMpI+YcGgAKvTntSMxBB6+tMBGHOFwaeCV4700ZznikJ/OkBJjPB6U0NncAOKVmwtJjgmnsMVCcZI5oGQTSr8r+xpSwH3TmpEID83ue1Bfk4A4/lTQQXG7r1FKcA5xyaBjQ3IAbAp64GfmNN2Y4PU0hDLnjvQPcbJCjtlhk0qZT5S3GeKFGPvHmnsoYnH1GKLIVxSMBdppSCcHjjmkIIU7+BjNNwQARk9qBBKNuCBz0p6/InANNfaRhiQDxTdxC8EZ6/hQO2gsh/dkvyB+tR5yPlzwc04ngA8854pjyAA8HFUguKPUduABSsMA5zTQ569Ae9IJQSwx3xmgY/cCMHFNXhj3U80jjPIApiEng8j+lAIVm69sc8U4LuHrnpRjjAwBTWJH3Mbh/Kge5Ljfg5yKcFK5wT+NRRkg+g70/cS3HIPIzTFqOzyOAT709eVAPWmqcE5waRjkHaScfnTETqTx1HtSDk4qJSSSOcUpYAZJ59aAJODjPOPWmufm6YApoYEjPGacSOeaBAQQevPalB65IFIB3NEqlh1xQK4xjgmmMfXNOyCxLcUrY6DpSARWC9cUu444BOfSosbjjuDUq8LzzQJjgeBz260uajBDfQUu7HrTEwZvWjIwRjjFQu/GBTQ3P1qEy7FhTk+1BPp+tQhlA2jinIwPBHGe1A7EmR1IqGSTLgDPPHTvUikt1GBmmkZ47UhDRy2B260pUkYzjuaXIDY9s5pJHIxtGfX6UAOJGce1PG7HPA9TUSL0LDHepicjqNppsGBAC9R+NNBB+lMcgn5T09acq4UE9akB5cZ96QNhfpTQBglqMZVj69KAEVyw3hsjNO3EgZznvQCEHAwKZxyc8HtQMeCSe1SghQeOT6VXV8ggdu1OIyuQcGqAV2Y/KTxTC5yADmgghQM1C3L8NmkBKzZ5x054pgxv3jrjFIWANKDhR+lMNhSTxwRSA5OMcDkUuBjOW55pMc8dMUwuDYwASMD9KUKMDGOBmmOcnHakLcEZ+hoBjnJUjkYHpQTzyefamgAcmlJAOM5xQCYE4Xrx2zTww454NQSMMLuHfpSr82G5Az0p3KJhg5HQGlGBn2qMNz61KMc4+7+tAmOX7o6A+9OHGQfzqLPUZyKco7evrTEObC5xnPXApVXIXk4pjYPvxT1yfWgQoA5zwakPI6c+tRO4HXimSSkAAHg96A3LCEA4pJMbxjIFQLJhcFifepC4ZefxpBYHQN24ozTyOMUwgdCcZpkjMYJPelZsYGCDSj5TjqKTBJ4zigYgwOO9MZufapAuSQetMcY74oJK8Z+8cDdQWOOOD3qKBPmzTboMEJThs1lc3SJAzBsZyPpVhCOuCBiqcLMzA8beh9qtp94A0BNE2eoPpSg7snPGKY21+/SnAYHSmZidSAaABk5zQnB5PJpdwCn8qQCHnjHHenqo6A8elRk/Lk08EZoAULyc9KAOgzxTXXODn6U9Rjp6UAIcHj8qA3tz60YIPHSkwck5464oAC4Iww7UwkAZI4HpSkcEg4pq8gk5xTGAI+9ggU9RlctxTGJH3Wzx0pM8AE0CHF+SMDimcEg9aU47ikxw3JA9qACQZUAD60xM4pWIGfSmqwYDApoBWZjnDYAP6UbgBtBPSkI/QdqahIySuadxjxgr69qYdxYY4FOyxHIAB9KTA44OR/jQAY9TwaNpFKSM4zgikOSOAMdaBEF6xjidhyQM1l6VrHnSGKRcHoCOlbTKrcNzxVNdOt1kDxqFPXAFJp30NoSjytSRfDNuB7VIG4yRxUI4GDmlLA/Xoaoz9CYtlSOR9KRTuwc8UwE8H8KEYMTlTimBI2eNoHWnB8AZHFM3AIMH9KjZietMkWVwBtWoS5PtiiU4x3FQeZ+8I96m5pFD5HZVyDzU8UmcHPWqch3Nj0pIXYNyDz61Nx2ujZjYY5PNO+8TnrVKJ8kZ71ZVuRgA+lUmZNEmO5pMEcg0oPGSOKCR0pkjOTkmo3YA4PWpsZBxULrk0Bcgi7g0pRSw3c9xT4gucd6kCgHNZ2K5rEEUO1mx3OQKnAI57+tP4zk8UjnAyenfNIOa41QBnOAKfk9OoxzTG4AFAPFACnB+v8qaqYHqOtKMgnPSj0HQUACjzCAKV/kxSr8pGPzpx5/CgQgGCO/FKCc4AOe1BPofyppO0gHd6cDpTGtRWJH9aTfkfMPxpSyknJzURbpzz6CgALdk5pU3bD3x604YC5GMUjZxkHn0ppXC5GQwYelKwwAScDoDSOSRwMntipGG6PDYz1phsQyAspG7HoaVVIRQTz6+tOC4HHBoDKTnHNIBknPf86RMk/L0HrROeM4yfamq/QqDg0ASKvPuBSE+2AaYxIHoc04EYz396aEAJ5pu70pM46dOlKxBz6+1MpAVzyDikzjkc0pOfloXCgDHHWgBP4gOnbilzjtn6UE+o60zOM9SOo9qASJTwOnehSFHP4U3OeQelKeQM/lQOw5hkbh2oBz/AEpAAenQ0D5SenXimIduIXg1CzADg1IQcnBPzevaoXUbentQxoick8ZqMghqkVgD2x7018HmoLG7iQM9aVcgg5yDUW/5iMEYqQMMADrSGWFPfNXI2GMVQQbjnpVyJuCAapESLQPGKa3IKnPPpTVJXHNIAdxBPXpVGdib+EYPNRHHc0oPPNRvyaCB6hc5FLnr60DGM4pu4YOB9TUIe4gLDqcmnZ4O454pAcg9hQSOMUihWGRxTdu046mn5OCAKQgB8UADNk4xx2NIAN3OSPWlLYHpgfhQH6D8eKAHAYHp6VGwzjmnDkdf/wBdN4H3sZNADlfZgYqncpJJco2dqp0APFWlBJyccU1wM+pNFilJx2GquWPXHepwoGSBVdVYuW3HA9KkBO4k5xjpTuJsBkc9sUSOFU54464pRlV4Ge9MdN3B+YelMExV5wTjPtTs5OOCBTPuY+Xk8UuRwoGKLgxXXtyccZphXf8AdFTL2yecdKbnA9/agRHIu4AgkVGAFJBzk1O2cDPSohkk5PfpRYYOuSM9O/NNP3xxx0p5yRjGTSgAn696BDFzjqKTHfp3px9qQA569eaYxMHd+tLjPsaVQSckEULgDBxkUIBGOMDGeaCBzzn1zTc8jAxS9eKBoBtAPpSDAGWxjsaPX+tIM45FAx6NgHjHpSnntwfakVevWnEdcUyRucEDBIPf0oYcEYyaAW3Y4xSkAHr0oGRC3UnJGKidQp2noOlXcjHSmSoCOmaVgUjPZdwBHOO9LGvOSKtlBtPAHtR5YxSaK5iJOpxU1pHs3ZY8tuwaVU/u06MMHIJ+WmkJsnPQjjGKbu4zT8D8+tN4HbpxTM7igjqaY7e+KH4BxTG+bFBJLuzjPFNDAucZ2+lRqTnrx3p+F3dTUFkhPGRTOOM01j0AOadgdR1x3pAKHYj05pXyB1pMj8abJ82M8GgAL5PIwPUUrMQRg5z0x2qF5DkLwBjqaf0Ubadhkg+UEc80mckhxk0hyaXaAOaLCFweCCR6j1p23OTxSfw9aeMY68UILjE4UZP4mjC7cYzikIO7PBweKCvGRTEKxGOKbuxgH/69IG+XB5J9KcueM84oHsKDkjK96XjrQecYzS57UCEJydvcCkOOhB+tKMnJ4waahPdulKw0NDbh3980mDyMU/IxwOfQVC0xB60WHa5IMj15oJzgYx3qINheDRG2MZYkkk/hTsKw48k8Glxk89qF6nHenZ4JPTrTC43cFweuf501wOMHv60rckjFG3jvmkFxvIAxzSDqSB19aBk59KUsO/ancY1ScY70oBHOc04DIzj6U3HPrTGKhzkelOIx1pqkg8jFOLYBzQAxm9etQ4lE+8tiPHapwpIBFHUHNMaYqyAuCOlOBJJ5qNAOQDwKcPlY45zQSx3bvSjgcc0mcYpV4FIQ4c9qVh+ApoIGfegv1x+dBLuOBxzkZNN5bqcelMLbTzVWW5+bCnaO9BSi3sXSxAyaiZ8k7elZj3bZJDfSo2vG7E/gKLjdLQ2A3BGBmlyQME85pgbPtQnULyR61Ah7uWzgYPrTkbKju1G0flSqFwe1MBP4s96DyMjr70h6j1oB65FKwCMoOMjmnqp4AOBTQdxHNOb7uOnvQAj9CB2qRSCvHNN3AA4FBODkUCZIMfd60gwe/OOaaCNvTGaYgJP3qYbkpwoHPPtTWbnH8qQYTI5NBI3e1AAmcjsTTwMDHeoZHIwEwD3qTzMjNMLMfyPc0DjryTSFwDmoZ5wg4PQ0khpNk7kBRu6e9QuVzxwR7VVM28HPIpVfceP1pmnITb+vtUEp49QPSiRgOCB6VWlYjBHTpzRuUkK07gkKMAcVJHLkAnqPTpVOVhkgnk9KVZdoGM8ilctx0NNXHJ4qVWBAAPBrKWQrzzircMgPHPNBjKFtSw5II2jOetOLYAoz0PNDf3sZFNkDD3HakxuycdKcw7UZwMnHFIY0YLYH40/buPXFAIHXpShcn+VMY3A4x2pQcDkEGgja3XgUSMOO9MQbs54NJimBxnBoMnHOKB2HnHpSqcHnvUDXMfIU8jrTWuUXnd9KAsy1uBPNGeetRJKGGcj2pc5oJY4/SmucDIPagkc1BNKAuBmgFqQvKdx3cLnOapTPuJyePappiChHOR0qkSc4xz60mbpCM2ThR8vTFMdgvGSKe3B44NV3OGOck0JDk9DqPrTlGOmc+tQZ7kVJGeOMn61JzE5IBoBIx+lRHpnNC5IBpgSMfSl6j+dM4JyeuadnmgBRjoPpTl9DUSt24p2ckc80gY84z9elIrY47+pozx7Ug55oDoPAAGc80H7vUnHTFAIxzUE8vYfrTGlclZsDJqtJL+QODUUkpwCKjDhgwz060GyhYkklZhlR19aVJjt+ZhuFQb8cZBNAIAHPJouVYtG5yuc8DjFQSSZHOfaohz1PU0p578YpodkiVQWUjpSgeWOWzmoyTwRnHSmyOWAA6ilcQ9nzyfxFRO28c4xngUmfn5PBqIZwVYjINFykhlwFDcDJxxUMZIZRknB/KppiRgr16VV3FQRjJzk570maR2NBGyR3q1GDkEnj0rOhkBG1Tlh96rMcuXAJzQYyRqphl69qkHt61Wt24I4xU4BB9MUzme4v3unXtTimQeM9qaBzk/hTixwCP1oAaE45Ge1IAAT6U4sf4vWoppFVST+lMpahIQM88VUnn2EHgDOKbJLvbKHiqkr7CcjI/lRc1jEkMp3Y7/zqOSYgk9cdBURO49P1pvPc81NzTlSHhmZfRj1PrQvBG4k/0qNn4OO3ameYc9OKAsWAWV+HNSR3Eu8tk7R0FU2k5BH0o3k45496YnHuXlun74x3pslyD0zVQPjAHelLZ7UXJskSs+RimkdcdO9Rjgn6UNMAMYpoTYOu1eOcdayru7RJMbgPqaNW1SK1t3d2CIoyT7V4/wCIfEc2o3xeN2jhXIQDjj1rRIylOx9Dhjng8VZRuOKyRcNwFqzFcEjn0rnuDiXwR1JpytxVJZS2fX0qVXPT1p3E4loH1xQcnpzUKtyKk8znFArDhmnY6Uzd83Tj1pJMnHOPpQFtSXjIyaQsAODUYYgjOMChm+XA+tMaiJNL6nj2qqzEk8n60+TAHHaq+WxkjjsKDeKSHFgxz169BTGPy8etITjpwe1RsWUgZoNEh+/ketO5Yk5FRNnjjk4qSIEH5sCgBSAccnNKAR8xz16U4ITnn8aXhV7kjvTSJuMkY5xjjHGKjbk5HUc1I53DrgVBuw27HHpQxoVm4GentTQeuMGkLEnnrSIQpyaRQsi7m7np0qGSHc5IPT1q0sh6kHI9KFQ7+elAudogSPy8N/F04qa3jPm+9SrGCcHr1FTwoAc5H1oJlMtQrjAFTDGMsOaYi4Ix1p5GTjjB4po5W7inJIx07U7GAO1ITxx1xT+MdKYrkbdOSDVebCip5DjI6VTuTlCM++aDSKKsuAGIx9KrFtx74xginMwJOBnBpo5JOMGpOhKwmwnLDgVEzbRzU7D5cZyarsPlwQSBSGncazckjqajLHrT8EDmmdT6GixaBB82Sf8A9dPK5b1FMK5Pb1qSNSW/2aZEgVCevSpHO0HJpWKoPWqs0mTTRk7sSe4ODjgisfUdS+zxyM7YAGc1LeSYBIyK4jxPdtJbvEp4PWmKWiOf1/xBNqTOEYrb9Avr7mucU4JJA59aeh/d47jNRnJrQ5HK59J28isB6mrsW09Dz3rnbO48xVKt2rUglYDP61zHTys1Y0ABweam4JGDzVOKUnGasJk9Tx7UEu5OB6VIq8frUanA606MfNTQh55GKOo9qUDbgD8KeORgkUxoiJOahfKk8d+KtNgVA2ckY4NUaIiLg5z1xmotxJqwFGAMc+tJ5WV/2qRdyrJwoBFMPBq+Ycj5scUgiGeVFOwcxVSNs5PSns3GQBmpnQAHB6Cq5wpIbpTHuOV8rgk0jEcZzikGBkj0pjEfKe560BYa33sjNM57deScUrSqNxTB+lIpOehpNFXG4JLHj1pMZUkdc4HtSs+cgDr09qQKcfNjcfSkAqnOe1SLJ1XnI6GmQjqOxPNWEiDnKGglsdEmeeetWlQk8ihYiFHrUiAjrTRhKRKvA5pQQx61GD8ue3TFPGPeggfk4HFCk5IPTNISQAc0Ak57fSgQpAZePm9Kz7pDuwc7e9aAHFQy4OQRmmXF2MV3AbaBn0+lNAB5JIAq1cwENlQB9KrxjdkMcAevekzpVmroaenA70hUgbm6+lSFlySOoNRuzZ56VLEI6hiGHJPpTRGM5FSKeNo71G+cfMQKYXFCgZDYpzYReOtIwPUkCo2zsJyDTRLI5HOM9+tUJ5gqn1qaZsxjPPes67IGQepoAztSu/lIHWuP1H5w5P610Gocsawr5cKRii5nM4qZds0g6c1GDVrU02XBPrVUDitFsczPZdOlaPAJ4rp7GZXABPNcxYoJIgP4h0rZsY2DD2Ncx2XujpIUQ8VaRRj6VStMgDPNX4xz7UzGTJVHpTlwDSoAeaeFBPHSqFcjHP0oBx2+lWQOOBTCnHSmUmQScA5OCRwKYfmxnvU7jJ5qF4xv6nA9DTsaIeFHUcmpFXHamjAPPXtTi4GR680wAjrkVEzYJ/nSyMMhsn3qrJIeeeOgFFxpD3HJY5zUDcduelKW569aJmDAAEDigojZxGOR0qCRs4Bbr+lK65Gc96jbPJPQ0my7DWyu1Rz61Kh+Qg5pi4xnPWnk5AzSEMlwv3c5HGKEy3AOOKVxkjnmrNtAzHgZIAoQNpIWKM8D8quwRbFPHNSxQhQMjnFPIGcdqqxzyncZketNckqQnXpStGNjKh2+4oRWVQCc4FIzWg5c7Bu6nrTugyPSmg8cU7kCkxgDzg0/HFMxnmnY45poWwo/Sk2jk96ac9qFai4xrRK4P0qtLZrg7B81XcijimNTaMSa3kjXvnvxUMokGOMEnjPWuhKgjBGahktUY7iPmHelY1VXuYcmYyAV/wDrU12zIemOtaFxYEglc7mOeajFnswCeOrEUWNOaL2M9iS2FyKhfPIB6datPtQNnPJ4PtVbbg98EZpjKk/IIBxWdchj+FaMqs6EgdTxUL2rMfm6YqRbGBcQkluPzrE1KIehzXX3UY6KKwNShOGyKaRlLU8+1pMEN74rLzgCug12L5G4PFc9Wkdjmloz2fTTjHeuitQccVzWmyoTgnBzXT2XIAHSuY6GjSgbaARWhC3vk1Vt4xtwBnitCGMdx+VUiGPUnIqZDzz0pUjBHFP27eSapEgvqBxTieOtQPdRhSVxxxVCW6ZnXaw69KZpGDZdmdUQkjPFRHoDnjgionlV25/OmpMo+XPNFzVRsWgwxkYz3qNn+YEfSo92SQB370yVuCKLhYkkcDknGapyMC2SASppXY4PJ/GoRnIw3PrSKSJN+ecZFQ7nVsFc55FP2HkipY43bgfrTsO9iFgxYDA9KFRyCpGT2rRitgX+9jmp47RBMXySenNOxLqJGSsOSB37VLHZu7cIRx3rZFrFvyVBINTqgH3RgUrGbrdjMt7HEm5wCRwKupEFPAA4qc4xwKbjn0qjJzchm0ZyfTpTHAHTNPY+2aZIcZI6UEjAOetIOM45pwI/pS4B6UguNHPtTh70oXIOQOtJ0PFKw7idDxmndBRznHSj270wGHjmg9aeRxyaacEe9IBvI5p24Fee9GMjmkYDApjFDdPSl3ZHtUeODycUAmmMkJyPwqpKMjIOee9XEztx61BKvHA5NA4vUxLhQ0nUg98+lQFAV+U9egrUltmdunFNSyYL846dKRvzqxj+VhwMgKOtF5mSPbb8kdT6Vqz2eVPQZ61DHaLChWkS5JmAbcgENzmsm/t/lbNdQtqYy+9yxYlvp7Vk6knBAz1NNIh7nm+uQfeFcdKuxyvoa9G1uDJbiuF1OArcdKqL1Mpo9KsFcNuPSur0Zy6AuDyeKyLSANEQOuOK2bFWhMKYyDXOdV7o6K16DFX0II61lWTPltw4HSrrsUZR2NWjJwLofC+1VXmB3AsTjHIqORvMYgZxjgU2OM4PGBTLjBIqsSVZc9TxUJLBsnGc8VoPByCO9VmiyG64PQ0jVSIlkYe2e1SK/wA5JBI709EAySOe1PePcM9PpQDYiSOR170SOWx1yKasZ5B6DpS7PmOScimiSOQk45wfpUQcqTn6CpHTv1qB3LMVxx2oGh4lJDA5BpUlKtgHOep9ajwznI5pyIfl7npRcdkWknYyJnjnJrVgkyBj61l2to7S5fhBz9TWxBCFHA6VaMajRMGO3k8mlU5FJjnnn0pMjcPpQc47OBikY5z2ppwcUh5/rQAxyKYzHoelPao2GT160ALnniheOR0xSDgc/jSYJ5FAEmevrQoqNVOcZNSjGDSAXB9c03GCME5p27+6eKFIxnv6UAIQcc80FRwMUE4HBpTnPHX3p2GNYYHXijHOOxoIOT0pW3YJoAaBz1xQBzmk74IoPB5P0oAeCBxQWGRTC2OeTz2pjt6mgdibgccYqInnjBAqFmbNKhpj5Qkzg8VXkUnnHSrTgEe9VpWNA0ULkDDe1YtyuQd3etq4I4XjJrPuIjjnqeKRRx2sQgq2eRXE6jb5n6Zr0jVIsqeK4vUIwJzxQQzu7EfKDW3Z4O1T1PSseyx361s2agsPUd6xRtYvhWQjb0AxUyux2h/vACnREAc8k9qSYcp2DHFWhx1BmCOQOSRmp4jkYwRkdKrRcu+7HIyv1qeMnA2nPANM0a0HyEgdaj3DGOlTb1yQ3OaYVUglec0iCF9pwc9+KAw8zGacFGBuzTsICW7YoGO+UDK8nvTAAF5GR2IoBXPsaQycfN27CmSI6LxjIOaheMA+n+NPcsxXpg9qnjjDqM8UWHexWSByvyAZ7Zq3BZKdhcfMPep40wRjtU6HHQU0jOU2ORFwMcD1qXBHI6VA9xHFw7qpJ6VKkgddyng0zFp9Rx49qbtHX0pdueTxS5OBmgQ0kZNNPtxQSAcng0bs5xg0AR5OeaYxx1p5PJ9ulMbJ6cUCDv1prMQB+VMk3EginLk9uooAlBBH0pfTtTAMHjHWgevIPtSAkY8dKBjOAaj3ZGKASB7UyiUqKDkDPekDDqetGTnrmmA7qMkc01l560m7BIoJJ7HFILB0zmmkjPahs8U0jByKY7C5+cYxSHnjApCvI60nIOKB2Ajn6UmQvXtTJN5yBxQicYbmgqwM4fO01CY2I61OUAxgYpX4GM8UCKEkA3E457GqF1GOnYVsSAcis66GKLBc5/UYxtJIritVi/0jgV3N/wAqRXKaigE9CJZ01ooyCfzrZtBkn1FY9oPlHHFa0HoM5rBG5oQEkZHamXcwAClcncPwpltIRgZwxp8482FinOeKouCsx+V2Yb14NPT5Rno2O9VgrCJS3PIWp2JUHjtxTKY9mbAOMnpSeaQ23GOM0xFJGGGWB5ApdoZyOmKBA04yBupN5wMEAg96ikUK68HH1pwUlfm4+tCG0hsxPlM45K84qWJgUViDluopVjzw3OetJHFsk4BxTQrpln5SwwMj1qaM9qiAUnAXFSRoCcjNMybJtwzgCpEz2zTUUbh15qZRg0zJsrtaRSyiSRMkdM1aUbcAdKQ5FL8o79KRLbe4pOB1yaTO3mlLDIwBim7wc8d+9MLCctzjikVcH2p4yegFIwOeKBEM80cSZOOeKb94ZHA7U9kBHO0jOeaik49PakOwH60LjgAVA7kDjmmpMTx0YUx8pcPTFIT8wHaokkyck0/AakKw8YxwKXHB4zTQpxgdKBkfSgaHAcUvTAPBpF680MM9KBig80m/HUZNIxwNvp0pMEjPOaYx3Y8Gm8AZFIrb2xggVKy8UARKc8UOCCMdalAAyBSYwcjvTC5CS3pT1VuKeCSucjI96VQdpP5UAxrgY5AOKruwDEE/hVhzj61A6DPTmmIikIIqhcnOR3q9IMHpxVKfktkYHagDFvEzuOOlcvqKgT8iuvu1IB+lcrqK/v8AkfrQJm9ajO3itWBPz9qzbY4Ra0bZn3EEDZ2NY2Ni8sKsPc0qQ7ISi8kHNS2zZGD07VYCA9OCaqwlNojaEMqkHGDk1WdXF1sYZB+YGr20496YAxb5gCcdSKLFxmVUDiZnyc5A6dqlWNmk3p07irS46YGPanhB/DimNzM24gdpEdVwAe9TrCd/zdKuBCv0pNoPUHNDQnO5AkY74zUqRjnPSnE5PTjtTiV2kHrRYzbE8oDGO9OCANk8UnUDGcUcnI60ySQAjOOlLvPJH41Hz2zQpIHHegRL1A4oIyc1GckU5cY96BCg9Tk5pcZJJ60hahTkc0ASpj86bkAnPNAIA96QnOaCRHHHFV3Tk+hqfd2zzTXxxQBRnjJUkdaZHGyjc3U81d4I6daQoNvFBrzlQE9ccUGYo6DnBqw8fHNR+V82RnmkK6JFlyRmp1bI4qv5ZOMdadDHIGO4jHtTBpE5AIpGbstLuGcA/jSEDPOcUEgo4yetIWJOOg9qR2znFAG4elBVhc4GMik6jg0gTg8mpI12n5utMAVcYGCKfgD/AOvTh7UckknoKBCKic59OtIwwOOfSnADJJzjqKVm7Y5FAEDdP6VG2PmHY1OwIJqnJJsznkk0x2uJIOMYqnc4PIq0SSuT3qlcZ4AoJMy6IwfT0rmdQQGbkGuouwQrdM1zeog+cOKB9DUtTlRWrbLwPyrBs5M4retHVgo71kjRpo0oUyOvAq0ikGqsRG3rxVlGyAB1qzMnC5AzQVyT6UDJFPA5IJ4osFyJUwcDt1qRQ2CTUgCgKaeMYoDmIUQk89Kdgg5HNSEjHvTC2fy6UAHP8QHtTDywyBn2obkdSKjLBWGDzQMlbgcAU0E45A4phkGPfNIXBPtQFh55ABz1o3KtN3E84GDTH5IxTAeJBkjtSh+aj4HFKOg9aTAcWyKch6UzB7U4ZpCepMCO9AHQjFRryOc9aU8Ypk2FKjOaaTuwKM8c0iqSaB2GkntS8EjFOK4zilEYB49KQCYyfWgindG4peaBCBPXrUZPJGcCpTuLADpQyDGT2plEZXHJprMWPGQBUu3ccj04pnlnPHf1oGhoBIJNPU8U4RkfShUyeRxQME4609lyRinhR09RUZOCAO1MVrjuMZ705CSTntULBlG40IGY55C470DsTM5P3cYpDggYPI6imBvugVICqqRjv1pisRSHPA6VXkjHLY5B4q6VHJxUchAANAim6tu3cbcdKqTZ2kYyfWrx+Zj9KrSockDmgDGvQSWNYdzEC/PWuivIzgetY9zH89IZm2x4GOtbdjkYzjOa5uxnBALdK2bO6UHbnvWSN9bHSWxyuM81ciJBHrWVa3CnHPNacTZANaGMk1uWo8jAPWp1IIJ98VVDg59qlVxTJJWHHHSlXdjaajD8YPU8U4SHkdqBWFckZAqEhmwx7VKSzDr1pMYXjg96CkRHnqe9NIySCM4qZgDjpTeBQUR4PcEZFJjjP4VKihs8mnmPC8mkK5AOD3pcZ+lWFhORnPNKEDE4bigRXCZPHJ704LjH9anIxtAprxnHAzSAjA5AxTiDggVKkZ44qQx9R096BEHl9s0mCMg/e6VZWPLck0OuecUCZBs446elIy4NTgYPXimspxj0oAg+tIcj6fWnMpJoI5ANAxufmyaUuC3HahhuHy00Jjn3pgOUYLMTn0qRcsuT0pAowc1IBgD2oECqCQDSkhSMUEEsBjil2YbJAxQMaQRkmmhjwOnvU4UEkA0jRjHqBTHcjycYPNJ5a9uKXbgZz3pFYsw5GBQMPLYjmlZPmCgcU4MdxHb1pSx4IpiGgKBwOnWkwOuMgU4DknuetKEOT+dAhm4nOenWo2j3MPSrLRkjp9KikOMjFAyBoxg4+9UMq4HvVwJyD3xUMgJY+mKCWY11GT2rIulCvgV0FyC3UYrGu0PmfL0osM4DSpvOhRs8MOa14GwVrlfDMuVeMn7pyBXWW5XADd+lY7HRTldXNCGdkxg8jmugsrtZIuTyKwFhUhcNzirFozeWT0OaaZUkpI6ZGzgg9eoqwuMDcevSsezuDuAI5PWtWJwVxVpmMo2ZOihs+o6VYVAV/Gqyvxx1qSJmyc8560ENFnyhz6U14jnOeCKFdycH7vtT1JJ+btQIrtHnpnNOEORuPNWsryAOtAKjsM0DIBFg8dMVIkfKgVKWXIA9af0Yds9KBELxnZnNLHCuecZxUxP5UmRkdmHagYwxL6UrRgYxUgALHjgVIqbsbhx1oEyuEzTypUYx0q2sAxnHNSCI9x1oJuZ+3j5gfXikCEp0zmtIW4PNN8lVHJ9+KQJmcIjjFBTOR3q4xxxio3QMD+ZosP1Khixz1qGQdMjrV5gAQaikXPI+tFhogVBtJI70qqOh5NWVg4wG2+1OWDB+XnNMGQBQABgc1HsPGBxVp0KvtxT1Q5JK0gK4TCjdxio8Z3e9XJE3HFMaMAZwM9qYyAjdggYAp/fHbpUgTjNNZcZI54pgRlA2QO3NIYsuAvSpVGznuetMaQKpOaBDfLBwBxinBOAM1UN/EW+U59veqsmoP5ke3G1s7qLotQbNcAYPFG9AcA8ispr/AGkr/FUIuGjuvMY5DDBFFxqn3NgTAnb6UnlAksTisgXbeczKeDxirsUzOOTnNFwdOxY4Y8VXuVwy1ZBAXODk1HIBjmmiGZdwAOnbp71lz8v8qg1tTw7xwTWbcRgPgfjVCex4foEuzUtg/iWu6tfm25Fedaa+zWoT2JxXpNioZQe1YPUdKWli7Eu2RO45xVxAuFAxuNFtCGUDHPvWlDaAur5GQKFodKkiKNDv3jgkdKuQTFIfnHzCrHkgDOOakW3RwxYHJHNVcnmT3EWUfLk4zx+NWk3jryKiS2XaBkmrSIV460Eyt0AZyT0p+5vUc8UgHB7dqVYz1BpkWE3HPHWkDNznrTlibJ65p/lMTQFhofABYnNOMoJ4GTml8nI57etPWPC5ximKwu7JBzT1BLZ9O9IigrwPyq1Go2Z4pCFijBxnrVlVUgE0yNQG9j3qYdMDtnBpkMcCBkL1p5OcYNRDKsBinlivODkUWEKR8pHQGoZAuzA6ipUfzjkfLSTBY/mAoEVmjwSSORThEMEZpXkLcAZBp2Npz60h3K7xY69O1IoUA46mpZMnGTTFUbuT1FBSYjKM80rgryvel2BTknIqRlHRjyaaQmQhdx56mno+3PGRUsZjVuRzT3EQBwuTRYGVup5NMdN3I5AqZmUdV4HTFJ5ZbBAwM96Y9is/Cbh0qtPKFI+bH9auzoMHknntWFcRukZfnepOKT0NIRUtyOXUT8y55WqK3ErK+HJBOakYOxZpFG41BGxjwBg57VDkzoUUthi7kOV5oO4sWyQOtWyvAEY6elII85G2kO5XgJLZbPNSyKcZ5OKcBtwCvTvSSEEHBOKBbsW32sxXbtPWtCzhIRWJJycVDp9sWfJB9K24oETr09qpGc5dCNk3IOmKglyF6ZIPNXcED5cmoJU24JPOKtIwKMqkjJbHHSs+ZQG4rTcjJzVGZMtzxVJESZ82zyeTepIONrA/ka9S0k+bHG6kFSAR+NeT3pJmJr0LwBefa9MiGfnjJjI/l+lYpDps7u2jzgDtWnDGQ2Md6rWe0xg+nPFakaYORzzTsaXFRTnleOlTpHycDtSxAFTweTUyxEKCBxnFMaZHHE3GOmM5NSqj5AYc1OkYPO7FTLE46EUD5ir5fXrSrHjo351aMbAjp7UhjbPSiwrlcKT/ABfWnbeODwan8sjHHOKREGcH8BQFyJVBbGTmnouU9BThHtZjg8GpgmRjtTE2Qqu0Yxip0A64NKFB69AKmWM7QF7U0ibjdrBfl6HmlTOQM8GpAh25LD0pCg9eD0xQIepHC5z/ADqQjIyOxqNUPRSN3WpApUZYj3FAmN2KgIU4J5prrlMt0IqcRrkEnNN2L0H60WJuVwF6Y7UrYI9aezcHAzzUrZOAuBSsK5UMOSPmGetKIgoBYgjNTmJmOR61E8Rxy3zf1p2HcibbvbaOv86ZGrMCVzmpwiJyzdeDj1pSQh4NFguRrEGTcT0pyRbeSeCOtMBIJzxmpCcAn9KBocI1B5+YiniIlcE89aoLcFnYbWGP1qaGZnUFgQaY2mPeJefpVG4gBC4PfpV8MD1OTTWSMnjrQ1cFKxzV5alGlY529RisOGOZ5mcLiMnv1ruJrbzEIXHI71RNpGmfMGB0GKzcTqhWstjCibahJO3nvUiyJv255PSpdQtWkULCuFzyarpp/kwFwGY/1pbF6NXFLrgLnknFS2toXY+YCQTU9pp7NIkknTHIrajVUU7EGaaRnKfLoivDCyDAGBipdpA5zTySMA9KaVGAN3XpV2RjvqIzBAeSMVV+eTLYwp9atsEUdM1E7nO0dKpIlsrMuxgH578dKo3BzJxwKvXBAB3HNYl5OBIAzYP1qiGfOOodDXSfCsn7RdjJxwcUUVgh09z16w+4PoK27fotFFUbF+ADFW4RzRRQIRwADgCliJ3NzRRSGiYcnmmgnceaKKAHxdKmjA2E45zRRTJY0/danqBt6CiimgQ1+BxUkf8Aqj9aKKBMRvv/AIipQBzxRRQJhIAIxgYp4+4aKKCGIfv049RRRTRJEPvrT16iiihDY6PrUDH5h+NFFMaIm++aZ3oopMbHr0H1pZOtFFCEM7mkTvRRTKYHr+FSR0UUEks33Vqg4y3PNFFSy4kEgG2mwAeWOO1FFSa9CZO1TdHwOlFFUjNjG/1lQL/D/vUUUDHTdfwpsvQUUVaIZm3RODzXDeLHZbmLazD73Q/SiiqjuRI//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, irregular, erythematous patches on the back of a patient with large plaque parapsoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33376=[""].join("\n");
var outline_f32_38_33376=null;
var title_f32_38_33377="False knot";
var content_f32_38_33377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    \"False\" knots - tortuosities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33377=[""].join("\n");
var outline_f32_38_33377=null;
var title_f32_38_33378="Aortic root enlargement";
var content_f32_38_33378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic root enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal aortic root (RT) and ascending aorta (AAo) are seen in panel A; slight prominence of the sinuses of Valsalva (SinV) can be appreciated. Panel B is the aortic RT and AAo from a patient with the Marfan syndrome; the SinV are large while the AAo is relatively normal, a pattern that seems unique to the Marfan syndrome. In panel C, a greatly enlarged aortic (Ao) RT is also seen, but the pattern differs from that seen in the Marfan patient; the dilatation begins at the aortic ring and continues beyond the sinotubular junction well into the AAo, considered to represent aortoannular ectasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33378=[""].join("\n");
var outline_f32_38_33378=null;
var title_f32_38_33379="Gadoversetamide: Patient drug information";
var content_f32_38_33379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gadoversetamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=see_link\">",
"     see \"Gadoversetamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3414728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OptiMARK&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15572566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      OptiMARK&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, this drug may cause a very bad health problem. Call your doctor right away if you have joint stiffness, muscle weakness, very bad bone pain in the hips or ribs, yellow eyes, or very bad skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during an MRI (magnetic resonance imaging) test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gadolinium, versetamide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain in the hips or ribs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11745 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33379=[""].join("\n");
var outline_f32_38_33379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414728\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15572566\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029188\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029190\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029189\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029193\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029194\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029196\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029192\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029198\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/55/25461?source=related_link\">",
"      Gadoversetamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33380="Vitamin B6 (pyridoxine): Patient drug information";
var content_f32_38_33380=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin B6 (pyridoxine): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39254?source=see_link\">",
"     see \"Vitamin B6 (pyridoxine): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/60/33733?source=see_link\">",
"     see \"Vitamin B6 (pyridoxine): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aminoxin&reg; [OTC];",
"     </li>",
"     <li>",
"      Pyri-500 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop and treat low vitamin B",
"       <sub>",
"        6",
"       </sub>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid side effects from isoniazid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat isoniazid or cycloserine overdose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pyridoxine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796283",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Damage to the nerves. This can be long-lasting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation where this drug goes into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695979",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, under the skin, or into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12049 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-13A6B4C64B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33380=[""].join("\n");
var outline_f32_38_33380=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216001\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016965\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016964\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016969\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016970\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016972\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016967\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016968\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016973\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016974\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39254?source=related_link\">",
"      Vitamin B6 (pyridoxine): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/60/33733?source=related_link\">",
"      Vitamin B6 (pyridoxine): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33381="Serum enzymes in patients with renal failure";
var content_f32_38_33381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Serum enzymes in patients with renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Ramesh Soundararajan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33381/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/38/33381/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum enzymes of patients with end-stage renal disease (ESRD) are commonly abnormal. This is due in part to the absence of renal excretion and to the frequent presence of multiple comorbid conditions. Since the diagnosis of many diseases is based upon the detection of elevated levels of these enzymes, the accurate clinical assessment of the patient with ESRD is hampered by a paucity of knowledge concerning the serum concentrations of different enzymes in various disease states.",
"   </p>",
"   <p>",
"    The use and significance of variations in the concentrations of serum enzymes in dialysis patients will be reviewed here. A discussion of serum cardiac enzymes in patients with renal failure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIVER ENZYMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum enzymes most commonly used to help assess the diagnosis of hepatobiliary disease include the aminotransferases, alkaline phosphatase, and gamma glutamyl transpeptidase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aminotransferases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of aspartate and alanine aminotransferase (AST [SGOT] and ALT [SGPT]) are routinely measured to assess liver function in patients with and without renal failure. The aminotransferases are normally present in the circulation in low concentrations, usually less than 40",
"    <span class=\"nowrap\">",
"     IU/L.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=see_link\">",
"     \"Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The concentrations of serum aminotransferases in both chronic dialysis and chronic renal failure patients most commonly fall within the lower end of the range of normal values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Although the exact cause is unknown, possible underlying reasons may be related to pyridoxine deficiency (pyridoxal phosphate is a necessary coenzyme for ALT and AST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/5-7\">",
"     5-7",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of an inhibitory substance in the uremic milieu [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, an increase in serum AST was observed after hemodialysis, suggesting the removal of an inhibitory substance with dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/1\">",
"     1",
"    </a>",
"    ]. This effect was not due to urea alone since the addition of urea to normal serum was not associated with a decline in the activity of AST. In this observational report, serum AST also positively correlated with the level of renal function in a transplant recipient, declining in association with rejection or the need to resume hemodialysis.",
"   </p>",
"   <p>",
"    The use of standard reference values for aminotransferases to help detect liver disease is therefore less useful in patients undergoing chronic dialysis therapy. In one study of over 500 dialysis patients, standard cutoff values for aminotransferases were found to be poor indicators of active liver disease among hepatitis C antibody positive individuals who were undergoing liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, some investigators have suggested that, to increase the sensitivity of liver function tests among dialysis patients, lower \"normal\" values of aminotransferases should be adopted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one study, the conventional upper limit of normal of 40",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    for AST and ALT was changed to 24 IU",
"    <span class=\"nowrap\">",
"     /L",
"    </span>",
"    and 17",
"    <span class=\"nowrap\">",
"     IU/L,",
"    </span>",
"    respectively. To detect liver disease resulting from hepatitis B, these altered values enhanced the sensitivity in patients undergoing peritoneal dialysis from about 27 to 72 percent for AST and from 18 to 64 percent for ALT. We therefore recommend using levels of 24",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    and 17",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    for AST and ALT, respectively, as the upper limits of normal in dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gammaglutamyl transpeptidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum concentration of gammaglutamyl transpeptidase (GGT) is usually normal in patients with ESRD and the absence of liver disease. However, approximately 10 percent of patients with ESRD have unexplained elevations in serum GGT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alkaline phosphatase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma alkaline phosphatase activity can originate from liver, bone, intestine, or placenta; in most patients and normals, the majority of circulating activity consists of isoenzymes derived from either liver or bone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum levels of alkaline phosphatase are elevated in many dialysis patients because of concurrent renal osteodystrophy. The most reliable method of determining the tissue origin of the enzyme is polyacrylamide gel electrophoresis, a test that is not routinely performed in most clinical laboratories. Since bone-derived alkaline phosphatase is heat-labile but liver-derived is not, the source of elevated levels of this enzyme may be partially uncovered by the exposure of serum to elevated temperatures.",
"   </p>",
"   <p>",
"    As a result, elevations in serum alkaline phosphatase alone in dialysis patients only minimally suggest possible obstructive biliary disease. The possibility of hepatobiliary disease should be more seriously entertained if persistent elevations of this enzyme are found in conjunction with increased serum GGT or 5'-nucleotidase and if hyperparathyroidism has been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PANCREATIC ENZYMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked elevations of amylase and lipase are frequently used to help diagnose pancreatitis in patients without renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .) However, serum concentrations of pancreatic amylase and lipase are elevated in patients with ESRD in the absence of acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/12-22\">",
"     12-22",
"    </a>",
"    ]. The highest levels of amylase and lipase are noted in hemodialysis patients, but marked elevations can also be seen in patients with chronic renal failure and in those undergoing peritoneal dialysis. A threefold to fivefold increase in amylase and lipase levels is most commonly observed but the absolute values do not exceed",
"    <strong>",
"     three times",
"    </strong>",
"    the upper limit of normal. The degree of elevation is roughly proportional to the degree of renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Amylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in serum amylase among patients with renal failure or ESRD are most likely due to impaired renal clearance. In one study, the serum amylase began to rise only when the creatinine clearance dropped below 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dialysis procedure alone does not appear to alter serum amylase. In one study, for example, no change was observed in serum amylase in samples obtained pre- and post-dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these observations are confounded by the failure to correlate levels of amylase with variations in dialysis membrane clearance. In this study, one patient with acute pancreatitis had an increase in the P3 isoamylase band, a finding not observed in those without acute pancreatitis.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    as an osmotic agent for peritoneal dialysis may decrease measured serum amylase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Based upon competition for enzymatic cleavage, icodextrin reduced measured amylase activity by 90 percent in one study of peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/23\">",
"     23",
"    </a>",
"    ]. Lipase activity, however, was not affected. The serum amylase should not be used for the diagnosis of pancreatitis among patients utilizing icodextrin in their peritoneal dialysis regimen. Icodextrin and its metabolites are essentially completely cleared from the circulation by one week after discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lipase",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with amylase, the elevations in serum lipase observed in patients with ESRD are most likely due to renal dysfunction. However, unlike amylase, the levels of lipase are also increased by the dialysis procedure itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of increased serum lipase in postdialysis samples may be related to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during dialysis. Consistent with this hypothesis is the observation that the postdialysis rise in serum lipase can be prevented by replacing heparin with alternate anticoagulants, nafamostat mesylate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/18\">",
"     18",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/8/41091?source=see_link\">",
"     defibrotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apparent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced postdialysis elevation in serum lipase may be attributable to the following properties of heparin:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lipolytic activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cross reactivity with lipoprotein lipase and hepatic triglyceride lipase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ability to induce endothelial lipoprotein lipase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trypsinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased serum concentrations of trypsinogen have been observed in asymptomatic dialysis and chronic renal failure patients; it is therefore of diminished utility in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chronic threefold to fivefold increase in serum amylase and lipase concentrations among dialysis and chronic renal failure patients interferes with the serologic diagnosis of suspected pancreatitis. In addition, since hemodialysis elevates lipase levels, postdialysis increases in serum lipase must be interpreted with caution. Thus, whenever possible, the serum concentration of lipase should be evaluated when the patient is not exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Among dialysis patients suspected of pancreatitis, a rise in serum amylase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipase levels that is temporally associated with the onset of abdominal pain or is more than",
"    <strong>",
"     three times",
"    </strong>",
"    the upper limit of normal may be helpful. In addition, determination of the P3 isoamylase band may help distinguish elevations of amylase resulting from true pancreatitis from those caused by renal failure alone. Furthermore, based upon limited evidence, the measurement of lipase may be preferred to amylase for the diagnosis of pancreatitis among peritoneal dialysis patients using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33381/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CARDIAC ENZYMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of cardiac enzymes are utilized to help assess the presence or absence of acute myocardial injury. Abnormal elevations in the serum concentrations of these enzymes may be the key diagnostic element in determining admission to the hospital",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coronary care units. The principal cardiac enzymes are the MB isoenzyme of creatine kinase (CK-MB), cardiac troponin T, and cardiac troponin I. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .) Since coronary artery disease is highly prevalent in patients with ESRD, accurate interpretation of serum concentrations of these enzymes is extremely important.",
"   </p>",
"   <p>",
"    A review of the evaluation and use of cardiac enzymes in patients with renal failure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263399866\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum aminotransferase concentrations are commonly low normal in both chronic dialysis and chronic renal failure patients. In order to increase the sensitivity of liver function tests among dialysis patients, we recommend using levels of 24",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      and 17",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      for AST and ALT, respectively, as the upper limits of normal in dialysis patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Liver enzymes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ten percent of patients with ESRD have unexplained elevations in serum GGT. Serum levels of alkaline phosphatase are elevated in many dialysis patients because of concurrent renal osteodystrophy thus isolated elevations in serum alkaline phosphatase only minimally suggests possible obstructive biliary disease in dialysis patients. Hepatobiliary disease is more strongly suggested by persistent elevations of alkaline phosphatase in conjunction with increased serum GGT or 5'-nucleotidase and if hyperparathyroidism has been excluded. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Liver enzymes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum pancreatic amylase and lipase concentrations are elevated in patients with ESRD in the absence of acute pancreatitis. The degree of elevation is roughly proportional to the degree of renal dysfunction but the absolute values do not exceed",
"      <strong>",
"       three times",
"      </strong>",
"      the upper limit of normal. Serum lipase is increased due to renal dysfunction and by the dialysis procedure itself in patients with ESRD, possibly related to the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . Among dialysis patients suspected of pancreatitis, a rise in serum amylase",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lipase levels that is temporally associated with the onset of abdominal pain or is more than",
"      <strong>",
"       three times",
"      </strong>",
"      the upper limit of normal may be helpful. The use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"       icodextrin",
"      </a>",
"      as an osmotic agent for peritoneal dialysis may decrease measured serum amylase activity. The serum amylase should not be used for the diagnosis of pancreatitis among patients utilizing icodextrin in their peritoneal dialysis regimen. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pancreatic enzymes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/1\">",
"      Cohen GA, Goffinet JA, Donabedian RK, Conn HO. Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976; 84:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/2\">",
"      Nanji AA. Decreased activity of commonly measured serum enzymes: causes and clinical significance. Am J Med Technol 1983; 49:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/3\">",
"      Guh JY, Lai YH, Yang CY, et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/4\">",
"      Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001; 38:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/5\">",
"      Wolf PL, Williams D, Coplon N, Coulson AS. Low aspartate transaminase activity in serum of patients undergoing chronic hemodialysis. Clin Chem 1972; 18:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/6\">",
"      Hamfelt A. The effect of pyridoxal phosphate on the aminotransferase assay in blood. Scand J Clin Lab Invest Suppl 1966; 18:Suppl 92:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/7\">",
"      Rej R, Fasce CF Jr, Vanderlinde RE. Increased aspartate aminotransferase activity of serum after in vitro supplementation with pyridoxal phosphate. Clin Chem 1973; 19:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/8\">",
"      Fabrizi F, Lunghi G, Andrulli S, et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol Dial Transplant 1997; 12:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/9\">",
"      Hung KY, Lee KC, Yen CJ, et al. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B. Nephrol Dial Transplant 1997; 12:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/10\">",
"      Espinosa M, Martin-Malo A, Alvarez de Lara MA, et al. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin Nephrol 2000; 54:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/11\">",
"      Fine A, McIntosh WB. Elevation of serum gamma-glutamyl transpeptidase in end-stage chronic renal failure. Scott Med J 1975; 20:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/12\">",
"      Royse VL, Jensen DM, Corwin HL. Pancreatic enzymes in chronic renal failure. Arch Intern Med 1987; 147:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/13\">",
"      Bastani B, Mifflin TE, Lovell MA, et al. Serum amylases in chronic and end-stage renal failure: effects of mode of therapy, race, diabetes and peritonitis. Am J Nephrol 1987; 7:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/14\">",
"      Vaziri ND, Chang D, Malekpour A, Radaht S. Pancreatic enzymes in patients with end-stage renal disease maintained on hemodialysis. Am J Gastroenterol 1988; 83:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/15\">",
"      Lin XZ, Chen TW, Wang SS, et al. Pancreatic enzymes in uremic patients with or without dialysis. Clin Biochem 1988; 21:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/16\">",
"      Caruana RJ, Altman R, Fowler B, et al. Correlates of amylase and lipase levels in chronic dialysis patients. Int J Artif Organs 1988; 11:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/17\">",
"      Kimmel PL, Tenner S, Habwe VQ, et al. Trypsinogen and other pancreatic enzymes in patients with renal disease: a comparison of high-efficiency hemodialysis and continuous ambulatory peritoneal dialysis. Pancreas 1995; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/18\">",
"      Shibasaki T, Matsuda H, Ohno I, et al. Significance of serum lipase in patients undergoing hemodialysis. Am J Nephrol 1996; 16:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/19\">",
"      Masoero G, Bruno M, Gallo L, et al. Increased serum pancreatic enzymes in uremia: relation with treatment modality and pancreatic involvement. Pancreas 1996; 13:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/20\">",
"      Collen MJ, Ansher AF, Chapman AB, et al. Serum amylase in patients with renal insufficiency and renal failure. Am J Gastroenterol 1990; 85:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/21\">",
"      Jiang CF, Ng KW, Tan SW, et al. Serum level of amylase and lipase in various stages of chronic renal insufficiency. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/22\">",
"      Robitaille R, Lafrance JP, Leblanc M. Altered laboratory findings associated with end-stage renal disease. Semin Dial 2006; 19:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/23\">",
"      Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 2002; 17:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/24\">",
"      Anderstam B, Garc&iacute;a-L&oacute;pez E, Heimb&uuml;rger O, Lindholm B. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int 2003; 23:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33381/abstract/25\">",
"      Montalto G, Soresi M, Carroccio A, et al. Influence of haemodialysis on lipase activity. Eur J Clin Chem Clin Biochem 1997; 35:237.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1895 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-210.101.131.232-947418B5B9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33381=[""].join("\n");
var outline_f32_38_33381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H263399866\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIVER ENZYMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gammaglutamyl transpeptidase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alkaline phosphatase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PANCREATIC ENZYMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Amylase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lipase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trypsinogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Conclusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CARDIAC ENZYMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263399866\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5446?source=related_link\">",
"      Patterns of plasma aspartate and alanine aminotransferase levels with and without liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33382="Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases";
var content_f32_38_33382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the use of immunosuppressive and disease-modifying drugs in the rheumatic diseases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     Philip Seo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33382/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/38/33382/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive drugs other than glucocorticoids are used in the treatment of various rheumatologic conditions to achieve one or more of the following goals:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To induce or maintain a remission",
"     </li>",
"     <li>",
"      To reduce the frequency of flare or relapse",
"     </li>",
"     <li>",
"      To allow tapering of glucocorticoids while maintaining disease control",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the use of immunosuppressive drugs in various rheumatic diseases. Detailed discussions concerning the use of these drugs in specific rheumatic disorders are presented in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive drugs act by a variety of mechanisms. In general, the precise mechanisms responsible for most therapeutic benefits observed with these agents are understood only partially. Unlike biologic agents that selectively inhibit a proinflammatory cytokine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    block its receptor, conventional immunosuppressive drugs interfere with combinations of critical pathways in the inflammatory cascade (",
"    <a class=\"graphic graphic_table graphicRef78362 \" href=\"mobipreview.htm?13/39/13949\">",
"     table 1",
"    </a>",
"    ). Among the immunosuppressive drugs, several are &ldquo;cytotoxic,&rdquo; causing either cell death or impaired proliferation; such drugs include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Other drugs suppress the immune system by inhibiting the proliferation or function of lymphocytes. This class includes drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , which specifically target calcineurin and thereby inhibit the production of interleukin (IL)-2 by activated T-lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33382/abstract/1\">",
"     1",
"    </a>",
"    ]. Others prevent lymphocyte proliferation by inhibiting nucleotide synthesis. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil blocks the synthesis of purines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    inhibits pyrimidine synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33382/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Glucocorticoids have many effects upon innate and acquired immunity. An overview of the effects upon the immune system is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELATIVE TOXICITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No medication is without potential side effects. When selecting a drug, one must weigh its potential benefits against its possible untoward effects. The characteristics of the specific disease for which the patient is being treated also strongly influence the choice of immunosuppression. Such characteristics, which may vary from patient to patient within the same disease category, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The extent of organ involvement",
"     </li>",
"     <li>",
"      The severity of disease within a particular organ",
"     </li>",
"     <li>",
"      The rate of disease progression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In acute, rapidly progressive, clinical situations that threaten either the patients&rsquo; lives or the function of critical organs (eg, fulminant systemic vasculitis or systemic lupus erythematosus [SLE]), concerns about long-term toxicity are secondary to the need to halt inflammation as quickly as possible. In such settings, high doses of glucocorticoids combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be indicated. By comparison, safer approaches, such as low doses of glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , are more appropriate for vasculitis limited to the skin and for milder forms of SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MONITORING FOR TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential risks of adverse reactions can be minimized by regular clinical and laboratory assessment. Recommended monitoring depends upon the agent being used (",
"    <a class=\"graphic graphic_table graphicRef58710 \" href=\"mobipreview.htm?22/62/23532\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33382/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk to benefit ratio of any immunosuppressive drug varies with the experience of the clinician doing the monitoring, with the compliance of the patient, and with the presence of comorbid conditions that may predispose to adverse effects or poor outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     USE OF IMMUNOSUPPRESSIVE DRUGS IN RHEUMATOID ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although treatment for rheumatoid arthritis (RA) has improved, there is no known cure. Nonsteroidal antiinflammatory drugs (NSAIDs) may alleviate the symptoms of RA but are inadequate as monotherapies because they fail to prevent irreversible joint damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are effective in suppressing the symptoms of RA and may have an impact on disease progression. However, because of their associated toxicities, they are not ideal for the long-term management of RA. The use of glucocorticoids in the treatment of RA and the adverse effects of these medications are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disease-modifying antirheumatic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because active RA may lead to irreversible joint damage early in the disease process, treatment with disease-modifying antirheumatic drugs (DMARDs) should not be delayed for patients with confirmed RA and persistent synovitis. A discussion of the use of DMARDs in RA is presented in elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are general observations on the use of DMARDs in RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a marked variability among patients in the response to DMARDs.",
"     </li>",
"     <li>",
"      A high rate of discontinuation is noted for many agents because of either drug toxicity or lack of long-term efficacy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33382/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because of the high risk that discontinuation of DMARD therapy will lead to disease exacerbation, some clinicians believe that DMARDs, if successful in achieving disease control, should be continued indefinitely unless significant medication-related toxicity occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33382/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination DMARD therapy is sometimes necessary to achieve disease control in patients with severely active RA and may also be appropriate for some patients with early, moderately active disease. The use of combinations of DMARDs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Approach to drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detailed discussions of the individual DMARDs in the treatment of RA are presented elsewhere. (See appropriate topic review for the DMARD of interest.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Biologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of biologic agents represented an advance in the treatment of RA comparable to the introduction of glucocorticoids. The cytokines interleukin (IL)-1 and tumor necrosis factor (TNF)-alpha both mediate inflammation and bone resorption in RA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=see_link&amp;anchor=H2#H2\">",
"     \"Role of cytokines in rheumatic diseases\", section on 'Rheumatoid arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents that inhibit B-cell function, T-cell function, and the actions of proinflammatory cytokines (eg, the human recombinant IL-1 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , and anti-TNF-alpha agents including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ) are all used for the treatment of RA. The role of biologic agents for the treatment of RA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     USE OF IMMUNOSUPPRESSIVE DRUGS IN OTHER AUTOIMMUNE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of immunosuppressive drug therapy in the treatment of connective tissue diseases other than RA varies widely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive drugs are useful for a broad spectrum of disease manifestations in patients with systemic lupus erythematosus (SLE).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antimalarial drugs are used in the treatment of arthritis, serositis, and cutaneous lesions associated with SLE. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link&amp;anchor=H20#H20\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Systemic lupus erythematosus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whenever possible, glucocorticoids are reserved for the treatment of glomerulonephritis, central nervous system manifestations, severe hematologic manifestations, and serositis refractory to NSAIDs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link\">",
"       \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of immunosuppressive drugs as glucocorticoid-sparing agents is important because glucocorticoids may contribute to accelerated atherosclerosis and to numerous other side effects. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .) Atherosclerosis is a major cause of morbidity and mortality in patients with SLE. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=see_link\">",
"       \"Coronary heart disease in systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the most severe forms of SLE (eg, alveolar hemorrhage, transverse myelitis, and cerebritis), initial therapy often involves monthly intravenous administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      followed by maintenance with less toxic agents, if possible. For many forms of glomerulonephritis associated with SLE,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil is becoming the treatment of choice. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=see_link\">",
"       \"Neurologic manifestations of systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37365?source=see_link\">",
"       Belimumab",
"      </a>",
"      , a monoclonal antibody that inhibits B-lymphocyte stimulator, has been approved by the US Food and Drug Administration for the treatment of SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33382/abstract/7\">",
"       7",
"      </a>",
"      ], although its precise role has not been determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inflammatory myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimetabolites such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are first-line therapies for the treatment of the idiopathic inflammatory myopathies. The use of immunosuppressive agents in the treatment of inflammatory myositis (eg, dermatomyositis and polymyositis) is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Scleroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many interventions may ameliorate the impact of scleroderma spectrum diseases on particular organs, sometimes with life-saving effects. For example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is used in the treatment of alveolitis. The use of cyclophosphamide and other agents in scleroderma is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vasculitides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to treatment of systemic vasculitis vary widely, depending in part upon whether the disease is self-limited, such as in most cases of Henoch-Sch&ouml;nlein purpura (IgA vasculitis), or is immediately life-threatening, as in disseminated granulomatosis with polyangiitis (Wegener&rsquo;s) with pulmonary hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal failure. In addition, variability of clinical course often exists among patients with the same disease. As a result, treatment decisions must be individualized based upon the extent, severity, and rate of progression of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the mainstay of therapy for some of the systemic vasculitides such as giant cell arteritis, mild polyarteritis nodosa, and Takayasu&rsquo;s arteritis. The use of glucocorticoids in these and other vasculitic disorders is discussed in the topics dealing with treatment. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cytotoxic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of the addition of cytotoxic drugs to glucocorticoids is most obvious in granulomatosis with polyangiitis (Wegener&rsquo;s), which can be abbreviated as GPA, and in the related disorder, microscopic polyangiitis (MPA). Untreated patients and those treated with glucocorticoids alone have mean survival rates of 5 and 12 months, respectively. The addition of daily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to glucocorticoids contributed to a substantially improved survival rate and to the length of remissions in many patients. The use of cyclophosphamide in the treatment of GPA and MPA is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents other than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    may be effective in patients with limited GPA and in some patients with other systemic vasculitides. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, or anti-TNF-alpha therapies in glucocorticoid resistant Takayasu arteritis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/60/3015?source=see_link\">",
"       \"Treatment of Takayasu arteritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , or anti-TNF-alpha therapies for Beh&ccedil;et&rsquo;s disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33498?source=see_link\">",
"       \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      in temporal arteritis, which has not been associated with a significant benefit in all clinical trials (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=see_link\">",
"       \"Treatment of giant cell (temporal) arteritis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7568353\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunosuppressive drugs are used for the treatment of rheumatologic conditions to induce or maintain remission, to reduce the frequency of flare or relapse, and to facilitate tapering of glucocorticoids. The immunosuppressive drugs have a variety of actions, generally interfering with combinations of critical pathways in the inflammatory cascade, while biologic agents each selectively inhibit B-cell activation, T-cell activation, or the function of a proinflammatory cytokine (",
"      <a class=\"graphic graphic_table graphicRef78362 \" href=\"mobipreview.htm?13/39/13949\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characteristics that affect the choice of agent in a given disease include the extent of organ involvement, the severity of disease within a particular organ, and the rate of disease progression. The urgency and degree of immunosuppression required will also affect drug choice. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Relative toxicities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential risks of adverse reactions can be minimized by regular clinical and laboratory assessment (",
"      <a class=\"graphic graphic_table graphicRef58710 \" href=\"mobipreview.htm?22/62/23532\">",
"       table 2",
"      </a>",
"      ). The risk to benefit ratio of any immunosuppressive drug varies with the presence of comorbid conditions that may predispose to adverse effects or poor outcomes and with other factors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Monitoring for toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of individual immunosuppressive drug therapies in the treatment of rheumatoid arthritis and other systemic rheumatic diseases varies widely. The uses of these medications in the rheumatic diseases in which they are utilized are discussed in the topic reviews for each disorder (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Use of immunosuppressive drugs in rheumatoid arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Use of immunosuppressive drugs in other autoimmune disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/1\">",
"      Zimmerman R, Radhakrishnan J, Valeri A, Appel G. Advances in the treatment of lupus nephritis. Annu Rev Med 2001; 52:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/2\">",
"      Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/3\">",
"      Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002; 323:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/4\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/5\">",
"      van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with \"second-line\" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/6\">",
"      ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33382/abstract/7\">",
"      Navarra SV, Guzm&aacute;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7996 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33382=[""].join("\n");
var outline_f32_38_33382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7568353\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELATIVE TOXICITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MONITORING FOR TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      USE OF IMMUNOSUPPRESSIVE DRUGS IN RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disease-modifying antirheumatic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Biologic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      USE OF IMMUNOSUPPRESSIVE DRUGS IN OTHER AUTOIMMUNE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inflammatory myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vasculitides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cytotoxic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7568353\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/39/13949\" title=\"table 1\">",
"      Actions of immunosuppressives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/62/23532\" title=\"table 2\">",
"      Monitoring immunosuppressives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/13/28889?source=related_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/60/3015?source=related_link\">",
"      Treatment of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33383="Approach to evaluating childhood vasculitis";
var content_f32_38_33383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to evaluating childhood vasculitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     David Cabral, MBBS, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     Kimberly Morishita, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33383/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/38/33383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is defined as the presence of inflammation in a blood vessel that may occur as a primary process or secondary to an underlying disease. Clinical symptoms vary widely depending upon the type and location of the vessels involved and the extent of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/1\">",
"     1",
"    </a>",
"    ]. Because of the multisystem nature of these disorders, many pediatric subspecialties, including rheumatology, dermatology, nephrology, and cardiology, may be involved in the diagnostic workup and ongoing care of a child with vasculitis.",
"   </p>",
"   <p>",
"    Although most types of primary vasculitis in childhood are rare, with an estimated incidence of 20.4 per 100,000 children below 17 years of age, prompt recognition and treatment of these disorders are important as these can be severe and life-threatening conditions without appropriate management.",
"   </p>",
"   <p>",
"    The approach to evaluating a child with suspected vasculitis is reviewed here. The classification and overview of the management of childhood vasculitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9657?source=see_link\">",
"     \"Overview of the management of vasculitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary vasculitis is challenging because the clinical presentation of childhood vasculitis varies widely depending upon the type and location of the vessels involved, the extent of inflammation, and subsequent vessel wall damage with associated hemodynamic changes (",
"    <a class=\"graphic graphic_table graphicRef71389 \" href=\"mobipreview.htm?43/11/44219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients ultimately diagnosed with a specific vasculitis will have presented initially with a combination of fever, constitutional symptoms, skin lesions, and laboratory evidence of inflammation. These early findings are neither specific nor sensitive for vasculitis and may be found in other conditions including common infections. In patients with such nonspecific systemic symptoms, vasculitis should be strongly considered if symptoms do not resolve as would be expected in a \"self-limited\" infectious illness. In addition to systemic symptoms, the presence of multiorgan involvement should heighten one's suspicion of vasculitis.",
"   </p>",
"   <p>",
"    In some cases, certain combinations of clinical features or patterns of organ involvement are suggestive of, and sometimes sufficient for the diagnosis of, a specific vasculitis (pattern or syndrome recognition). As an example, the combination of lower extremity purpura, abdominal pain, joint pain and glomerulonephritis would suggest the diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis) (",
"    <a class=\"graphic graphic_picture graphicRef63367 \" href=\"mobipreview.htm?32/32/33282\">",
"     picture 1",
"    </a>",
"    ), whereas the syndrome of persistent fever, conjunctivitis, rash, mucocutaneous changes and swelling of the hands and feet would suggest the diagnosis of Kawasaki disease (",
"    <a class=\"graphic graphic_picture graphicRef78898 \" href=\"mobipreview.htm?15/1/15376\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68321 \" href=\"mobipreview.htm?0/2/43\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59319 \" href=\"mobipreview.htm?19/34/20004\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72040 \" href=\"mobipreview.htm?25/12/25793\">",
"     picture 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Kawasaki disease and Henoch-Sch&ouml;nlein purpura (IgA vasculitis) are primary vasculitides of childhood that are relatively common compared to the other vasculitides and are usually acute and self-limited. Their clinical features have been well described in children. The other chronic idiopathic vasculitides (eg, granulomatosis with polyangiitis [Wegener&rsquo;s], polyarteritis nodosa, microscopic polyangiitis, Takayasu arteritis) are relatively rare in childhood, and although typical characteristics and clinical \"syndromes\" have been described for adults, the presentation in children may not be so \"typical,\" and the diagnostic process often requires consideration of a wider differential diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIATING PRIMARY VASCULITIS FROM OTHER DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial evaluation of a child with suspected vasculitis, it is critical to distinguish primary vasculitis from other diseases that can either mimic vasculitis or cause secondary vasculitis. Because of the rarity of the primary vasculitides, when patients with overt recognizable vasculitis syndromes have been excluded, a patient with clinical features \"suggestive\" of vasculitis is more likely to have another disease. In the early stages of presentation when there are no overt \"vasculitic lesions,\" the differential diagnosis includes (",
"    <a class=\"graphic graphic_table graphicRef69111 \" href=\"mobipreview.htm?28/32/29195\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , tumor necrosis factor (TNF) inhibitors, and anti-thyroid agents.",
"     </li>",
"     <li>",
"      Infections:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Bacterial/fungal:",
"      </span>",
"      Subacute bacterial endocarditis and bacteremia, particularly meningococcemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=see_link\">",
"       \"Clinical manifestations of meningococcal infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral: HIV, hepatitis, cytomegalovirus, Epstein Barr virus, parvovirus B19, and herpes",
"      <span class=\"nowrap\">",
"       zoster/varicella.",
"      </span>",
"     </li>",
"     <li>",
"      Other organisms: Tuberculosis, syphilis, Rocky Mountain spotted fever, typhus, and rickettsial pox.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy: lymphoma, leukemia.",
"     </li>",
"     <li>",
"      Rheumatologic disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Systemic lupus erythematosus (SLE). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link\">",
"       \"Systemic lupus erythematosus in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic onset juvenile idiopathic arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile dermatomyositis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these conditions are themselves causes of secondary vasculitis. In addition, even in the presence of apparent vasculitic lesions, there are other noninflammatory mechanisms involving blood vessels that might cause similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For example, cutaneous lesions (eg, purpura) may be caused by vascular occlusion. The following noninflammatory mechanisms may mimic vasculitis by virtue of blood vessel occlusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions outside the vessel wall &mdash; Neurofibromatosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lesions inside the vessel wall &mdash; Thrombocytopenia, thrombotic conditions (eg, antiphospholipid syndrome), embolic conditions (eg, atrial myxoma). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24295?source=see_link\">",
"       \"Clinical manifestations and evaluation of thrombocytopenia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spasm of the vessels &mdash; Drug-induced vasospasm (eg, ergot, cocaine, phenylpropanolamine) and Raynaud's phenomenon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal vessels themselves &mdash; Coarctation of the aorta. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical correlation with vessel size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once diseases or conditions mimicking vasculitis or causing secondary vasculitis have been excluded, further consideration can be given to reconciling whether the findings are consistent with one of the known types of primary vasculitis.",
"   </p>",
"   <p>",
"    The primary types of vasculitis are commonly classified and differentiated according to vessel size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Although early in the course of the disease, nonspecific complaints (ie, fever, fatigue, anorexia, weight loss, and arthralgias) are generally present irrespective of the size of the involved vessels (as discussed above), over time and with further evaluation, clinical features may become evident or particular patterns of organ involvement recognized, such that certain diseases become more likely than others. Kawasaki disease and Henoch-Sch&ouml;nlein purpura (IgA vasculitis) are two previously discussed examples of this.",
"   </p>",
"   <p>",
"    Clinical correlations can sometimes be made between the size and location of vessel involved, and disease manifestations. However, in childhood many primary vasculitides will involve vessels of many sizes, and such distinctions are not always evident:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large- and medium-size vessels &mdash; When predominately large- or medium-sized vessels are involved (such as in patients with Takayasu's arteritis or polyarteritis nodosa), symptoms and clinical manifestations of arterial insufficiency to the affected organs become apparent. Involvement of large vessels to the extremities, such as the subclavian or femoral arteries, leads to claudication, while involvement of the visceral vessels may lead to hypertension (renal arteries), abdominal pain (mesenteric arteries), chest pain (aorta or coronary arteries), or neurologic symptoms (cerebral vasculature).",
"     </li>",
"     <li>",
"      Small vessels &mdash; Inflammation of smaller vessels (such as in granulomatosis with polyangiitis [Wegener&rsquo;s], microscopic polyangiitis, Henoch-Sch&ouml;nlein purpura (IgA vasculitis), and Churg-Strauss syndrome) leads to symptoms in richly vascularized organs including the skin, lungs, kidneys, gastrointestinal tract and brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/1\">",
"       1",
"      </a>",
"      ]. Symptoms and findings might include hemoptysis, abdominal complaints, hematuria, and neurological dysfunction. Characteristic vasculitic skin lesions include palpable purpura (",
"      <a class=\"graphic graphic_picture graphicRef63367 \" href=\"mobipreview.htm?32/32/33282\">",
"       picture 1",
"      </a>",
"      ), livedo reticularis (",
"      <a class=\"graphic graphic_picture graphicRef67495 \" href=\"mobipreview.htm?41/27/42418\">",
"       picture 6",
"      </a>",
"      ), nonblanching lesions, nodules, ulcers, and",
"      <span class=\"nowrap\">",
"       palmar/plantar",
"      </span>",
"      erythema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with vasculitis will be diagnosed by pattern recognition, in that the clinically-diagnosed syndromes Henoch-Sch&ouml;nlein purpura (IgA vasculitis) and Kawasaki disease account for a sizeable majority of all cases of childhood vasculitis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children with clinical features highly suggestive of systemic vasculitis (and who do not have Henoch-Sch&ouml;nlein purpura (IgA vasculitis), Kawasaki disease, or another overtly recognizable vasculitis syndrome), it remains paramount to rule out other diseases, as these are still much more likely than a primary vasculitis. Systemic diseases that mimic vasculitis or cause secondary vasculitis may have significant morbidity and mortality and require timely and appropriate treatment. In addition, other diseases that are not primary vasculitides may be less likely to require invasive biopsies for diagnostic confirmation.",
"   </p>",
"   <p>",
"    Although each type of vasculitis may be described as having a characteristic pattern of organ involvement, children do not always present in this classic manner nor do they necessarily present with the same degree or extent of vascular involvement as adults with primary vasculitis. This was illustrated in reviews of two pediatric rheumatology registries from the early 1990s, which reported that up to two-thirds of children with chronic primary vasculitis did not fulfill diagnostic classification criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a survey of pediatric rheumatologists from the United States and Canada performed in 2005, clinicians reported that one-third of patients were categorized as having \"unclassified vasculitis\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/9\">",
"     9",
"    </a>",
"    ]. Hence, the diagnostic process in a child suspected of having vasculitis may require consideration of a wide differential diagnosis. Further evaluation requiring imaging or histologic review of tissue samples from involved organs may be necessary to make a more definitive diagnosis, especially in children with severe disease who may require therapy that has potentially serious adverse effects.",
"   </p>",
"   <p>",
"    The variability of clinical manifestations of the primary vasculitic disorders precludes a single uniform approach. However, assessment is helped by having knowledge of the basic common clinical features of vasculitis, familiarizing oneself with the specific vasculitic disorders and their manifestations, and being aware of the other diseases that mimic vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation includes a detailed history, comprehensive physical examination, and basic laboratory testing for all children and adolescents suspected of having vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutional symptoms such as malaise, fatigue, and fever are frequently present; however, they are nonspecific. A careful and detailed history should identify which organ systems are affected and the extent and severity of their involvement.",
"   </p>",
"   <p>",
"    The history should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough review of each major organ system to determine whether organs other than those implicated by the presenting complaint are involved, and also to determine if there is a specific pattern of findings that may be suggestive or diagnostic of a particular disease.",
"     </li>",
"     <li>",
"      Recent illness, particularly infections, either in the patient or in close contacts.",
"     </li>",
"     <li>",
"      Recent travel to a tuberculosis-endemic country would raise suspicion of a mycobacterial infection.",
"     </li>",
"     <li>",
"      Exposure to any medications or toxins that may cause secondary vasculitis.",
"     </li>",
"     <li>",
"      History of any predisposing condition for secondary vasculitis such as hepatitis, systemic lupus erythematosus, juvenile dermatomyositis, or malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough physical examination may reveal involvement of organs or systems that was not apparent on the history. Specific identified abnormalities (below) may support a diagnosis of vasculitis, and other findings such as hepatosplenomegaly or widespread lymphadenopathy may be more characteristic of a malignancy or a systemic infection.",
"   </p>",
"   <p>",
"    The physical examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Palpation of all pulses for volume and symmetry.",
"     </li>",
"     <li>",
"      Measurement of blood pressure (BP). BP values are compared to normative BP percentiles based upon data on gender, age, height, and blood pressure measurements from the National Health and Nutrition Examination Survey (NHANES) and other population-based studies (",
"      <a class=\"graphic graphic_table graphicRef63856 \" href=\"mobipreview.htm?7/45/7894\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52646 \" href=\"mobipreview.htm?7/46/7910\">",
"       table 4",
"      </a>",
"      ). The age- and height-specific blood pressure percentiles may be determined using calculators for boys (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) or for girls (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\"",
"      </a>",
"      .) BPs should be measured in all four limbs because a significant asymmetry between limbs would raise the suspicion of Takayasu arteritis.",
"     </li>",
"     <li>",
"      Auscultation of the neck, abdomen, and extremities to detect the presence of a bruit, which would suggest altered blood flow through an affected vessel.",
"     </li>",
"     <li>",
"      Examination of the skin for lesions suggestive of vascular insufficiency or inflammation, such as palpable purpura, livedo reticularis (",
"      <a class=\"graphic graphic_picture graphicRef67495 \" href=\"mobipreview.htm?41/27/42418\">",
"       picture 6",
"      </a>",
"      ), nodules, ulcers, and nonblanchable rashes.",
"     </li>",
"     <li>",
"      Examination of the ocular fundi and pre-ungual capillary beds for evidence of vascular abnormalities (",
"      <a class=\"graphic graphic_picture graphicRef57651 \" href=\"mobipreview.htm?1/23/1407\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory tests to diagnose vasculitis; however, there are tests that indicate the presence of systemic inflammation, such as elevated erythrocyte sedimentation rate and C-reactive protein.",
"   </p>",
"   <p>",
"    The initial laboratory analysis should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and differential &mdash; Elevated white count may be indicative of inflammation due to vasculitis or infection. Anemia can occur during inflammation or as part of a chronic disease.",
"     </li>",
"     <li>",
"      Platelet count &mdash; To eliminate any condition with thrombocytopenia as the cause of the purpuric or petechial skin lesions. Platelets are also nonspecifically raised during inflammation.",
"     </li>",
"     <li>",
"      Urinalysis &mdash; An abnormal urine sediment (eg, hematuria) may be the only sign of renal involvement in some cases of systemic vasculitis.",
"     </li>",
"     <li>",
"      Liver enzymes &mdash; Detect hepatic involvement.",
"     </li>",
"     <li>",
"      Serum creatinine, and blood urea nitrogen &mdash; Detect renal involvement and evaluate renal function.",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein &mdash; As indicators of inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnosis of a specific vasculitis is not clear after the initial assessment, additional investigations are used to confirm the presence of vasculitis, and to identify the specific disorder, if possible. These include additional laboratory tests, organ specific imaging and functional studies, and tissue biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Additional laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory tests that may be helpful in confirming the presence of vasculitis or in making a specific diagnosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other markers of systemic inflammation such as hypergammaglobulinemia and elevation of plasma Von Willebrand factor (VWF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/10\">",
"       10",
"      </a>",
"      ]. VWF is released with vascular endothelium injury and is also elevated in patients with vascular damage due to stroke, trauma, and severe infection.",
"     </li>",
"     <li>",
"      Antineutrophilic cytoplasmic antibodies (ANCA) may be present in patients with small vessel vasculitis. Perinuclear ANCA (pANCA) that is directed against myeloperoxidase (MPO) on immunofluorescence is associated with microscopic polyangiitis, whereas cytoplasmic ANCA (cANCA) that is directed against proteinase 3 (PR3) is associated with granulomatosis with polyangiitis (Wegener's) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/11-15\">",
"       11-15",
"      </a>",
"      ]. The absence of ANCA in these conditions, however, does not necessarily preclude their diagnosis, as they are not present in all cases. Additionally, ANCA (mainly pANCA) can be detected in other autoimmune conditions such as SLE, rheumatoid arthritis, and inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/13\">",
"       13",
"      </a>",
"      ]. Thus, testing for ANCA is not useful unless the pre-test probability of a small vessel vasculitis is high [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=see_link\">",
"       \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=see_link\">",
"       \"Classification and incidence of childhood vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If systemic lupus erythematosus (SLE) is suspected, then testing for antinuclear antibodies (ANAs) is useful. A negative test result excludes the likelihood of SLE. A positive test is not valuable because it is present both in the normal population and in other conditions. More specific autoantibody tests are required to strongly support a diagnosis of SLE or other related conditions such as mixed connective tissue disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"       \"Measurement and clinical significance of antinuclear antibodies\"",
"      </a>",
"      .) In addition, antinuclear antibodies may interact with some assays of antineutrophil cytoplasmic antibodies, so knowledge of a patient's ANA status is also important for ruling out a false positive ANCA.",
"     </li>",
"     <li>",
"      Low serum complement levels may be present in essential mixed cryoglobulinemia, hypocomplementemic urticarial vasculitis, and SLE but not in most other vasculitic disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"       \"Overview and clinical assessment of the complement system\"",
"      </a>",
"      .) Among those with cryoglobulins, infection with hepatitis C virus must be considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for infectious diseases should include diagnostic studies to detect bacterial (eg, blood and urine cultures) or viral (eg, serology, culture, or rapid diagnostic studies) infections. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with fever of unknown origin\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Organ specific imaging and functional studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging and functional studies are used to evaluate involved organ systems or those that are suspected to be involved based upon the history, physical examination, and laboratory testing. The types of studies chosen will depend upon the particular organ system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary studies &mdash; For suspected pulmonary involvement, chest radiographs, pulmonary function tests, computed tomography (CT) scans, and sometimes bronchoalveolar lavage may be useful.",
"     </li>",
"     <li>",
"      Cardiac and vascular studies &mdash; Cardiac involvement should be investigated with an echocardiogram for both structural and functional abnormalities. The presence of coronary aneurysms with some other clinical features may be diagnostic of Kawasaki disease, although other vasculitides (such as polyarteritis nodosa), infections (Epstein-Barr virus), and inflammatory disorders (systemic onset juvenile idiopathic arthritis) also may cause coronary artery dilatation.",
"      <br/>",
"      <br/>",
"      Large and medium-sized vessel abnormalities may be detected by Doppler ultrasound, CT",
"      <span class=\"nowrap\">",
"       angiogram/magnetic",
"      </span>",
"      resonance arteriography (MRA), and conventional angiography (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65987 \" href=\"mobipreview.htm?35/54/36705\">",
"       image 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      MRA of the aorta and great vessels, including some major branches such as the coronaries and renal arteries, may be an alternative to contrast arteriography in children. When the two techniques were compared in 10 children with various vascular lesions (age range: 1 month to 16 years), excellent correlation was found between the images (r = 0.99) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33383/abstract/17\">",
"       17",
"      </a>",
"      ]. For conditions involving smaller vessels, conventional angiography remains the preferred imaging modality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for definitive diagnosis of a vasculitis remains histopathologic evidence of vascular inflammation. A tissue biopsy may be necessary if the diagnosis cannot be made on the basis of syndrome recognition with or without imaging studies. If the affected organ is easily accessible, such as the skin, the procedure is relatively minor and poses minimal risk to the patient. Other organs may be less accessible, such as the brain or the lungs. In this setting, the risk of doing the biopsy must be weighed against the risks of administrating a potentially long-term toxic treatment in a patient without diagnostic confirmation of a specific vasculitis. Such cases will need to be evaluated on their individual merits in consultation with experts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitis is defined as the presence of inflammation in a blood vessel, which may occur as a primary process or secondary to an underlying disease. Prompt recognition and treatment of these disorders are important as they can be severe and life-threatening conditions without appropriate treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of vasculitis should be considered in children and adolescents who present with persisting systemic symptoms and evidence of multiorgan dysfunction. Clinical symptoms vary widely depending upon the types and location of vessels involved, the extent of inflammation, and the degree to which vascular integrity has been compromised.",
"      <br/>",
"      <br/>",
"      In some cases, the initial presentation is restricted to a rash and nonspecific constitutional signs and symptoms, including fever, weight loss, weakness, or fatigue, which may be difficult to distinguish from findings seen in children with other disorders (",
"      <a class=\"graphic graphic_table graphicRef71389 \" href=\"mobipreview.htm?43/11/44219\">",
"       table 1",
"      </a>",
"      ). However, in the majority of cases, a particular combination of findings or pattern of organ involvement (pattern or syndrome recognition) are indicative and sometimes sufficient to diagnosis a specific vasculitis, such as Henoch-Sch&ouml;nlein purpura (IgA vasculitis) or Kawasaki disease, the two most common causes of primary vasculitis in childhood. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary vasculitides are commonly classified and differentiated according to vessel size. Although early in the course of the disease, nonspecific complaints (ie, fever, fatigue, anorexia, weight loss, and arthralgias) are generally present irrespective of the size of the involved vessels, over time and with further evaluation, some clinical features may correlate with the size and location of vessel involvement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical correlation with vessel size'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=see_link\">",
"       \"Classification and incidence of childhood vasculitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with other disorders including those associated with secondary vasculitis can present with symptoms and findings similar to those with a primary vasculitis. A combination of clinical, pathologic, immunologic, and radiologic features will generally distinguish a primary vasculitis from other conditions including noninflammatory conditions (",
"      <a class=\"graphic graphic_table graphicRef69111 \" href=\"mobipreview.htm?28/32/29195\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Differentiating primary vasculitis from other disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of any child suspected of having vasculitis includes a detailed history, comprehensive physical examination, and basic laboratory testing. The goal is to both support a diagnosis of vasculitis and to exclude other, more common conditions that may present similarly. In most cases, the diagnosis of a primary vasculitis is made based upon clinical findings and pattern recognition of the characteristic findings associated with the specific disease.",
"     </li>",
"     <li>",
"      If the diagnosis of a specific vasculitis is not clear after the initial assessment, additional investigations including imaging and tissue biopsy are used to differentiate vasculitis from other conditions and to determine the specific vasculitic disorder. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/1\">",
"      Dedeoglu F, Sundel RP. Vasculitis in children. Rheum Dis Clin North Am 2007; 33:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/2\">",
"      Ozen S. Problems in classifying vasculitis in children. Pediatr Nephrol 2005; 20:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/3\">",
"      Athreya BH. Vasculitis in children. Pediatr Clin North Am 1995; 42:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/4\">",
"      Roane DW, Griger DR. An approach to diagnosis and initial management of systemic vasculitis. Am Fam Physician 1999; 60:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/5\">",
"      Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/6\">",
"      Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/7\">",
"      Bowyer S, Roettcher P. Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 1996; 23:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/8\">",
"      Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996; 23:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/9\">",
"      Wilkinson NM, Page J, Uribe AG, et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007; 34:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/10\">",
"      Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol 1989; 16:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/11\">",
"      Akikusa JD, Schneider R, Harvey EA, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007; 57:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/12\">",
"      Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 2002; 17:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/13\">",
"      Gross WL, Trabandt A, Reinhold-Keller E. Diagnosis and evaluation of vasculitis. Rheumatology (Oxford) 2000; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/14\">",
"      Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/15\">",
"      Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/16\">",
"      Xin G, Zhao MH, Wang HY. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis. Clin Diagn Lab Immunol 2004; 11:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33383/abstract/17\">",
"      Katayama H, Shimizu T, Tanaka Y, et al. Three-dimensional magnetic resonance angiography of vascular lesions in children. Heart Vessels 2000; 15:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6430 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33383=[""].join("\n");
var outline_f32_38_33383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIATING PRIMARY VASCULITIS FROM OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical correlation with vessel size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Additional laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Organ specific imaging and functional studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6430|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/54/36705\" title=\"diagnostic image 1\">",
"      Renal arteriogram in polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6430|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/32/33282\" title=\"picture 1\">",
"      Rash - Henoch Schonlein purpura IgA vasculitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/1/15376\" title=\"picture 2\">",
"      Conjunctivitis in Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/2/43\" title=\"picture 3\">",
"      Strawberry tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/34/20004\" title=\"picture 4\">",
"      Cracked red lips seen in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/12/25793\" title=\"picture 5\">",
"      Edema of hands in Kawasaki disease - acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/27/42418\" title=\"picture 6\">",
"      Livedo reticularis in lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/23/1407\" title=\"picture 7\">",
"      Capillary loop changes JDM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/11/44219\" title=\"table 1\">",
"      Findings child vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/32/29195\" title=\"table 2\">",
"      Diff dx child vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7894\" title=\"table 3\">",
"      Normal BP boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/46/7910\" title=\"table 4\">",
"      Normal BP girls",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24295?source=related_link\">",
"      Clinical manifestations and evaluation of thrombocytopenia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/27/9657?source=related_link\">",
"      Overview of the management of vasculitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33384="X-linked lymphoproliferative disease";
var content_f32_38_33384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   X-linked lymphoproliferative disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33384/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33384/contributors\">",
"     Jack JH Bleesing, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33384/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33384/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/38/33384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked lymphoproliferative disease (XLP, also called Duncan disease) is a rare disorder that was first identified in the Duncan family, in which six of eighteen males died of lymphoproliferative disease, including fulminant infectious mononucleosis and lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is caused by mutations in the SLAM-associated protein (SAP) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    XLP is characterized by severe dysregulation of the immune system, often, but not always, in response to Epstein-Barr virus (EBV) infection. The three most common clinical manifestations are fulminant infectious mononucleosis, dysgammaglobulinemia, and lymphoma, usually of B-cell origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/5\">",
"     5",
"    </a>",
"    ]. Additional presentations include lymphocytic vasculitis, aplastic anemia, and lymphomatoid granulomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    X-linked inhibitor of apoptosis (XIAP) deficiency was initially considered a form of XLP (XLP type 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, after further characterization of the disorder, it appears that XIAP deficiency is better classified as X-linked familial hemophagocytic lymphohistiocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link&amp;anchor=H19715226#H19715226\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'XIAP (BIRC4)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, clinical manifestations, diagnosis, and management of XLP. Other combined immunodeficiencies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;XLP affects one to three of every million males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, the incidence is probably underreported, since males with fatal fulminant infectious mononucleosis (FIM) are not always evaluated for XLP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/14\">",
"     14",
"    </a>",
"    ]. There is no racial or ethnic predilection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A worldwide XLP registry was established in 1980 as a resource for diagnosis, treatment, and research. By 1995, there were 272 males from 80 families registered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most females who carry the SAP gene mutation are clinically unaffected. Random inactivation of one of the two X chromosomes during embryogenesis in females, termed lyonization, usually leaves an adequate number of wild-type X chromosomes to prevent phenotypic disease. However, non-random or skewed inactivation can lead to predominant expression of the mutated X chromosome, and therefore, clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, any condition associated with loss of an X chromosome, such as in Turner syndrome, can lead to clinical XLP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;XLP (MIM 308240) is caused by mutations in the gene for the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP, also called SH2 domain protein 1A [SH2D1A] or DSHP, MIM 300490) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] in about 60 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3,7,17,18\">",
"     3,7,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    XLP is inherited in an X-linked recessive manner. De novo mutations are rare. There is a broad spectrum of SAP mutations that lead to abnormal or absent SAP expression, including deletions or insertions, single nucleotide substitutions, and splice-site abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12,13,17,18\">",
"     12,13,17,18",
"    </a>",
"    ]. Mutations can cause abnormally truncated SAP protein, alter its function, or destabilize protein folding and expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important aspect of genetics concerns the relationship between genetic defects (genotypes) and clinical manifestations (disease phenotypes). There is no consistent correlation between SH2D1A genotypes and phenotypes in XLP, as exemplified by the observation of considerable variability in phenotype within families sharing the same genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanisms underlying the clinical features of XLP remain unclear, even though a genetic defect has been identified that causes this syndrome. The clinical manifestations may be related to lack of immune surveillance for Epstein-Barr virus (EBV) or other unidentified antigenic stimuli or due to ineffective T and NK cell interaction with B cells. There is dysfunction of both cellular immunity (cytotoxic T cell and NK cell dysfunction resulting in decreased cytokine production), and humoral immunity (abnormal immunoglobulin levels and abnormal antibody responses to infection and vaccination) in XLP. EBV infection may be particularly problematic in patients with XLP because of its B cell trophism.",
"   </p>",
"   <p>",
"    About 60 percent of cases of XLP are caused by defects in SH2D1A that encodes for SLAM-associated protein (SAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. SAP is expressed in T cells, natural killer (NK) cells, invariant natural killer T (iNKT) cells, and some B cells. SAP binds to most members of the signaling lymphocyte activating molecule (SLAM) family of receptors, which are immunoglobulin-like receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/22\">",
"     22",
"    </a>",
"    ]. SLAM (CD150) is a costimulatory receptor that triggers T cell activation via a protein tyrosine phosphorylation signal that is dependent upon SAP expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. SAP assists in the recruitment of the Src-related protein tyrosine kinase, Fyn, to SLAM and activation of Fyn. SAP mutants have significantly decreased binding to SLAM peptides and to Fyn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SAP also interacts with other members of the SLAM family, including CD84, CD229, CD244 (2B4), NTBA, and CS1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/24\">",
"     24",
"    </a>",
"    ]. These cell-surface receptors are adhesion molecules that are located in the synapse between T cells and antigen presenting cells (APCs) and between NK and target cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/22\">",
"     22",
"    </a>",
"    ]. SAP regulates these cellular interactions, which are required for normal development and function of the immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, SAP plays a role in the development of T cell populations that have innate immune cell features, such as invariant natural killer T (iNKT) cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/13,25-27\">",
"     13,25-27",
"    </a>",
"    ]. iNKT cells are absent in patients with SAP deficiency.",
"   </p>",
"   <p>",
"    Activation of T cells via the SLAM-SAP signaling pathway can alter the profile of cytokines produced. As an example, interleukin-10 production by CD4+ T cells is defective in patients with XLP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/28\">",
"     28",
"    </a>",
"    ]. These T cells do not provide adequate B cell help, which may contribute to the hypogammaglobulinemia and humoral immunodeficiency seen in patients with XLP.",
"   </p>",
"   <p>",
"    The primary immune response in normal individuals infected with EBV is proliferation of CD8+ cytotoxic T cells and NK cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/29\">",
"     29",
"    </a>",
"    ]. There are at least three potential mechanisms to explain abnormal response to EBV infection in patients with XLP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SAP enhances apoptosis in T and B cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/30\">",
"       30",
"      </a>",
"      ]. Apoptosis plays a role in lymphocyte homeostasis and elimination of DNA-damaged cells. This important process constrains T cell expansion during antigen-induced immune responses. A decrease in apoptosis due to deficiency of SAP may explain the intense, unchecked CD8+ T cell cytotoxicity stimulated by acute EBV infection in patients with XLP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. Uncontrolled expansion and activation of T cells can occur even in the absence of EBV infection in patients with XLP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another explanation for the increased cytotoxic cellular responses to EBV is that SAP-deficient CD8+ cytotoxic T cells (CTLs) from patients with XLP display a lytic defect against autologous EBV infected B cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/35\">",
"       35",
"      </a>",
"      ]. The lytic machinery normally polarizes to the area where CTLs contact EBV-infected cells, but this does not occur in SAP-deficient CTLs. Other studies have confirmed the impairment of CD8+ T cell response to EBV-transformed B cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The receptor 2B4 can activate, costimulate, or inhibit NK cell cytotoxicity, depending upon its interactions with other molecules [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/26,29,37,38\">",
"       26,29,37,38",
"      </a>",
"      ]. SAP normally inhibits interactions between the 2B4 receptor and negative regulatory molecules. Thus, NK cell activation is inhibited by 2B4 when SAP is absent, leading to reduced NK cell lysis of EBV-infected B cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average age at presentation, usually with EBV infection, is 2.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3\">",
"     3",
"    </a>",
"    ]. Most affected individuals have no apparent disease prior to presentation, although immunologic abnormalities may be present prior to EBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three most common phenotypes of XLP are due to an abnormal immune response to Epstein-Barr virus (EBV) infection causing severe and often fulminant infectious mononucleosis (58 percent), dysgammaglobulinemia (22 to 31 percent), and lymphoproliferative disease, including lymphoma, usually of B-cell origin (30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It was previously thought that these clinical manifestations of XLP always occurred as a consequence of EBV infection. However, these manifestations, except for FIM, can occur without prior EBV infection, suggesting that there are other stimuli that trigger abnormal immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12,15,22,39\">",
"     12,15,22,39",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 18 of 82 (22 percent) males with XLP and lymphoma had no evidence of prior EBV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series of 309 males with XLP from 89 families found that 12 percent developed dysgammaglobulinemia, lymphoproliferative disease, or aplastic anemia, despite having no evidence of EBV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fulminant infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fulminant infectious mononucleosis (FIM) is the most common clinical manifestation of XLP and also has the worst prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6,22,39,41\">",
"     6,22,39,41",
"    </a>",
"    ]. Ninety-six percent of individuals with FIM die, usually within one month of onset of disease.",
"   </p>",
"   <p>",
"    EBV infection causes a dysregulated and exaggerated immune response in patients with XLP, with excessive proliferation of EBV-infected B cells, cytotoxic T cells, and macrophages in various tissues, including hematopoietic organs, liver, brain, and heart. Massive infiltration of these cells into lymphoid tissues and other organs, in combination with abnormal cytokine release, can cause extensive parenchymal damage, including hepatic necrosis and bone marrow failure. Thrombocytopenia, anemia, hepatic dysfunction, and meningoencephalitis are common in patients with FIM. Many patients develop fulminant hepatitis and virus-associated hemophagocytic syndrome (VAHS), also referred to as acquired or secondary hemophagocytic lymphohistiocytosis (HLH). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The minority of patients who survive FIM may have fulminant hepatitis upon reexposure to EBV, and usually have residual immune dysfunction, such as abnormal immunoglobulin levels (increased IgA or IgM, decreased IgG1 or IgG3), impaired antibody responses, and defective natural killer cell function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dysgammaglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysgammaglobulinemia occurs in approximately one-third of XLP-affected males and has the best prognosis, with greater than 50 percent survival, especially when treated with immune globulin replacement therapy. Patients typically have decreased levels of IgG1 and IgG3, whereas levels of IgA and IgM are elevated, possibly secondary to decreased ability to class-switch from IgM to IgG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/15,22,42\">",
"     15,22,42",
"    </a>",
"    ]. Dysgammaglobulinemia can progress over time to include deficiencies of all subclasses of immunoglobulins. Patients often have minimal antibody response to tetanus and diphtheria toxoids after multiple immunization attempts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/22\">",
"     22",
"    </a>",
"    ]. B and T cell numbers are normal, although abnormalities of B, T, and NK cell function can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. Dysgammaglobulinemia occurs in some patients prior to exposure to EBV, indicating that not all hypogammaglobulinemia in patients with XLP is acquired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with dysgammaglobulinemia secondary to XLP are erroneously diagnosed with common variable immune deficiency (CVID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. One study reported a case of a 17 year old male with a history of multiple infections and hypogammaglobulinemia leading to a diagnosis of CVID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/43\">",
"     43",
"    </a>",
"    ]. He later developed pancytopenia and died from fulminant infection (without evidence of prior EBV infection). Genetic analysis identified a mutation in the SH2D1A gene. Another study reported cases of two unrelated boys with recurrent respiratory tract infections and dysgammaglobulinemia that led to the diagnosis of CVID in both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/44\">",
"     44",
"    </a>",
"    ]. Further reviews of patient and family histories, including multiple male family members who died at young ages in the family of the second boy, raised suspicions for XLP. Genetic testing in both boys showed SH2D1A mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomas, primarily high-grade and of B-cell origin, occur in about one-third of males with XLP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. The excessive proliferation of B cells may be due to impaired immune surveillance by T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/22\">",
"     22",
"    </a>",
"    ]. Lymphomas are often extranodal, with 75 percent occurring in the ileocecal region. They can also occur in the central nervous system, liver, and kidneys. Histologic classes of lymphomas include Burkitt's lymphoma (53 percent of all B-cell lymphomas), immunoblastic lymphoma, small cleaved or mixed cell lymphoma, and unclassifiable lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6,45\">",
"     6,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional presentations include lymphocytic vasculitis, aplastic anemia, and lymphomatoid granulomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6,7,34,46\">",
"     6,7,34,46",
"    </a>",
"    ]. These each occur in about 3 percent of patients with XLP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Lymphomatoid granulomatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with XLP demonstrate vigorous cytotoxic cellular responses, predominantly involving polyclonally activated alloreactive cytotoxic CD8 T cells, during acute EBV infection. Those who survive acute EBV infection usually have extensive immune defects. B and T cell numbers are normal to increased, but function is abnormal. IgG is low and IgM is often increased. NK cell activity is reduced. Anemia and thrombocytopenia may also be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for XLP should be considered in all males diagnosed with CVID or other hypogammaglobulinemia, hemophagocytic lymphohistiocytosis with early mortality (especially if EBV-associated), severe infectious mononucleosis, or lymphoma (especially B cell, non-Hodgkin lymphoma affecting extranodal sites), and in males with a family history of XLP. Carrier testing is possible in females with a family history of a known genetic mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are generally first screened for",
"    <span class=\"nowrap\">",
"     SAP/SH2D1A",
"    </span>",
"    defects. Although genetic testing is the gold-standard for diagnosing XLP, genetic testing takes weeks to complete and delayed diagnosis of XLP could be detrimental to treatment. A more rapid assay that detects presence or absence of SAP protein expression via flow cytometry is also available and provides a useful screening tool to quickly diagnose XLP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=see_link&amp;anchor=H7730509#H7730509\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\", section on 'X-linked lymphoproliferative (XLP) syndrome and X-linked inhibitor of apoptosis (XIAP) deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of families with two or more individuals with clinical XLP, SH2D1A mutations were detected in 97 percent of affected males and 75 percent of carrier females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12,48\">",
"     12,48",
"    </a>",
"    ]. However, SH2D1A mutations were identified in only about 60 percent of individuals with XLP phenotype and pertinent family history in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3,7,17,18\">",
"     3,7,17,18",
"    </a>",
"    ]. These differences in SH2D1A mutation prevalence may be due errors in testing, promoter or regulatory defects of SH2D1A that were not identified, or defects in other genes not identified causing similar phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal testing is possible for pregnancies of women who are carriers and preimplantation genetic diagnosis may also be available for families in which the disease-causing mutation has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes common variable immunodeficiency, hemophagocytic lymphohistiocytosis, Chediak-Higashi syndrome, and Griscelli syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common variable immunodeficiency (CVID) is defined as reduced IgG and low levels of IgA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgM, abnormal production of specific antibodies, and absence of any other defined immunodeficiency. Affected individuals experience frequent infections, often of the respiratory tract. The number of affected females and males is equal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/39,44\">",
"       39,44",
"      </a>",
"      ]. There are reports of males diagnosed with CVID who were later found to have XLP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Distinguishing between XLP and CVID is paramount, since the treatment and prognosis differ greatly. Patients with XLP have a 70 percent mortality rate within 10 years of diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/15\">",
"       15",
"      </a>",
"      ], whereas two-thirds of patients with CVID are alive 20 years after diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30457?source=see_link\">",
"       \"Treatment and prognosis of common variable immunodeficiency\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H9\">",
"       'Dysgammaglobulinemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=see_link\">",
"       \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemophagocytic lymphohistiocytosis (HLH) often occurs in individuals without XLP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/50\">",
"       50",
"      </a>",
"      ]. There are familial forms of HLH and forms associated with a number of different infections (including EBV), autoimmune disorders, or malignancies. Secondary EBV-associated HLH accounts for about one-third of cases of HLH in North America. These persons often present beyond infancy and may enter prolonged remission with therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chediak-Higashi syndrome is an autosomal recessive disorder caused by mutations in CHS1, which encodes a protein involved in intracellular vesicle formation. Affected individuals have severe immunodeficiency, partial albinism, and platelet dysfunction. Patients who do not die from infection eventually enter a lymphoma-like \"accelerated phase\" of the disease characterized by massive lymphohistiocytic infiltration of virtually all organ systems and an even more profound immunodeficiency. This phase is thought to be triggered by viral infections, particularly EBV, and is usually lethal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=see_link\">",
"       \"Chediak-Higashi syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Griscelli syndrome type 2 (GS2) is an autosomal recessive disorder affecting cytotoxic T lymphocytes. It is caused by mutations in RAB27A, a small GTPase, which controls vesicle movement within cells. Clinical manifestations include immunodeficiency, hemophagocytic lymphohistiocytosis (often viral triggered), neurologic abnormalities, and partial albinism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=see_link&amp;anchor=H8#H8\">",
"       \"Syndromic immunodeficiencies\", section on 'Griscelli syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of XLP focuses upon three aspects: treatment of disease manifestations, prevention of further sequelae, and curative therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with antiviral agents and immune globulin with high anti-EBV titers has been marginally beneficial in the setting of acute EBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/51\">",
"     51",
"    </a>",
"    ]. An alternative is ablative B cell therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (anti-CD20), which was used successfully in a few patients to control acute primary EBV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/26,52\">",
"     26,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals who develop hemophagocytosis should be promptly treated with HLH-specific therapy, for example according to the HLH-2004 protocol (Histiocyte Society) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , glucocorticoids, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , to induce remission prior to hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with lymphoma should be treated with standard chemotherapy for the specific type of lymphoma and should achieve clinical remission if possible prior to undergoing HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Preventive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulin replacement therapy has been used in an attempt to prevent primary or subsequent acute EBV infection in patients with XLP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the effectiveness of such therapy has not been determined, and there are case reports of acute EBV in patients receiving intravenous immune globulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    was shown to prevent severe EBV infection and clinical deterioration prior to allogeneic hematopoietic cell transplantation in EBV-negative individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preemptive therapy for asymptomatic affected male relatives (siblings) should be considered. The goal is prevention of disease manifestations that are lethal (eg, fulminant infectious mononucleosis)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pose a risk for successful outcome of HCT. One option is treating with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , in combination with immune globulin replacement therapy, as soon as the diagnosis of XLP is suspected (eg, based on flow cytometric measurement of SAP expression) or confirmed (genetic testing), keeping in mind that only HCT provides curative treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Curative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) is the only curative treatment for XLP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/55-60\">",
"     55-60",
"    </a>",
"    ]. Reduced-intensity preparative regimens offer lower morbidity and mortality than myeloablative preparative regimens and have been used successfully in primary immunodeficiencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6\">",
"     6",
"    </a>",
"    ]. The authors' treatment protocol includes campath,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    as the reduced-intensity regimen. This conditioning regimen is well tolerated and thus far has not been associated with engraftment or graft-versus-host issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/61\">",
"     61",
"    </a>",
"    ]. The use of cord blood as a source of stem cells, either from a sibling or from a cord blood bank, has the theoretical advantage of being EBV-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conditions associated with XLP should be treated prior to HCT to improve clinical status and success of HCT. Methods to protect individuals from infections should also be implemented to prevent clinical deterioration prior to HCT. This includes prophylaxis for Pneumocystis carinii (P. jirovecii) pneumonia (PCP). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain laboratory studies should be obtained in males with suspected or confirmed XLP as part of the initial evaluation and ongoing monitoring for disease progression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General laboratory studies include a complete blood count with differential, renal and liver profiles, and coagulation studies",
"      <span class=\"nowrap\">",
"       (PT/INR,",
"      </span>",
"      PTT), fibrinogen, triglycerides, and LDH to monitor for hemophagocytic lymphohistiocytosis (HLH) activity and liver involvement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory markers, including soluble interleukin-2 receptor alpha (sIL2Ra), ferritin, and C-reactive protein (CRP) can be used to follow disease progression, especially in patients with associated HLH.",
"     </li>",
"     <li>",
"      Further laboratory studies include evaluation of NK cell function, enumeration of lymphocyte subpopulations, quantitative immunoglobulin levels, and EBV studies, including qualitative",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      quantitative EBV-PCR and EBV serology (the typical finding is positive",
"      <span class=\"nowrap\">",
"       IgG/IgM",
"      </span>",
"      titer to EBV viral capsid antigen [VCA], but negative IgG titer to EBV nuclear antigen [EBNA]).",
"     </li>",
"     <li>",
"      Additional viral studies (eg, adenovirus, cytomegalovirus [CMV], human herpesvirus-6 [HHV-6] PCR) are considered in males with XLP who are acutely ill or who are definitively diagnosed with XLP, but lack evidence of EBV infection.",
"     </li>",
"     <li>",
"      Bone marrow biopsy can be performed to confirm hemophagocytosis, evaluate cytopenias, and identify infiltrating marrow infections. It is also performed as part of lymphoma staging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic counseling is recommended to provide patients and families with information on the nature of the disease, its inheritance, and implications for affected relatives and carriers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1995, the overall survival was reported to be 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/15\">",
"     15",
"    </a>",
"    ], and in 1998, mortality was reported as approximately 70 percent by 10 years of age and 100 percent by 40 years of age without hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3\">",
"     3",
"    </a>",
"    ]. Survival has improved since then with the advent of better treatment options. In a series of 91 patients published in 2011, overall survival was 71 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33384/abstract/63\">",
"     63",
"    </a>",
"    ]. Eighty-one percent of the 43 patients who underwent HCT survived, whereas survival for the 48 untransplanted patients was 62 percent. Mortality has decreased for patients with HLH (from 96 to 65 percent). However, HLH is still a poor prognostic indicator, with survival decreasing to 50 percent in transplanted patients and 19 percent in untranslated patients. The oldest surviving patient from this cohort was a 46 year old untransplanted patient on immune globulin replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked lymphoproliferative disease (XLP) is a rare disorder characterized by severe dysregulation of the immune system, usually in response to Epstein-Barr virus (EBV) infection. Both cellular and humoral immunity are defective. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      XLP is caused by mutations in the SLAM-associated protein (SAP) gene in about 60 percent of patients. X-linked inhibitor of apoptosis (XIAP) deficiency was initially considered a form of XLP (XLP type 2). However, after further characterization of the disorder, it appears that XIAP deficiency is better classified as X-linked familial hemophagocytic lymphohistiocytosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link&amp;anchor=H19715226#H19715226\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'XIAP (BIRC4)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The average age at presentation, usually with EBV infection, is 2.5 years. Most affected individuals have no apparent disease prior to presentation. The three most common clinical manifestations are fulminant infectious mononucleosis, dysgammaglobulinemia, and lymphoma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of XLP focuses upon three aspects: treatment of disease manifestations, prevention of further sequelae, and curative therapy (hematopoietic cell transplantation). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/1\">",
"      Purtilo DT, Cassel C, Yang JP. Letter: Fatal infectious mononucleosis in familial lymphohistiocytosis. N Engl J Med 1974; 291:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/2\">",
"      Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975; 1:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/3\">",
"      Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/4\">",
"      Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/5\">",
"      Shinozaki K, Kanegane H, Matsukura H, et al. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 2002; 14:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/6\">",
"      Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ. X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol 2002; 119:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/7\">",
"      Gilmour KC, Cranston T, Jones A, et al. Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. Eur J Immunol 2000; 30:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/8\">",
"      Rigaud S, Fondan&egrave;che MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006; 444:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/9\">",
"      Pachlopnik Schmid J, Canioni D, Moshous D, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 2011; 117:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/10\">",
"      Marsh RA, Madden L, Kitchen BJ, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010; 116:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/11\">",
"      Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood 2010; 116:3398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/12\">",
"      Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000; 96:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/13\">",
"      Nichols KE, Ma CS, Cannons JL, et al. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 2005; 203:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/14\">",
"      Arico M, Imashuku S, Clementi R, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001; 97:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/15\">",
"      Seemayer TA, Gross TG, Egeler RM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995; 38:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/16\">",
"      Woon ST, Ameratunga R, Croxson M, et al. Follicular lymphoma in a X-linked lymphoproliferative syndrome carrier female. Scand J Immunol 2008; 68:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/17\">",
"      Yin L, Ferrand V, Lavou&eacute; MF, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet 1999; 105:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/18\">",
"      Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 1998; 95:13765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/19\">",
"      Li C, Iosef C, Jia CY, et al. Disease-causing SAP mutants are defective in ligand binding and protein folding. Biochemistry 2003; 42:14885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/20\">",
"      Morra M, Simarro-Grande M, Martin M, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem 2001; 276:36809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/21\">",
"      Sumegi J, Seemayer TA, Huang D, et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma 2002; 43:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/22\">",
"      Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 2003; 3:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/23\">",
"      Latour S, Gish G, Helgason CD, et al. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001; 2:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/24\">",
"      Rezaei N, Mahmoudi E, Aghamohammadi A, et al. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol 2011; 152:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/25\">",
"      Schwartzberg PL, Mueller KL, Qi H, Cannons JL. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 2009; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/26\">",
"      Bassiri H, Janice Yeo WC, Rothman J, et al. X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses. Immunol Res 2008; 42:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/27\">",
"      Pasquier B, Yin L, Fondan&egrave;che MC, et al. Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 2005; 201:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/28\">",
"      Ma CS, Hare NJ, Nichols KE, et al. Impaired humoral immunity in X-linked lymphoproliferative disease is associated with defective IL-10 production by CD4+ T cells. J Clin Invest 2005; 115:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/29\">",
"      Sharifi R, Sinclair JC, Gilmour KC, et al. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 2004; 103:3821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/30\">",
"      Nagy N, Matskova L, Kis LL, et al. The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease. Proc Natl Acad Sci U S A 2009; 106:11966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/31\">",
"      Howie D, Sayos J, Terhorst C, Morra M. The gene defective in X-linked lymphoproliferative disease controls T cell dependent immune surveillance against Epstein-Barr virus. Curr Opin Immunol 2000; 12:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/32\">",
"      Chen G, Tai AK, Lin M, et al. Increased proliferation of CD8+ T cells in SAP-deficient mice is associated with impaired activation-induced cell death. Eur J Immunol 2007; 37:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/33\">",
"      Snow AL, Marsh RA, Krummey SM, et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 2009; 119:2976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/34\">",
"      Talaat KR, Rothman JA, Cohen JI, et al. Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer 2009; 53:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/35\">",
"      Dupr&eacute; L, Andolfi G, Tangye SG, et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005; 105:4383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/36\">",
"      Hislop AD, Palendira U, Leese AM, et al. Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood 2010; 116:3249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/37\">",
"      Nakajima H, Cella M, Bouchon A, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 2000; 30:3309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/38\">",
"      Eissmann P, Beauchamp L, Wooters J, et al. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 2005; 105:4722.",
"     </a>",
"    </li>",
"    <li>",
"     Sumegi J, Johnson J, Filipovich A, Zhang K. Lymphoproliferative disease, X-linked. GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, updated June 2009. www.genetests.org (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/40\">",
"      Brandau O, Schuster V, Weiss M, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999; 8:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/41\">",
"      Mroczek EC, Weisenburger DD, Grierson HL, et al. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 1987; 111:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/42\">",
"      Grierson HL, Skare J, Hawk J, et al. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. Am J Med Genet 1991; 40:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/43\">",
"      Aghamohammadi A, Kanegane H, Moein M, et al. Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency. Int J Hematol 2003; 78:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/44\">",
"      Soresina A, Lougaris V, Giliani S, et al. Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. Eur J Pediatr 2002; 161:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/45\">",
"      Harrington DS, Weisenburger DD, Purtilo DT. Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer 1987; 59:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/46\">",
"      Kanegane H, Ito Y, Ohshima K, et al. X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol 2005; 78:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/47\">",
"      Tabata Y, Villanueva J, Lee SM, et al. Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood 2005; 105:3066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/48\">",
"      Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/49\">",
"      Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/50\">",
"      Mischler M, Fleming GM, Shanley TP, et al. Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics 2007; 119:e1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/51\">",
"      Purtilo DT. Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients. AIDS Res 1986; 2 Suppl 1:S177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/52\">",
"      Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005; 105:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/53\">",
"      Trottestam H, Beutel K, Meeths M, et al. Treatment of the X-linked lymphoproliferative, Griscelli and Ch&eacute;diak-Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer 2009; 52:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/54\">",
"      Okano M, Bashir RM, Davis JR, Purtilo DT. Detection of primary Epstein-Barr virus infection in a patient with X-linked lymphoproliferative disease receiving immunoglobulin prophylaxis. Am J Hematol 1991; 36:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/55\">",
"      Lankester AC, Visser LF, Hartwig NG, et al. Allogeneic stem cell transplantation in X-linked lymphoproliferative disease: two cases in one family and review of the literature. Bone Marrow Transplant 2005; 36:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/56\">",
"      Vowels MR, Tang RL, Berdoukas V, et al. Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med 1993; 329:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/57\">",
"      Williams LL, Rooney CM, Conley ME, et al. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet 1993; 342:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/58\">",
"      Gross TG, Filipovich AH, Conley ME, et al. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant 1996; 17:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/59\">",
"      Vowels MR, Tiedemann K, Lam-Po-Tang R, Tucker DP. Use of granulocyte-macrophage colony-stimulating factor in two children treated with cord blood transplantation. Blood Cells 1994; 20:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/60\">",
"      Ziegner UH, Ochs HD, Schanen C, et al. Unrelated umbilical cord stem cell transplantation for X-linked immunodeficiencies. J Pediatr 2001; 138:570.",
"     </a>",
"    </li>",
"    <li>",
"     Bleesing J, et al, unpublished observations.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/62\">",
"      Filipovich AH. Unrelated cord blood transplantation for correction of genetic immunodeficiencies. J Pediatr 2001; 138:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33384/abstract/63\">",
"      Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011; 117:53.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3915 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33384=[""].join("\n");
var outline_f32_38_33384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fulminant infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dysgammaglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Preventive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Curative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42278?source=related_link\">",
"      Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/22/40295?source=related_link\">",
"      Syndromic immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30457?source=related_link\">",
"      Treatment and prognosis of common variable immunodeficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33385="Date rape: Risk factors and prevention";
var content_f32_38_33385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Date rape: Risk factors and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Constance M Wiemann, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Samantha D Harrykissoon, JD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Vaughn I Rickert, PsyD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33385/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/38/33385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H35319396\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology, risk factors, and prevention of date rape will be discussed here. The identification and management of date rape, sexual abuse, and the evaluation and management of sexual assault are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15561?source=see_link\">",
"     \"Date rape: Identification and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11510?source=see_link\">",
"     \"Management and sequelae of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095688\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    Sexual assault &ndash; Sexual assault is an inclusive term that refers to any form of forced or inappropriate unwanted sexual contact ranging from forced touching or kissing to verbally or physically coerced vaginal, oral, or anal penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This includes situations in which the victim is unable to consent because of intoxication, inability to understand the consequences, misperceptions because of age, or other incapacities.",
"   </p>",
"   <p>",
"    Rape &ndash; The legal definition of rape varies from state to state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/4\">",
"     4",
"    </a>",
"    ]. It generally encompasses nonconsensual vaginal, anal, or oral penetration that involves force or threat of force (physical or psychological), lack of consent, or inability to provide consent because of age, intoxication, or mental status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Rape is categorized according to the relationship between the perpetrator and the victim.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stranger rape",
"      </strong>",
"      describes nonconsensual sexual penetration between individuals who do not know each other before the sexual act [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Acquaintance rape",
"      </strong>",
"      describes nonconsensual sexual penetration between individuals who know each other in some capacity before the sexual act [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Date rape",
"      </strong>",
"      is a subset of acquaintance rape in which nonconsensual sexual penetration occurs between two people who are in a romantic relationship [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/7\">",
"       7",
"      </a>",
"      ]. Date rape can occur when the victim is alert and rational or irrational, semiconscious, or unable to respond due to alcohol or other drug use. Verbal coercion, threats or use of physical force, or the use of alcohol or illicit drugs may occur as precipitating events.",
"      <br/>",
"      <br/>",
"      In many cases, date rape occurs within the context of a heterosexual dating relationship, with the male as perpetrator and the female as the victim. Same gender and female to male sexual violence also occur in dating relationships [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/8\">",
"       8",
"      </a>",
"      ]. However, because these types of dating violence are not well studied, this topic will focus on heterosexual dating violence with male perpetrators and female victims.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20956908\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent and young adult women (16 to 24 years of age) are more likely to be victims of sexual assault than are women in all other age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Adolescents who have experienced a rape or attempted rape are three to four times as likely as those without this history to experience subsequent sexual assault during their college years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of rapes in adolescent and young adult females are committed by someone who is known to the victim; as many as 80 to 90 percent of rapes on college campuses perpetrated by a date or acquaintance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Approximately one-fourth of college-age men report having used coercion during sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although nonconsensual sexual activity is common among adolescents and young adults, prevalence estimates vary widely depending on how the data are collected and measured, as illustrated below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 2011 Youth Risk Behavior Survey, 8 percent of high school students reported that at some point during their lifetime they had been forced to have sexual intercourse when they did not want to [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/16\">",
"       16",
"      </a>",
"      ]. The prevalence of forced sexual intercourse was greater among females than males (11.8 versus 4.5 percent) (",
"      <a class=\"graphic graphic_table graphicRef78367 \" href=\"mobipreview.htm?11/22/11630\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a longitudinal cohort, 40 percent of adolescent women (14 to 17 years of age) reported having had unwanted penile-vaginal intercourse in the previous three months in face-to-face interviews [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In cross-sectional survey of adolescent and young adult women (14 to 23 years of age) at an urban health care facility, 30 percent reported an unwanted sexual experience (touching or kissing without permission,",
"      <span class=\"nowrap\">",
"       rape/attempted",
"      </span>",
"      rape, or being talked or pressured into having unwanted intercourse) in the previous 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cross-sectional survey of dating violence among adolescents (13 to 21 years of age) evaluated in an urban pediatric emergency department, 34 percent of females reported sexual victimization in the previous 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2011 literature review, the rate of reported rapes among female college students ranged from 14 to 22 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Common locations for date rape among college-age women include apartments or private houses, fraternity houses, residence halls, and parked cars [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Most sexual assaults reported in individuals &ge;18 years occur in the late evening and early morning hours (between 9 PM and 3 AM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095695\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the risk factors for date rape is the first step in prevention. Risk factors for date rape can be broadly classified into those related to the victim, those related to the perpetrator, and those related to the dating situation (",
"    <a class=\"graphic graphic_table graphicRef75628 \" href=\"mobipreview.htm?11/29/11739\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20956916\">",
"    <span class=\"h2\">",
"     Victim characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victim characteristics that are associated with an increased risk of date and acquaintance rape include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6,18,20,26\">",
"     6,18,20,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronologic age &ndash; Adolescents and young adults 16 to 24 years of age incur sexual assault in greater numbers than women in other age groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Previous history of victimization &ndash; Past history of victimization (sexual or physical) is one of the most important risk factors for date and acquaintance rape [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/11,12,27\">",
"       11,12,27",
"      </a>",
"      ]. Adolescents who have experienced a rape or attempted rape before the age of 18 are three to four times more likely to experience a subsequent sexual assault during their college years than those without this history [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The increased risk of revictimization may be related to increased use of alcohol or drugs, increased numbers of consensual sexual partners,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased ability to resist unwanted sexual advances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/27-31\">",
"       27-31",
"      </a>",
"      ]. However, it is not clear whether these associated factors are precursors to victimization, consequences of victimization, or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/32\">",
"       32",
"      </a>",
"      ]. An observational study found that women who reported past experience with sexual aggression during dating situations were more accepting of violence toward women and rape myths than women who did not report victimization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Greater number of dating or sexual partners (which increases the exposure to potential perpetrators) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acceptance of rape myths &ndash; Acceptance of rape myths encourages and reinforces forceful sexual behavior. (See",
"      <a class=\"local\" href=\"#H20956954\">",
"       'Acceptance of rape myths'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20956924\">",
"    <span class=\"h2\">",
"     Perpetrator characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential perpetrators of date rape are difficult to identify in advance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6\">",
"     6",
"    </a>",
"    ]. However, some characteristics that may increase the possibility of sexual coercion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strong belief in traditional gender roles &ndash; When establishing their sexual identity, adolescent and young adult men who have strong belief in traditional gender roles may feel the need to be forceful, aggressive, or dominant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/23,35,36\">",
"       23,35,36",
"      </a>",
"      ]. Men with strong belief in traditional gender roles have attitudes more accepting of rape [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/37\">",
"       37",
"      </a>",
"      ]. These attitudes may be reinforced by certain types of media [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19095737\">",
"       'Adolescent perceptions of sexual behavior'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Acceptance of rape myths &ndash; Acceptance of rape myths encourages and reinforces forceful sexual behavior. (See",
"      <a class=\"local\" href=\"#H20956954\">",
"       'Acceptance of rape myths'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Early initial sexual experiences (forced or voluntary) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcohol misuse and abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20960515\">",
"    <span class=\"h2\">",
"     Situational factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Situational factors that may predispose to acquaintance or date rape include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Existing relationship &ndash; An existing relationship between the victim and perpetrator where there is a power differential or the victim cares for or is attracted to the perpetrator [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Misperceptions &ndash; Misperceptions of date-specific factors by the perpetrator may increase the risk of sexual aggression. The perpetrator may perceive the victim&rsquo;s nonverbal communication, mode of dress, use of alcohol, or willingness to be alone as a willingness to have sex despite verbalizations to the contrary. Acceptance of rape myths, the use of alcohol or other drugs, and belief in traditional gender roles may contribute to such misperceptions. (See",
"      <a class=\"local\" href=\"#H64192887\">",
"       'Other contributing factors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Date-specific factors &ndash; Certain factors specific to the date may increase the risk of date or acquaintance rape. These include who initiated the date, how expensive the date was, who paid the expenses, who drove, and the location of the date activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/23,41-44\">",
"       23,41-44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19095737\">",
"       'Adolescent perceptions of sexual behavior'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Both males and females perceive a female as more interested in sex if she initiates and pays for the date [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Both males and females see the date location and context as a measure of willingness to engage in sexual intercourse. Dating situations where the female goes to her partner&rsquo;s",
"      <span class=\"nowrap\">",
"       apartment/home",
"      </span>",
"      or they are alone could appear to indicate to the male, especially, that intercourse is allowed and desired. The notion of control may be associated with the perpetrator&rsquo;s &ldquo;turf&rdquo;; this can make a man&rsquo;s car or apartment a more likely location for sexual aggression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Gender and ethnic differences in perceptions of the role of date-specific factors in date rape have been reported among adolescents and young adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095709\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol use contributes to the occurrence of date and acquaintance rape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/32,50-55\">",
"     32,50-55",
"    </a>",
"    ]. Alcohol consumption by the perpetrator, victim, or both, is estimated to be involved in approximately one-half of sexual assaults among adolescents and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/55\">",
"     55",
"    </a>",
"    ]. Sexual assaults involving alcohol are more likely to occur between partners who are acquaintances or casual dates than between partners who are steady dates.",
"   </p>",
"   <p>",
"    Alcohol contributes to sexual assault through multiple pathways, often exacerbating other risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/10,56\">",
"     10,56",
"    </a>",
"    ]. The use of alcohol may affect both the perpetrator and the victim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/53\">",
"     53",
"    </a>",
"    ]. Alcohol use may lead the perpetrator to misinterpret friendly cues as sexual invitation, to inaccurately discriminate the date&rsquo;s sexual intentions, to be unable to recognize the perpetrator&rsquo;s own inappropriate sexual behavior, or to overestimate the date&rsquo;s sexual arousal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/53,57\">",
"     53,57",
"    </a>",
"    ]. Several studies suggest that men perceive a woman who is drinking alcohol to be more sexually available and more likely to have sex with her partner than a woman who is not drinking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/58\">",
"     58",
"    </a>",
"    ]. Some male perpetrators may encourage their dates to drink because they believe that alcohol increases the woman&rsquo;s interest in sex, decreases her sexual inhibition, and increases her sexual initiative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6,22,56,59,60\">",
"     6,22,56,59,60",
"    </a>",
"    ], whereas others may consume alcohol as a means of justifying their behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20956954\">",
"     'Acceptance of rape myths'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The effects of alcohol may reduce the victim&rsquo;s perception of sexual assault risk, diminish the victim&rsquo;s ability to cope with or ward off unwanted sexual advances, or to be aware of or remember the assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/53,61,62\">",
"     53,61,62",
"    </a>",
"    ]. Victims who have used alcohol may feel responsible for the sexual assault. Such perception of self-responsibility may have long-lasting psychologic implications for the victim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15561?source=see_link&amp;anchor=H49780769#H49780769\">",
"     \"Date rape: Identification and management\", section on 'Symptoms and sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278703864\">",
"    <span class=\"h2\">",
"     Illicit drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illicit drugs also may contribute to date and acquaintance rape and coercive sexual violence. These include flunitrazepam (Rohypnol), 3,4-methylendioxymethamphetamine (MDMA or ecstasy),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    , and gamma hydroxybutyrate (GHB), among others. The combination of alcohol with any of these drugs can lead to adverse reactions and death.",
"   </p>",
"   <p>",
"    Flunitrazepam is a sedative that is prescribed in Latin America and Europe for the treatment of insomnia and as a preanesthetic medication, but has not been approved in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/63\">",
"     63",
"    </a>",
"    ]. It is used illicitly to heighten the effect of alcohol and other drugs. It is ten times more potent than",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    . When mixed with alcohol it is incapacitating and anamnestic, increasing vulnerability to sexual assault. In a cross-sectional survey of adolescents and young women attending university-based ambulatory reproductive health clinics, 1 in 10 adolescent and young adult females who reported voluntary use of flunitrazepam also reported experiencing physical or sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MDMA, GHB, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    are additional &ldquo;date rape&rdquo; drugs. MDMA is a psychoactive drug with amphetamine and hallucinogenic properties. It reduces inhibitions and produces feelings of empathy for others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/65\">",
"     65",
"    </a>",
"    ]. Effects of MDMA include confusion, severe dehydration, muscle tension, and blurred vision. Trends in MDMA use among adolescents and adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21560?source=see_link&amp;anchor=H17436336#H17436336\">",
"     \"MDMA (ecstasy) intoxication\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    and GHB are central nervous system depressants. They are often colorless, tasteless, and odorless, and can easily be added to beverages. Ketamine can cause delirium, amnesia, and depression. GHB induces dizziness, nausea, and visual disturbances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40935?source=see_link&amp;anchor=H5#H5\">",
"     \"Ketamine poisoning\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/25/31130?source=see_link&amp;anchor=H7#H7\">",
"     \"Gamma hydroxybutyrate (GHB) intoxication\", section on 'Clinical features of acute toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64192887\">",
"    <span class=\"h1\">",
"     OTHER CONTRIBUTING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other factors that may contribute to date rape include acceptance of rape myths, adolescent perceptions of sexual behavior, and cultural considerations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20956954\">",
"    <span class=\"h2\">",
"     Acceptance of rape myths",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rape myths are prejudiced, stereotyped, or false beliefs about rape, rape victims, and rapists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/33\">",
"     33",
"    </a>",
"    ]. Acceptance of rape myths perpetuates unwanted sexual contact by encouraging and reinforcing coercive sexual behavior. Examples of rape myths include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/23,33,35,66\">",
"     23,33,35,66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Most rapists are strangers.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Acquaintance rape is not &lsquo;real rape&rsquo; and does not harm the victim.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;All women want to be raped.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;No means yes.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Only bad girls get raped.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Any healthy woman can resist a rapist if she really wants to.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Women who dress promiscuously are &lsquo;asking for it.&rsquo; &rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Women lead men on therefore deserve to be raped.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Women &lsquo;cry rape&rsquo; only when they&rsquo;ve been jilted or have something to cover up.&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;A woman who goes to a man&rsquo;s home on their first date implies that she is willing to have sex.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095737\">",
"    <span class=\"h2\">",
"     Adolescent perceptions of sexual behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of how adolescents view sexual behavior is critical to the prevention of date rape. Many adolescents do not perceive date rape as rape unless it occurred with physical force or verbal threats [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. When presented with vignettes depicting date rape scenarios, adolescents rarely describe rape that occurred in a dating relationship as &ldquo;real rape&rdquo; because of the voluntary association between the victim and the perpetrator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/67\">",
"     67",
"    </a>",
"    ]. In many instances, there may have been prior consensual sex or some other form of intimacy with this partner.",
"   </p>",
"   <p>",
"    Male and female adolescents often follow a script in which males are viewed as initiators and females as &ldquo;gatekeepers&rdquo; of sexual intercourse. Because of these perceived roles, date-specific characteristics can be over-interpreted as signals for sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/67,69\">",
"     67,69",
"    </a>",
"    ]. Females who wear short skirts, for example, may be viewed by males as willing to have sex, regardless of their actual intent. Similarly, it is assumed that females who have reputations for being &ldquo;easy&rdquo; are going to have sex with every dating partner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2925465\">",
"    <span class=\"h3\">",
"     Strong belief in traditional gender roles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional gender roles encourage men to be aggressive, forceful, and dominant. When establishing their sexual identity, adolescent and young adult men who believe in traditional gender roles may feel the need to be aggressive or dominant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/23,35\">",
"     23,35",
"    </a>",
"    ]. These attitudes may be reinforced by certain types of media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/38\">",
"     38",
"    </a>",
"    ]. Males and females with strong beliefs in traditional gender roles have attitudes more accepting of sexual coercion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2925472\">",
"    <span class=\"h3\">",
"     Acceptability of forced sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In surveys of adolescents and young adults, the degree of perceived acceptability of sexual coercion varies depending upon the context. However, in a survey of high school students, it was universally perceived that when a female uses physical force and says &ldquo;no&rdquo; to sexual advances, she does not want to engage in sexual activity and the male does not have the right to use coercion or force against her [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/70\">",
"     70",
"    </a>",
"    ]. Similarly, college students identified inappropriate sexual activity earlier in a date rape vignette when they had heard a clearly articulated sexual boundary than when they had not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some aggressive behavior on the part of the male perpetrator may be seen as normative by some adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2,72,73\">",
"     2,72,73",
"    </a>",
"    ]. Males generally are more likely than females to support the use of sexually coercive behaviors across a variety of situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/48,70\">",
"     48,70",
"    </a>",
"    ]. In a survey of high-school students, 60 percent of males reported that it was acceptable for a boy to force sex on a girl in one or more situations (eg, they have had sex before; she says yes at first but then changes her mind and says no; she&rsquo;s wearing",
"    <span class=\"nowrap\">",
"     revealing/sexy",
"    </span>",
"    clothing) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/48\">",
"     48",
"    </a>",
"    ]. Male support of sexually coercive behaviors appears to decrease with age, suggesting that belief in rape myths diminishes as adolescents make the transition to adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among college women, forced sexual intercourse appears to be perceived as more permissible when the perpetrator is a date or acquaintance than a stranger [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/7,74\">",
"     7,74",
"    </a>",
"    ]. Young women may endorse some of the same cultural stereotypes and attitudes reported by date rapists. (See",
"    <a class=\"local\" href=\"#H20956954\">",
"     'Acceptance of rape myths'",
"    </a>",
"    above.) Such attitudes may encourage victims of date rape to believe that they were responsible for the rape and prevent them from disclosure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15561?source=see_link&amp;anchor=H25482454#H25482454\">",
"     \"Date rape: Identification and management\", section on 'Barriers to disclosure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of perceived acceptability of sexual coercion may be affected by the manner in which the victim dresses. In a survey in which adolescents were presented with vignettes of unwanted sexual intercourse in which the victim was and was not dressed provocatively, both male and female adolescents found the victim more responsible, the perpetrator&rsquo;s behavior more justified, and were less likely to judge the act as rape when the victim was dressed provocatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2925480\">",
"    <span class=\"h3\">",
"     Sexual rights and responsibilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both male and female adolescents believe that an ongoing dating relationship encompasses sexual rights and responsibilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/67\">",
"     67",
"    </a>",
"    ]. In one survey, four of five adolescents reported that forced sex is acceptable if a couple has been dating for six or more months and almost 50 percent reported that forced sex is acceptable if the female has gotten the male sexually excited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/67\">",
"     67",
"    </a>",
"    ]. In another survey of high-school students, 39 percent of boys and 12 percent of girls reported that it was &ldquo;okay for a boy to force a girl to have sex with him if they have had sex before&rdquo;; and 37 percent of boys and 23 percent of girls reported that it was &ldquo;okay for a boy to force a girl to have sex with him if she gets him sexually excited&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women may believe that once they are in a dating relationship they no longer have sexual choices. Data collected in a reproductive health clinic revealed that 20 percent of women aged 14 to 26 years who reported having a steady partner believed that they did not have the right to stop sexual foreplay at any time, including at the point of intercourse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/75\">",
"     75",
"    </a>",
"    ]. Moreover, 20 percent reported believing that once consensual sex between dating partners has occurred, they cannot refuse to have intercourse in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2925488\">",
"    <span class=\"h3\">",
"     Interpretation of nonverbal communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of sex is often determined more by perceptions and beliefs about nonverbal behaviors than by open and honest verbal communications. Unfortunately, cues and signals for sexual intimacy are perceived and interpreted differently by male and female adolescents and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/67,70\">",
"     67,70",
"    </a>",
"    ]. A male may perceive that if his female dating partner plays with her hair, looks into his eyes, or engages in discussions about sex, she wants to have intercourse. In contrast, a female displaying these behaviors may simply be interested in developing a more sophisticated relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49773827\">",
"    <span class=\"h2\">",
"     Cultural considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescent rape occurs in a sociocultural context in which issues of male dominance, appropriate gender behaviors, victimization, violence, and power imbalance in relationships are highly visible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2\">",
"     2",
"    </a>",
"    ]. Religious",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ethnic values may affect perceptions of appropriate gender roles and sexual behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2,49\">",
"     2,49",
"    </a>",
"    ]. The cultural beliefs of the patient&rsquo;s community, especially when the community has restricted beliefs about women&rsquo;s social roles and rights, play an important role in the assignment of moral as well as causal responsibility in sexual victimization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/76\">",
"     76",
"    </a>",
"    ]. It is important to consider these beliefs when providing anticipatory guidance about healthy dating relationships and sexual communication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095744\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377866399\">",
"    <span class=\"h2\">",
"     Anticipatory guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticipatory guidance for the prevention of date rape has several components, including the promotion of healthy dating relationships by helping patients learn to communicate effectively about sexual beliefs, desires, and boundaries; dispelling rape myths; educating patients to avoid risk factors for date rape; and advising them about what to do if they are sexually assaulted despite their precautions. Anticipatory guidance about healthy dating should be provided to both males and females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics&rsquo; Connected Kids: Safe, Strong, Secure program recommends that the concept of healthy dating be introduced at 11 to 14 years and reinforced at subsequent visits. The program includes educational brochures for teens and parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116831445\">",
"    <span class=\"h3\">",
"     Process",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to foster a better awareness and understanding of sexual violence, conversations about date rape specifically, and sexual coercion in general, should be interactive and occur at each visit. It is important to avoid lectures. Instead, present facts and listen to the concerns and reactions of the patient.",
"   </p>",
"   <p>",
"    To promote disclosure and encourage open and honest conversation about the topic of dating violence, providers can use an &ldquo;icebreaker&rdquo; before screening for dating violence. As an example, one could start by saying, &ldquo;Unfortunately, many of my patients have been hurt physically or sexually, either as children or during more recent relationships. Because I want to help my patients, I ask every patient who I see about these issues. I also know that it may be hard for some patients to talk about being hurt in their lives&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The health care provider must take all concerns seriously and answer questions honestly. In addition, the provider must confront distortions and myths. As an example, providers can say, &ldquo;While it is okay for a dating partner to be jealous, jealousy is not the same as love. A partner who tries to tell you what to do or who to hang out with, puts you down, or makes you feel guilty or bad about yourself is not acting out of love.&rdquo; Young patients need to be encouraged to trust their instincts about a given dating situation or partner. &ldquo;If your partner or relationship feels uncomfortable to you, talk about it with an adult you trust.&rdquo;",
"   </p>",
"   <p>",
"    Empathy induction is a tool that can be used to facilitate attitudinal and behavioral changes in males and females with regard to sexual assault prevention, and may be particularly helpful for adolescents who believe they are invulnerable to sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/79\">",
"     79",
"    </a>",
"    ]. Empathy induction involves asking the patient what it would be like for them, their sister, or their close friend to experience date rape. This allows the patient to better understand and listen to the information that the provider is sharing and allows the provider to make attributions to the patient&rsquo;s personal behaviors without being confrontational.",
"   </p>",
"   <p>",
"    Finally, it is useful to encourage the parent to be an active participant in discussions about dating violence and to provide information",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resources to the parents for these discussions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Parents can continue and extend the conversations after the visit; they can also monitor for signs that their adolescent may be in a violent dating relationship. These include a partner:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Who is jealous and possessive",
"     </li>",
"     <li>",
"      Who is bossy (eg, gives orders, makes all the decisions)",
"     </li>",
"     <li>",
"      Embarrasses or puts the adolescent down in front of others",
"     </li>",
"     <li>",
"      Has a history of losing his temper or physical violence",
"     </li>",
"     <li>",
"      Pressures the adolescent to use alcohol or drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116831464\">",
"    <span class=\"h3\">",
"     Components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticipatory guidance for the prevention of date rape includes promoting healthy dating relationships by helping patients learn to communicate effectively about sexual beliefs, desires, and boundaries; dispelling rape myths; educating patients to avoid risk factors for date rape; and advising them about what to do if they are sexually assaulted despite their precautions. Anticipatory guidance about healthy dating should be provided to both males and females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sexual communication",
"      </strong>",
"      &ndash; Health care providers for adolescents and young adults can help their patients to develop sexual communications skills and the corresponding self-efficacy to use them. In a survey of adolescent females, factors associated with consistent refusal to engage in unwanted sex included high safer sex self-efficacy (ie, belief in their ability to enact a behavior), few perceived barriers to negotiation with partners about condoms, and frequent conversations with parents about sexual issues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/80\">",
"       80",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Health care providers can assess their patients&rsquo; sexual communication skills by asking how the patient communicates sexual preferences and beliefs to their partner. Patients can be empowered by being told that discussing sexual intimacy does not mean that they have to be sexually intimate.",
"      <br/>",
"      <br/>",
"      It is important for adolescents and young adults to understand that they have choices in a sexual relationship regardless of the relationship&rsquo;s duration, and to be able to effectively communicate those choices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/71\">",
"       71",
"      </a>",
"      ]. Many adolescent and young adult couples do not openly discuss desires for sexual intimacy. As a result, communication about sexual intent usually relies on nonverbal cues and signals, which can lead to misinterpretation, particularly among younger teens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/83\">",
"       83",
"      </a>",
"      ]. To minimize misinterpretation, adolescents and young adults must learn to identify and communicate their sexual desires and needs to their partners in a healthy and straightforward manner. (See",
"      <a class=\"local\" href=\"#H20960515\">",
"       'Situational factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19095737\">",
"       'Adolescent perceptions of sexual behavior'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Correcting rape myths",
"      </strong>",
"      &ndash; The acceptance and perpetuation of rape myths contributes to date rape. Dispelling rape myths is an important component of date rape prevention. This entails helping adolescents (both males and females) understand that [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2,84,85\">",
"       2,84,85",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Forced intercourse without consent is rape, regardless of the context (eg, previous consensual sex; use of alcohol or drugs; ongoing dating relationship, etc); individuals who are raped should seek medical care",
"     </li>",
"     <li>",
"      The majority of rapes of adolescents and young adults are perpetrated by people they know and may trust; perpetrators usually cannot be identified before an attempt is made",
"     </li>",
"     <li>",
"      They have choices in a sexual relationship regardless of the relationship&rsquo;s duration; they have the right to set sexual limits and insist that their partner honor the limits; talking about sexual intimacy does not mean that they have to have sexual intercourse",
"     </li>",
"     <li>",
"      They should not be afraid to fight back; reinforcing verbal refusal of unwanted sexual activity with physical force (eg, kicking, biting, or hitting) may be effective in stopping the attack [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/70,86\">",
"       70,86",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Avoiding risky situations",
"      </strong>",
"      &ndash; Adolescents should be able to identify and avoid high risk situations, such as [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2,85\">",
"       2,85",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Leaving a party with someone they do not know",
"     </li>",
"     <li>",
"      Taking a drink from someone they do not know and trust",
"     </li>",
"     <li>",
"      Leaving their drinks unattended",
"     </li>",
"     <li>",
"      Meeting alone with people with whom they made initial contact through Internet",
"     </li>",
"     <li>",
"      Walking alone at night",
"     </li>",
"     <li>",
"      Allowing themselves to be pressured into using alcohol or drugs",
"     </li>",
"     <li>",
"      Accepting help from someone they do not know if they fall ill at a party (whether from having too much to drink or the possibility that a date rape drug was added to their drink)",
"     </li>",
"     <li>",
"      Dating individuals who are jealous and possessive; bossy; embarrass or put them down in front of others; or have a history of losing their temper or physical violence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adolescents should learn to trust their feelings and intuitions about potentially risky situations&mdash;if it feels wrong or unsafe, it probably is.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095774\">",
"    <span class=\"h2\">",
"     Prevention programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers who are interested may advocate for date rape prevention programs in schools, college campuses, and other locations where youth congregate in their communities. Formal date and acquaintance rape prevention programs typically target changes in rape awareness as well as attitudes and assertiveness to minimize the likelihood of rape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Programs targeting both male and female participants generally focus on cross-gender communication and dating expectations, with some emphasizing the &ldquo;shared responsibility&rdquo; of both partners in",
"    <span class=\"nowrap\">",
"     date/acquaintance",
"    </span>",
"    rape; they consistently report a decrease in rape-supportive attitudes or behaviors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/79,88\">",
"     79,88",
"    </a>",
"    ]. The Safe Dates Project evaluated the effects of primary and secondary prevention of dating violence among rural eighth and ninth-graders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. Using school- and community-based activities, the intervention program increased awareness, addressed help-seeking for dating violence, and provided training to improve health care providers&rsquo; ability to care for adolescents experiencing dating violence or",
"    <span class=\"nowrap\">",
"     date/acquaintance",
"    </span>",
"    rape. Participants in the intervention group reported less psychological abuse, sexual violence, and dating violence 12 months after the program ended. Most program effects were related to changes in dating violence norms, gender stereotyping, and awareness of services.",
"   </p>",
"   <p>",
"    Programs targeting women have been effective in improving participants&rsquo; awareness of rape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/79,91,92\">",
"     79,91,92",
"    </a>",
"    ]. Personalizing the program may increase the perception of vulnerability and the intent to avoid risk-taking behaviors (eg, using alcohol on dates and dating hostile or jealous individuals) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/92\">",
"     92",
"    </a>",
"    ]. One program was effective in decreasing the incidence of sexual assault among women without a history of sexual assault, but not among women with a history of sexual assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/91\">",
"     91",
"    </a>",
"    ]. This suggests a need for prevention programs tailored to women with a history of victimization who are at particular risk for future sexual assault. (See",
"    <a class=\"local\" href=\"#H20956916\">",
"     'Victim characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Programs targeting males also report success in modifying attitudes immediately following program participation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. However, one program observed a &ldquo;backlash&rdquo; effect, wherein a small number of males reported increased aggressive attitudes following an intervention, suggesting that males who are already sexually aggressive may require secondary, rather than primary, prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33385/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377866414\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resources related to",
"    <span class=\"nowrap\">",
"     date/acquaintance",
"    </span>",
"    rape for patients, parents, and providers are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.acog.org/~/media/Departments/Adolescent Health Care/Teen Care Tool Kit/AcquaintDateRape.pdf?dmc=1&amp;ts=20120611T0956431289\">",
"       The American College of Obstetricians and Gynecologists Acquaintance and Date Rape Fact Sheet",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/features/datingviolence/\">",
"       The Centers for Disease Control and Prevention Preventing Teen Dating Violence",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/violenceprevention/pdf/teendatingviolence2012-a.pdf\">",
"       The Centers for Disease Control and Prevention Understanding Teen Dating Violence Fact Sheet",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://mchlibrary.info/knowledgepaths/kp_domviolence.html\">",
"       The Maternal and Child Health Library (Georgetown University) Dating Violence Among Adolescents",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://victimsofcrime.org/help-for-crime-victims/get-help-bulletins-for-crime-victims/bulletins-for-teens/dating-violence\">",
"       The National Center for the Victims of Crime",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.nsvrc.org/\">",
"       The National Sexual Violence Resource Center",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://kidshealth.org/teen/your_mind/relationships/date_rape.html\">",
"       TeensHealth from Nemours",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19095781\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Date rape refers to nonconsensual sexual penetration that occurs between two people who are in a romantic relationship. (See",
"      <a class=\"local\" href=\"#H19095688\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Date rape occurs predominantly in adolescent and young adult women (age 16 through 24 years). Other risk factors for date are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef75628 \" href=\"mobipreview.htm?11/29/11739\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19095695\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other factors that contribute to date rape include acceptance of rape myths (prejudiced, stereotyped, or false beliefs about rape, rape victims, and rapists), strong belief in traditional gender roles, perceptions that forced sexual activity is acceptable in certain circumstances (eg, the victim has led the perpetrator on), the belief that sexual rights and responsibilities are inherent in a dating relationship, and the misperception of nonverbal cues or signals for desired sexual intimacy. (See",
"      <a class=\"local\" href=\"#H64192887\">",
"       'Other contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adolescents and young adults should be provided with anticipatory guidance to prevent date rape. This includes promoting healthy dating relationships by helping patients learn to communicate effectively about sexual beliefs, desires, and boundaries; dispelling rape myths; educating patients to avoid risk factors for date rape; and advising them about what to do if they are sexually assaulted despite their precautions. (See",
"      <a class=\"local\" href=\"#H19095744\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H377866414\">",
"       'Resources'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/1\">",
"      Young A, Grey M, Abbey A, et al. Alcohol-related sexual assault victimization among adolescents: prevalence, characteristics, and correlates. J Stud Alcohol Drugs 2008; 69:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/2\">",
"      Kaufman M, American Academy of Pediatrics Committee on Adolescence. Care of the adolescent sexual assault victim. Pediatrics 2008; 122:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/3\">",
"      Danielson CK, Holmes MM. Adolescent sexual assault: an update of the literature. Curr Opin Obstet Gynecol 2004; 16:383.",
"     </a>",
"    </li>",
"    <li>",
"     Rickert VI, Ryan O, Chacko M. Sexual assault and victimization. In: Adolescent Health Care: A practical guide, 5th ed, Neinstein LS, Gordon C, Katzman D, et al.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.1042.",
"    </li>",
"    <li>",
"     Bureau of Justice Statistics. Violence against women: Estimates from the redesigned survey. file://bjs.ojp.usdoj.gov/content/pub/pdf/FEMVIED.PDF (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/6\">",
"      Lam C, Roman B. When Granny Is the Wolf: Understanding and Approaching College-aged Female Victims of Acquaintance Rape. Psychiatry (Edgmont) 2009; 6:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/7\">",
"      Rickert VI, Wiemann CM. Date rape among adolescents and young adults. J Pediatr Adolesc Gynecol 1998; 11:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/8\">",
"      Porter J, Williams LM. Intimate violence among underrepresented groups on a college campus. J Interpers Violence 2011; 26:3210.",
"     </a>",
"    </li>",
"    <li>",
"     Rennison CM. Bureau of Justice Statistics Special Report. Intimate partner violence and age of victim, 1993-99. file://bjs.ojp.usdoj.gov/content/pub/pdf/ipva99.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/10\">",
"      Rickert VI, Vaughan RD, Wiemann CM. Adolescent dating violence and date rape. Curr Opin Obstet Gynecol 2002; 14:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/11\">",
"      Humphrey JA, White JW. Women's vulnerability to sexual assault from adolescence to young adulthood. J Adolesc Health 2000; 27:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/12\">",
"      Smith PH, White JW, Holland LJ. A longitudinal perspective on dating violence among adolescent and college-age women. Am J Public Health 2003; 93:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/13\">",
"      Peipert JF, Domagalski LR. Epidemiology of adolescent sexual assault. Obstet Gynecol 1994; 84:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/14\">",
"      Violence against women. Relevance for medical practitioners. Council on Scientific Affairs, American Medical Association. JAMA 1992; 267:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/15\">",
"      Koss MP, Gidycz CA, Wisniewski N. The scope of rape: incidence and prevalence of sexual aggression and victimization in a national sample of higher education students. J Consult Clin Psychol 1987; 55:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/16\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/17\">",
"      Blythe MJ, Fortenberry JD, Temkit M, et al. Incidence and correlates of unwanted sex in relationships of middle and late adolescent women. Arch Pediatr Adolesc Med 2006; 160:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/18\">",
"      Rickert VI, Wiemann CM, Vaughan RD, White JW. Rates and risk factors for sexual violence among an ethnically diverse sample of adolescents. Arch Pediatr Adolesc Med 2004; 158:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/19\">",
"      Foshee VA, Benefield TS, Ennett ST, et al. Longitudinal predictors of serious physical and sexual dating violence victimization during adolescence. Prev Med 2004; 39:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/20\">",
"      Lin AJ, Raymond M, Catallozzi M, et al. Relationship violence in adolescence. Adolesc Med State Art Rev 2007; 18:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/21\">",
"      Carroll BC, Raj A, Noel SE, Bauchner H. Dating violence among adolescents presenting to a pediatric emergency department. Arch Pediatr Adolesc Med 2011; 165:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/22\">",
"      Marx BP, Van Wie V, Gross AM. Date rape risk factors: a review and methodological critique of the literature. Aggres Violent Behav 1996; 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/23\">",
"      Muelenhard CL, Linton MA. Date rape and sexual aggression in dating situations: incidence and risk factors. J Counsel Psychol 1987; 34:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/24\">",
"      Miller B, Marshall J. Coercive sex on the university campus. J Coll Student Person 1987; 28:38.",
"     </a>",
"    </li>",
"    <li>",
"     Bureau of Justice Statistics. Sexual assault of young children as reported to law enforcement: Victim, incident, and offender characteristics. file://bjs.ojp.usdoj.gov/content/pub/pdf/saycrle.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/26\">",
"      Vicary JR, Klingman LR, Harkness WL. Risk factors associated with date rape and sexual assault of adolescent girls. Adolescence 1995; 18:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/27\">",
"      Mandoki CA, Burkhart BR. Sexual victimization: is there a vicious cycle? Violence Vict 1989; 4:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/28\">",
"      Wyatt GE, Guthrie D, Notgrass CM. Differential effects of women's child sexual abuse and subsequent sexual revictimization. J Consult Clin Psychol 1992; 60:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/29\">",
"      Watts WD, Ellis AM. Sexual abuse and drinking and drug use: implications for prevention. J Drug Educ 1993; 23:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/30\">",
"      Dembo R, Williams L, Wothke W, et al. The role of family factors, physical abuse, and sexual victimization experiences in high-risk youths' alcohol and other drug use and delinquency: a longitudinal model. Violence Vict 1992; 7:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/31\">",
"      Basile KC, Black MC, Simon TR, et al. The association between self-reported lifetime history of forced sexual intercourse and recent health-risk behaviors: findings from the 2003 National Youth Risk Behavior Survey. J Adolesc Health 2006; 39:752.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/32\">",
"      Champion HL, Foley KL, DuRant RH, et al. Adolescent sexual victimization, use of alcohol and other substances, and other health risk behaviors. J Adolesc Health 2004; 35:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/33\">",
"      Burt MR. Cultural myths and supports for rape. J Pers Soc Psychol 1980; 38:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/34\">",
"      Synovitz LB, Byrne TJ. Antecedents of sexual victimization: factors discriminating victims from nonvictims. J Am Coll Health 1998; 46:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/35\">",
"      Koss MP, Leonard KE, Beezley DA, Oros CJ. Nonstranger sexual aggression: A discrimant analysis of the psychological characteristics of undetected offenders. Sex Roles 1985; 12:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/36\">",
"      Ott MA. Examining the development and sexual behavior of adolescent males. J Adolesc Health 2010; 46:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/37\">",
"      Talbot KK, Neill KS, Rankin LL. Rape-accepting attitudes of university undergraduate students. J Forensic Nurs 2010; 6:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/38\">",
"      Kaestle CE, Halpern CT, Brown JD. Music videos, pro wrestling, and acceptance of date rape among middle school males and females: an exploratory analysis. J Adolesc Health 2007; 40:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/39\">",
"      Koss MP, Dinero TE. Predictors of sexual aggression among a national sample of male college students. Ann N Y Acad Sci 1988; 528:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/40\">",
"      Carr JL, Van Deusen KM. Risk factors for male sexual aggression on college campuses. Journal of Family Violence 2004; 19:279.",
"     </a>",
"    </li>",
"    <li>",
"     White JW, Humphrey JA. A longitudinal approach to the study of sexual assault: theoretical and methodological considerations. In: Researching sexual violence against women: methodological and personal perspectives, Schwartz MD (Ed), Sage Publications, Thousand Oaks, CA 1997. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/42\">",
"      Nurius PS, Norris J. A cognitive ecological model of women's response to male sexual coercion in dating. J Psychol Human Sexual 1996; 8:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/43\">",
"      Muehlenhard CL, Friedman DE, Thomas CM. Is date rape justifiable? The effects of dating activity, who initiated, who paid, and men's attitudes toward women. Psychol Women Q 1985; 9:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/44\">",
"      Basow SA, Minieri A. \"You owe me\": effects of date cost, who pays, participant gender, and rape myth beliefs on perceptions of rape. J Interpers Violence 2011; 26:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/45\">",
"      Botswick TD, Delucia JL. Effects of gender and specific dating behaviors on perceptions of sex willingness and date rape. Journal of Soc Clin Psychol 1992; 11:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/46\">",
"      Meuhlenhard CL. Misinterpreted dating behaviors and the risk of date rape. J Soc Clin Pyschol 1988; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/47\">",
"      Symons PY, Gro&euml;r MW, Kepler-Youngblood P, Slater V. Prevalence and predictors of adolescent dating violence. J Child Adolesc Psychiatr Nurs 1994; 7:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/48\">",
"      Davis TC, Peck GQ, Storment JM. Acquaintance rape and the high school student. J Adolesc Health 1993; 14:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/49\">",
"      Scott CS, Lefley HP, Hicks D. Potential risk factors for rape in three ethnic groups. Community Ment Health J 1993; 29:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/50\">",
"      Rhynard J, Krebs M, Glover J. Sexual assault in dating relationships. J Sch Health 1997; 67:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/51\">",
"      Harrington NT, Leitenberg H. Relationship between alcohol consumption and victim behaviors immediately preceding sexual aggression by an acquaintance. Violence Vict 1994; 9:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/52\">",
"      Canterbury RJ, Grossman SJ, Lloyd E. Drinking behaviors and lifetime incidents of date rape among high school graduates upon entering college. Coll Student J 1993; 27:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/53\">",
"      Abbey A. Acquaintance rape and alcohol consumption on college campuses: how are they linked? J Am Coll Health 1991; 39:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/54\">",
"      Lawyer S, Resnick H, Bakanic V, et al. Forcible, drug-facilitated, and incapacitated rape and sexual assault among undergraduate women. J Am Coll Health 2010; 58:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/55\">",
"      Abbey A, Zawacki T, Buck PO, et al. Alcohol and sexual assault. Alcohol Res Health 2001; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/56\">",
"      Abbey A. Alcohol-related sexual assault: a common problem among college students. J Stud Alcohol Suppl 2002; :118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/57\">",
"      Gross AM, Bennett T, Sloan L, et al. The impact of alcohol and alcohol expectancies on male perception of female sexual arousal in a date rape analog. Exp Clin Psychopharmacol 2001; 9:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/58\">",
"      Abbey A, Ross LT, McDuffie D, McAuslan P. Alcohol and dating risk factors for sexual assault among college women. Psychol Women Quarterly 1996; 20:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/59\">",
"      Adams-Curtis LE, Forbes GB. College women's experiences of sexual coercion: a review of cultural, perpetrator, victim, and situational variables. Trauma Violence Abuse 2004; 5:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/60\">",
"      Romero-S&aacute;nchez M, Meg&iacute;as JL. Alcohol use as a strategy for obtaining nonconsensual sexual relations: incidence in Spanish university students and relation to rape myths acceptance. Span J Psychol 2010; 13:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/61\">",
"      Davis KC, Stoner SA, Norris J, et al. Women's awareness of and discomfort with sexual assault cues: effects of alcohol consumption and relationship type. Violence Against Women 2009; 15:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/62\">",
"      Loiselle M, Fuqua WR. Alcohol's effects on women's risk detection in a date-rape vignette. J Am Coll Health 2007; 55:261.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Substance Abuse Research. Flunitrazepam (Rohypnol) file://www.cesar.umd.edu/cesar/drugs/rohypnol.asp (Accessed on April 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/64\">",
"      Rickert VI, Wiemann CM, Berenson AB. Prevalence, patterns, and correlates of voluntary flunitrazepam Use. Pediatrics 1999; 103:E6.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Substance Abuse Research. Ecstasy. file://www.cesar.umd.edu/cesar/drugs/ecstasy.asp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/66\">",
"      Burgess GH. Assessment of rape-supportive attitudes and beliefs in college men: development, reliability, and validity of the rape attitudes and beliefs scale. J Interpers Violence 2007; 22:973.",
"     </a>",
"    </li>",
"    <li>",
"     Goodchilds JD, Zellman GL, Johnson PB, Giarrusso R. Adolescents and their perceptions of sexual interactions. In: Rape and sexual assault II, Burgess A (Ed), Garland Publishing, 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/68\">",
"      Hall ER. Adolescents' perceptions of sexual assault. J Sex Educat Ther 1987; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/69\">",
"      Cassidy L, Hurrell RM. The influence of victim's attire on adolescents' judgments of date rape. Adolescence 1995; 30:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/70\">",
"      Feltey KM, Ainslie JJ, Geib A. Sexual coercion attitudes among high school students: the influence of gender and rape education. Youth Society 1991; 23:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/71\">",
"      Winslett AH, Gross AM. Sexual boundaries: an examination of the importance of talking before touching. Violence Against Women 2008; 14:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/72\">",
"      Boxley J, Lawrance L, Gruchow H. A preliminary study of eighth grade students' attitudes toward rape myths and women's roles. J Sch Health 1995; 65:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/73\">",
"      Kershner R. Adolescent attitudes about rape. Adolescence 1996; 31:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/74\">",
"      Muehlenhard CL, McNaughton JS. Women's beliefs about women who \"lead men on\". J Soc Clin Psychol 1988; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/75\">",
"      Rickert VI VI, Neal WP, Wiemann CM, Berenson AB. Prevalence and predictors of low sexual assertiveness. J Pediatr Adolesc Gynecol 2000; 13:88.",
"     </a>",
"    </li>",
"    <li>",
"     Lotte IL. Sexual socialization and attitudes toward rape. In: Rape and sexual assault II, Burgess A (Ed), Garland Publishing, New York 1988. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/77\">",
"      Committee on Injury, Violence, and Poison Prevention. Policy statement--Role of the pediatrician in youth violence prevention. Pediatrics 2009; 124:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/78\">",
"      Rickert VI, Vaughan RD, Wiemann CM. Violence against young women: implications for clinicians. Contemp Ob/Gyn 2003; 48:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/79\">",
"      Lonsway KA. Preventing acquaintance rape through education. Psychol Women Quarterly 1996; 20:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/80\">",
"      Sion&eacute;an C, DiClemente RJ, Wingood GM, et al. Psychosocial and behavioral correlates of refusing unwanted sex among African-American adolescent females. J Adolesc Health 2002; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/81\">",
"      Testa M, Hoffman JH, Livingston JA, Turrisi R. Preventing college women's sexual victimization through parent based intervention: a randomized controlled trial. Prev Sci 2010; 11:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/82\">",
"      Rothman EF, Miller E, Terpeluk A, et al. The proportion of U.S. parents who talk with their adolescent children about dating abuse. J Adolesc Health 2011; 49:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/83\">",
"      Craig ME. Coercive sexuality in dating relationships: a situational model. Clin Psychol Rev 1990; 10:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/84\">",
"      Fantasia HC, Fontenot HB. The sexual safety of adolescents. J Obstet Gynecol Neonatal Nurs 2011; 40:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/85\">",
"      ACOG educational bulletin. Adolescent victims of sexual assault. Number 252, October 1998. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999; 64:195.",
"     </a>",
"    </li>",
"    <li>",
"     Carter DL, Prentky R, Burgess A. Victim response strategies in sexual assault. In: Rape and sexual assault II, Burgess A (Ed), Garland Publishing, New York 1988. p.105.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/87\">",
"      Keitner GI, Miller IW, Fruzzetti AE, et al. Family functioning and suicidal behavior in psychiatric inpatients with major depression. Psychiatry 1987; 50:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/88\">",
"      Wolfe DA, Crooks C, Jaffe P, et al. A school-based program to prevent adolescent dating violence: a cluster randomized trial. Arch Pediatr Adolesc Med 2009; 163:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/89\">",
"      Foshee VA, Bauman KE, Greene WF, et al. The Safe Dates program: 1-year follow-up results. Am J Public Health 2000; 90:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/90\">",
"      Foshee VA, Bauman KE, Ennett ST, et al. Assessing the long-term effects of the Safe Dates program and a booster in preventing and reducing adolescent dating violence victimization and perpetration. Am J Public Health 2004; 94:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/91\">",
"      Hanson KA, Gidycz CA. Evaluation of a sexual assault prevention program. J Consult Clin Psychol 1993; 61:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/92\">",
"      Gray MD, Lester D, Quinn E, Bounds C. The effectiveness of personalizing acquaintance rape prevention: programs on perception of vulnerability and on reducing risk-behavior. J Student Dev 1990; 31:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/93\">",
"      Schewe PA, O'Donohue W. Rape prevention with high-risk males: short-term outcome of two interventions. Arch Sex Behav 1996; 25:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/94\">",
"      Foubert JD, Godin EE, Tatum JL. In their own words: sophomore college men describe attitude and behavior changes resulting from a rape prevention program 2 years after their participation. J Interpers Violence 2010; 25:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/95\">",
"      Jaffe PG, Sudermann M, Reitzel D, Killip SM. An evaluation of a secondary school primary prevention program on violence in intimate relationships. Violence Vict 1992; 7:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33385/abstract/96\">",
"      Vladutiu CJ, Martin SL, Macy RJ. College- or university-based sexual assault prevention programs: a review of program outcomes, characteristics, and recommendations. Trauma Violence Abuse 2011; 12:67.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14315 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-DE283444F4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33385=[""].join("\n");
var outline_f32_38_33385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19095781\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35319396\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19095688\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20956908\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19095695\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20956916\">",
"      Victim characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20956924\">",
"      Perpetrator characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20960515\">",
"      Situational factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19095709\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278703864\">",
"      Illicit drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64192887\">",
"      OTHER CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20956954\">",
"      Acceptance of rape myths",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19095737\">",
"      Adolescent perceptions of sexual behavior",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2925465\">",
"      - Strong belief in traditional gender roles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2925472\">",
"      - Acceptability of forced sexual activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2925480\">",
"      - Sexual rights and responsibilities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2925488\">",
"      - Interpretation of nonverbal communication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49773827\">",
"      Cultural considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19095744\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H377866399\">",
"      Anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H116831445\">",
"      - Process",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H116831464\">",
"      - Components",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19095774\">",
"      Prevention programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377866414\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19095781\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/22/11630\" title=\"table 1\">",
"      Dating violence in the US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/29/11739\" title=\"table 2\">",
"      Risk factors for date rape",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/12/15561?source=related_link\">",
"      Date rape: Identification and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/25/31130?source=related_link\">",
"      Gamma hydroxybutyrate (GHB) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40935?source=related_link\">",
"      Ketamine poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21560?source=related_link\">",
"      MDMA (ecstasy) intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/15/11510?source=related_link\">",
"      Management and sequelae of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33386="Mifepristone for the medical termination of pregnancy";
var content_f32_38_33386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mifepristone for the medical termination of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33386/contributors\">",
"     Irving M Spitz, MD, DSc, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33386/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/38/33386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/38/33386/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/38/33386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    (RU-486), an antiprogestin, is indicated for medical termination of pregnancies up to 49 days of gestation. The drug administered alone results in complete termination of pregnancy in 64 to 85 percent of women at this gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Since these efficacy rates are inadequate for general clinical use, a prostaglandin analog is administered after mifepristone. This leads to complete medical abortion in 92 to 98 percent of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/4-12\">",
"     4-12",
"    </a>",
"    ]. The remaining patients undergo surgical evacuation of the pregnancy.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    in combination with other medications for medical termination of pregnancy is reviewed here. Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    -alone for medical abortion and other methods of pregnancy termination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28330?source=see_link\">",
"     \"Misoprostol as a single agent for medical termination of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=see_link\">",
"     \"Overview of pregnancy termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BIOLOGY AND PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biological actions, pharmacology, and additional clinical uses of progesterone antagonists and progesterone receptor modulators are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8952?source=see_link\">",
"     \"Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25866?source=see_link\">",
"     \"Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PROVIDER REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Food and Drug Administration (FDA) requires that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    be prescribed only by physicians (not advanced practice clinicians) who are able to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Make an accurate assessment of gestational age",
"     </li>",
"     <li>",
"      Diagnose ectopic pregnancy",
"     </li>",
"     <li>",
"      Provide surgical intervention in cases of severe bleeding or incomplete abortion",
"      <strong>",
"       or",
"      </strong>",
"      make provisions to provide such care through another provider",
"     </li>",
"     <li>",
"      Assure patient access to medical facilities equipped to perform blood transfusions and resuscitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These physicians:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Must sign a prescriber's agreement with the manufacturer of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"     </li>",
"     <li>",
"      Require that patients read the manufacturer's Medication Guide and sign the Patient Agreement forms",
"     </li>",
"     <li>",
"      Report any ongoing pregnancy or other serious events (eg, hospitalization, blood transfusion).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The components of the patient agreement form are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef81053 \" href=\"mobipreview.htm?36/60/37835\">",
"     table 1",
"    </a>",
"    ). The necessary forms and medication guide are available on-line from the manufacturer (www.earlyoptionpill.com, or telephone 1-877-432-7596).",
"   </p>",
"   <p>",
"    Like the US, in most European countries, only physicians are allowed to prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    . However, a physician may delegate another health professional to administer the drug, but the physician should be on the premises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA has approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for medical termination of intrauterine pregnancy, through day 49 of pregnancy. Use beyond this gestational age is off-label (see",
"    <a class=\"local\" href=\"#H23\">",
"     'After 49 days gestation'",
"    </a>",
"    below). The alternative termination procedure is surgical termination of pregnancy. The advantages and disadvantages of each approach are discussed below (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Comparison with surgical abortion'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The manufacturer's list of contraindications to use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and prostaglandins for medical abortion is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef54726 \" href=\"mobipreview.htm?10/54/11115\">",
"     table 2",
"    </a>",
"    ). There are no data regarding safety and efficacy of mifepristone in women with chronic medical conditions such as cardiovascular, hypertensive, respiratory, hepatic, or renal disease, nor is there information in women with diabetes mellitus, severe anemia, or heavy smoking. Therefore, the drug should be used with caution in these women. Women with severe asthma uncontrolled by glucocorticoids are also not candidates for medical termination of pregnancy. This does not apply to women with mild asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific drug or food interactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    have not been studied. On the basis of this drug's metabolism by cytochrome P450 3A4 (CYP 3A4), it is possible that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , and grapefruit juice may inhibit mifepristone metabolism (increasing serum levels of mifepristone) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , St. John's Wort, and certain anticonvulsants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) may induce mifepristone metabolism (lowering serum levels of mifepristone).",
"   </p>",
"   <p>",
"    In addition, in vitro studies suggest that coadministration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    with drugs that are CYP 3A4 substrates may lead to increased serum levels of these drugs. Due to the slow elimination of mifepristone from the body, such interaction may be observed for a prolonged period after administration. Therefore, caution should be exercised when mifepristone is administered with drugs that are CYP 3A4 substrates and have narrow therapeutic range, including some agents used during general anesthesia.",
"   </p>",
"   <p>",
"    However, it should be noted that, to date, no drug interactions have been reported with the single dose administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    used for pregnancy termination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DRUG ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mifepristone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the manufacturer and the FDA recommend a single dose of 600 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    be given orally for termination of pregnancy, based on the efficacy of this dose in initial research studies. Based on subsequent dose-finding studies that reported that doses as low as 200 mg are equally effective, many providers use the 200 mg dose off-label [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. The efficacy of low doses is explained by the observation that there are no significant dose-dependent differences in serum mifepristone concentrations with oral doses of 200 to 800 mg (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Clinical protocol'",
"    </a>",
"    below). However, use of the 200 mg dose is called into question by a meta-analysis of four randomized controlled trials comparing the 600 and 200 mg dose regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/20\">",
"     20",
"    </a>",
"    ]. The two doses resulted in similar rates of complete abortion with no difference in adverse events. Among women who do not achieve abortion, some will have a continuing pregnancy. In this analysis, use of 200 mg versus 600 mg was associated with an up to 1 percent increase in the continuing pregnancy rate.",
"   </p>",
"   <p>",
"    Although a small study concluded that 100 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    was also effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/18\">",
"     18",
"    </a>",
"    ], this needs to be confirmed in larger series. In other studies, a single 50 mg dose was not able to consistently terminate pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prostaglandin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Misoprostol or gemeprost",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef74657 \" href=\"mobipreview.htm?1/8/1166\">",
"     figure 1",
"    </a>",
"    ), a synthetic prostaglandin E1, is used sequentially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    for medical abortion in the United States. The drug is inexpensive, can be stored at room temperature, and is widely available for the treatment and prevention of nonsteroidal drug-induced peptic ulcer.",
"   </p>",
"   <p>",
"    The gemeprost vaginal pessary can also be used as the prostaglandin (",
"    <a class=\"graphic graphic_figure graphicRef74657 \" href=\"mobipreview.htm?1/8/1166\">",
"     figure 1",
"    </a>",
"    ). However, it is expensive and thermolabile, and is not registered for use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    used for medical abortion range from 400 to 800 mcg; the buccal dose is 800 mcg; the vaginal dose is 800 mcg (four 200 mcg tablets are placed intravaginally). In the United States, the only FDA approved protocol for prostaglandin administration for medical abortion is 400 mcg of oral misoprostol.",
"   </p>",
"   <p>",
"    The usual dose of gemeprost is 1 mg, although 0.5 mg is also effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/23\">",
"     23",
"    </a>",
"    ]. A study comparing the efficacy of gemeprost and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    in the same clinic in women with a duration of gestation of 63 days found that the number of ongoing pregnancies was higher with oral misoprostol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Route of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several routes of administration for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , including: oral, buccal (holding the pills next to the inside of the cheek), sublingual, and vaginal. While the FDA has approved only oral administration for medical termination of pregnancy, use of buccal dosing is increasing.",
"   </p>",
"   <p>",
"    The vaginal route has been widely used in the United States because it is more effective than oral dosing and is associated with fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/24\">",
"     24",
"    </a>",
"    ]. However, it appears that vaginal dosing is associated with an increased risk of serious infection, including a possible role in rare cases of death after medical abortion (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Infection'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, women prefer oral administration to vaginal because of convenience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Patient satisfaction appears to be similar for both oral and buccal dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaginal versus oral administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    results in decreased time to expulsion and higher complete abortion rates for pregnancies &gt;49 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/4,6,24,30-36\">",
"     4,6,24,30-36",
"    </a>",
"    ]. The greater efficacy of the vaginal route is likely due to the increased bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, vaginal administration is associated with fewer gastrointestinal side effects than oral and sublingual administration. However, vaginal administration may be linked to an increased risk of infection (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Side effects and complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Infection'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The differences between oral and vaginal administration were illustrated in a World Health Organization double blind, randomized trial of early medical abortion (n = 2219 women) using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    followed by one of three",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    regimens 72 hours later: (1) 800 mcg orally then 400 mcg orally twice daily for seven days, (2) 800 mcg per vaginam then 400 mcg orally twice daily for seven days, or (3) 800 mcg per vaginam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Oral administration was associated with more side effects (diarrhea, vomiting, nausea) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/34\">",
"     34",
"    </a>",
"    ]. For pregnancies under 57 days, there were no differences among groups in the rate of failure to achieve complete pregnancy termination; however, the",
"    <span class=\"nowrap\">",
"     vaginal/oral",
"    </span>",
"    regimen resulted in significantly fewer continuing pregnancies at gestational ages greater than 57 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Buccal administration combines the benefits of both oral and vaginal dosing. The buccal route is the most similar physiologically to vaginal; serum levels peak late and remain elevated for a long period of time. Another oral route, sublingual dosing, has similar pharmacokinetics to oral, there is a rapid peak in serum level, which decreases in one to three hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28330?source=see_link&amp;anchor=H2#H2\">",
"     \"Misoprostol as a single agent for medical termination of pregnancy\", section on 'Pharmacokinetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Buccal dosing appears to perform similarly to vaginal dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, buccal dosing appears to be associated with fewer serious infections than vaginal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/25\">",
"     25",
"    </a>",
"    ]. Randomized trials comparing buccal administration with oral or with vaginal have found similar efficacy up to 57 days of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/29,39\">",
"     29,39",
"    </a>",
"    ]. However, the trial comparing buccal with oral dosing found that buccal had significantly higher rates of complete abortion in pregnancies from 57 to 63 days (95 versus 85 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/29\">",
"     29",
"    </a>",
"    ]. Buccal administration was associated with a slight increase in nausea over either oral or vaginal dosing. Patient satisfaction was high across all routes.",
"   </p>",
"   <p>",
"    Patient instructions for buccal dosing are as follows: place two",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    200 mcg tablets inside each cheek (total 800 mcg). Swallow any remaining pill fragments after 30 minutes.",
"   </p>",
"   <p>",
"    Initial results for sublingual dosing are also promising. A randomized trial comparing sublingual with vaginal dosing in pregnancies up to 63 days of gestation showed a slightly higher complete abortion rate with sublingual versus oral dosing (99 versus 94 percent); however, fever and chills were significantly increased in the sublingual group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is typically given 48 hours after ingesting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H28\">",
"     'Clinical protocol'",
"    </a>",
"    below). The addition of a second dose of misoprostol after three to four hours increases side effects, but may decrease the rate of ongoing pregnancy, especially at later gestational ages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/10,33,41\">",
"     10,33,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Varying administration intervals from 24 to 72 hours does not appear to affect efficacy. Similar success rates were observed when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (800 mcg by the vaginal route) was administered 24, 48, and 72 hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (200 mg) to women with gestation duration of up to 56 days, suggesting that the drug may be given 24 to 72 hours after mifepristone administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/42\">",
"     42",
"    </a>",
"    ]. In a systematic review comprising five randomized medical abortion trials including 4793 participants, it was shown that the interval between oral mifepristone and misoprostol 800 mcg vaginally could be decreased from 48 to 24 hours without a reduction in efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/43\">",
"     43",
"    </a>",
"    ]. This flexibility in dosing increases convenience for women, since they can schedule their abortion accordingly when time permits and a support person is available. There are no data on misoprostol administration more than 72 hours after mifepristone. Since the effectiveness may be lower after 72 hours, women should clearly understand that they must return to the clinic at the prescribed time.",
"   </p>",
"   <p>",
"    Randomized trials data are inconsistent regarding whether efficacy is decrease when the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    administration interval is shortened to 6 to 8 hours compared with 24 to 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. In one trial, shortening the interval between mifepristone and oral misoprostol (400 mcg) administration to six to eight hours reduced the number of complete abortions within 24 hours of prostaglandin administration from 91 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/47\">",
"     47",
"    </a>",
"    ]. On the other hand, in the Medical Abortion at the Same Time (MAST) trial, 1128 subjects up to 63 days gestation were given mifepristone (200 mg) and then randomly assigned to receive misoprostol (800 mg vaginally) immediately in the office or 24 hours later at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/44\">",
"     44",
"    </a>",
"    ]. The rate of complete abortion after immediate and delayed administration was 95.1 and 96.9 percent, respectively, showing that outcome with immediate administration was at least as effective as delayed administration. However, simultaneous therapy was associated with an increased frequency of nausea, diarrhea, and",
"    <span class=\"nowrap\">",
"     warmth/chills.",
"    </span>",
"    A meta-analysis comprising five randomized controlled trials compared the efficacy of mifepristone and misoprostol administration intervals between 0 and 72 hours in 5139 participants. This showed no statistically significant difference in efficacy between shorter and longer dosing intervals, although there was a trend toward slightly lower success rates with administration intervals earlier than eight hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When gemeprost is used as the prostaglandin, the success rate is identical when it is administered 24 or 48 hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Provider versus self administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is often given by the health provider, which is the FDA approved protocol; however, in many areas self-administration is allowed and in common practice (eg, Planned Parenthood Federation of America) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects following administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    primarily consist of pain, excessive bleeding, and gastrointestinal discomfort. Other adverse events, which occur rarely, include headache, dizziness, back pain, fever, chills, and fatigue.",
"   </p>",
"   <p>",
"    The FDA approved",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"      mifepristone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"      misoprostol",
"     </a>",
"    </span>",
"    for early pregnancy termination in September 2000. Since its approval, the manufacturer has reported that more than 460,000 procedures using mifepristone have been performed in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/50\">",
"     50",
"    </a>",
"    ]. As of November 2004, post-marketing experience reported to the FDA included 676 adverse events in patients who had taken mifepristone for medical termination of pregnancy. Adverse events appear to be related to pregnancies of longer duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/8,10,12,51\">",
"     8,10,12,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse events ranged from minor symptoms, such as nausea and dizziness, to more serious problems, including sepsis and death. In particular, 17 women had ectopic pregnancies, 72 women experienced blood loss requiring transfusions, and seven women serious bacterial infections. The cause of these events cannot be attributed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    with certainty because of information gaps about patient health status, clinical management of the patient, concurrent drug use, and other possible medical or surgical treatments. In addition, this generalizability of these data is limited, since they were obtained through voluntary reporting and the total number of patients who did not report use of mifepristone with or without adverse effects is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain and cramps are the most common side effects. Nearly all women complain of abdominal pain, many receive one or more medications for pain relief. The requirements for opioid medications appear to be less with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    combination therapy than when high doses of prostaglandins are used alone to terminate pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/11,16\">",
"     11,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In theory, nonsteroidal anti-inflammatory drugs (NSAIDs), including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , should be avoided for analgesia after prostaglandin administration since a decrease in efficacy of abortion could potentially occur due to the antiprostaglandin properties of these drugs. However, in a study of medical abortion that looked at this issue, NSAIDs did not interfere with the action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    to induce uterine contractions and pregnancy expulsion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/52\">",
"     52",
"    </a>",
"    ]. In another study in women with a duration of gestation of 13 to 22 weeks, co-treatment with an NSAID and misoprostol did not interfere with the action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    misoprostol to induce uterine contractions and pregnancy expulsion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/53\">",
"     53",
"    </a>",
"    ]. In a small double-blind randomized trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    was found to be more effective than paracetamol for pain reduction during first trimester medical abortion and there were no differences in the failure rate in the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Excessive or prolonged bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding is common and typically heavier than a period, but not usually excessive (",
"    <a class=\"graphic graphic_figure graphicRef56315 \" href=\"mobipreview.htm?36/3/36926\">",
"     figure 2",
"    </a>",
"    ). In one study, the mean fall in hemoglobin was 0.7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and fewer than 8 percent of patients had a loss exceeding 2",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/55\">",
"     55",
"    </a>",
"    ]. When objectively measured, blood loss ranged from 84 to 101 mL compared to a mean loss of 53 mL in women undergoing surgical abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/56\">",
"     56",
"    </a>",
"    ]. Blood loss is greater among pregnancies of longer duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mean duration of bleeding in women undergoing medical termination of pregnancy ranges from 8 to 17 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14\">",
"     14",
"    </a>",
"    ], but may be more prolonged. In one study, as an example, 9 percent of women still reported mild bleeding after 30 days and 1 percent after 60 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. The perception among women is that the bleeding is more pronounced after medical than surgical abortion because of the duration, rather than the volume, of blood loss. The prolonged bleeding is troubling to many women; attempts to reduce this by administration of an oral contraceptive or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    were ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood loss usually is not severe enough to require therapy, but may be treated with vasoconstrictor drugs, curettage, or intravenous administration of saline, if necessary. Blood transfusion is rarely required and occurred in only 0.12 percent of women (38 out of 29,720) in one large review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal discomfort",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea, vomiting, and diarrhea are also frequently reported adverse events and are a consequence of the prostaglandin component of the regimen. Nausea occurs in 34 to 72 percent of women, vomiting in 12 to 41 percent, and diarrhea in 3 to 22 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14\">",
"     14",
"    </a>",
"    ]. Women subjectively describe approximately 20 percent of these gastrointestinal side effects as severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. The incidence of gastrointestinal discomfort also rises with increase in duration of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of nausea and vomiting appears to be higher after oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    than after vaginal gemeprost, but the pain associated with misoprostol is less than with gemeprost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies report fewer side effects with vaginal, as opposed to oral,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/4,24,28\">",
"     4,24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of endometritis following medical abortion is lower than after surgical abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, infection with Clostridium sordelli is responsible for a small number of deaths following medical abortion. The initial report was of four septic deaths that occurred in California within one week after medical abortion. Clostridium sordellii infection was diagnosed in each [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/59\">",
"     59",
"    </a>",
"    ]. Subsequently, five more deaths from clostridial sepsis following medical abortion in the United States or Canada have been reported, two from Clostridium perfringens and three from Clostridium sordelli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. With one exception, all of the septic deaths involved the off-label dosing regimen consisting of 200 mg of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    followed by 800 mcg of intravaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . One of the patients with Clostridium perfringens infection received laminaria and vaginal misoprostol but no mifepristone to terminate a 19-week gestation. No abortion-related deaths from Clostridial infection have been reported in Europe, where mifepristone is widely used.",
"   </p>",
"   <p>",
"    Reports are rare of fulminant lethal clostridial sepsis in women of childbearing age, but there is generally an association with childbirth, abortion, or cervical or uterine procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/59,64\">",
"     59,64",
"    </a>",
"    ]. Sepsis related to Clostridium sordellii is unusual because of its subtle clinical manifestations and rapid progression to death (death within three days of hospitalization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients with Clostridium sordellii sepsis following abortion generally presented without fever, bacteremia, rash, or significant findings on pelvic examination, but did have dramatic leukocytosis with a marked left shift, hemoconcentration, tachycardia, hypotension crampy abdominal pain,",
"    <span class=\"nowrap\">",
"     pleural/peritoneal",
"    </span>",
"    effusion, and general malaise (weakness, nausea, vomiting, diarrhea). Gas gangrene was not noted. The organism can be difficult to identify because of fastidious anaerobic growth, variable staining characteristics, and complex biochemical profiles.",
"   </p>",
"   <p>",
"    Optimal therapy is unproven, but probably includes surgical debridement, removal of infected organs (eg, hysterectomy), and antibiotics with good anaerobic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=see_link&amp;anchor=H9#H9\">",
"     \"Toxic shock syndrome due to Clostridium sordellii\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A causal relationship between sepsis and the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    has not been established. The FDA is working with the manufacturers of mifepristone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    tablets to conduct special tests to ensure there is no contamination of either product with Clostridium sordellii. Because of the adverse events described above, the FDA required that a black box warning be included as part of mifepristone drug information.",
"   </p>",
"   <p>",
"    Over 1.5 million women in Europe have used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    . Two deaths have been reported, neither related to infection. One hypothesis for absence of similar cases of Clostridium sordellii infection in these women is that vaginal dosing is uncommon in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/26\">",
"     26",
"    </a>",
"    ] and prophylactic antibiotic treatment is often given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/26,66\">",
"     26,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, physiologic explanations for the development of serious infection have been proposed. Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    induce cervical dilation. Studies in rats show that cervical dilation with mifepristone may allow for ascending infection of necrotic decidual tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endocrinologic and immune mechanisms may also interact to increase the risk of infection in women undergoing",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"      mifepristone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"      misoprostol",
"     </a>",
"    </span>",
"    abortion. Mifepristone-induced glucocorticoid receptor blockade may result in an inappropriate cytokine response of the immune system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/65\">",
"     65",
"    </a>",
"    ]. Toxins from C sordellii may also repress glucocorticoid activity. Mifepristone and toxins additively prevent glucocorticoid suppression of tumor necrosis factor alpha (TNF alpha), therefore interfering with the immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/68\">",
"     68",
"    </a>",
"    ]. Misoprostol may suppress the immune reaction to clostridial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, there have been 10 deaths possibly related to",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"      mifepristone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"      misoprostol",
"     </a>",
"    </span>",
"    use in North America. One death was related to a ruptured ectopic pregnancy and nine deaths were associated with septic shock following medically induced abortion with mifepristone (200 mg) and vaginal misoprostol (800 mcg vaginally). One additional woman received laminaria and misoprostol to terminate a pregnancy of 19 weeks of gestation. This woman did not receive mifepristone (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Infection'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Despite these reports of adverse events, the total experience in the western world indicates that the fatality rate for medical abortion does not appear to be significantly higher than that of surgical abortion (case fatality rate",
"    <span class=\"nowrap\">",
"     0.6/100,000",
"    </span>",
"    legal induced abortions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/71,72\">",
"     71,72",
"    </a>",
"    ] and is much lower than that of pregnancy (12 maternal",
"    <span class=\"nowrap\">",
"     deaths/100,000",
"    </span>",
"    live births). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40888?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of maternal mortality\", section on 'Maternal mortality ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 71 cases of continuing pregnancy after failed medical termination of pregnancy reported malformations in eight cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/73\">",
"     73",
"    </a>",
"    ]. Prostaglandins, notably",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , have been associated with development of congenital abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/74\">",
"     74",
"    </a>",
"    ]. The malformations have included scalp or skull defects, cranial nerve palsies (Mobius syndrome), and limb deficiencies (eg, equinovarus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/75-78\">",
"     75-78",
"    </a>",
"    ]. The rise in uterine pressure related to uterine contractions or vascular spasm may be the mechanism leading to these teratogenic effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/75-78\">",
"     75-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most studies of medical termination of pregnancy, the number of women lost-to-follow-up ranges from 0.6 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14\">",
"     14",
"    </a>",
"    ], although it reached 11 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/79\">",
"     79",
"    </a>",
"    ]. The need for medical confirmation of pregnancy termination must be emphasized to users of this method, and women must be informed of the possibility of congenital abnormalities in the event that pregnancy continues. Because of a potential teratogenic risk, surgical abortion is recommended in cases of failed pregnancy termination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CLINICAL EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Up to 49 days gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The successful completion of medical abortion in pregnancies up to 49 days of gestation (presumed 28-day cycle) ranges from 92 to 98 percent; similar results have been reported with both gemeprost and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . The lower success rate of 92 percent described in one large multicenter United States trial may be related to the lack of experience with medical abortion, as well as stringent criteria for success (",
"    <a class=\"graphic graphic_figure graphicRef65526 \" href=\"mobipreview.htm?10/7/10367\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. The table also lists the reasons for failure of medical termination of pregnancy in this latter study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete expulsion before prostaglandin administration occurred in 1 to 5 percent of women in the United States trial, the frequency was higher at earlier gestations (",
"    <a class=\"graphic graphic_figure graphicRef65526 \" href=\"mobipreview.htm?10/7/10367\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. Similar results were noted in the French trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/7\">",
"     7",
"    </a>",
"    ]. Another 44 to 78 percent of women aborted in the four-hour observation period after oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef79736 \" href=\"mobipreview.htm?10/53/11102\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. The percentage was higher after vaginal, as opposed to oral, misoprostol (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Route of administration'",
"    </a>",
"    above)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     After 49 days gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    is not approved in the United States for pregnancies over 49 days because initial research reported a lower success rate beyond this gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/8,12,17\">",
"     8,12,17",
"    </a>",
"    ]; oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was used with mifepristone in these studies (",
"    <a class=\"graphic graphic_figure graphicRef65526 \" href=\"mobipreview.htm?10/7/10367\">",
"     figure 3",
"    </a>",
"    ). By comparison, success remained high (94 to 97 percent) until 63 days of gestation when gemeprost (0.5 or 1 mg) or vaginal misoprostol (800 mcg) was given 48 hours after mifepristone (200 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/4,9,11,14,51\">",
"     4,9,11,14,51",
"    </a>",
"    ]. Vaginal misoprostol was associated with fewer failures than gemeprost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    administered with vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    at later gestational ages has been confirmed in several series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      70 to 83 days &mdash; A small trial using 200 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      followed by 800 mcg vaginal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      reported successful medical termination of pregnancy in 97 percent of pregnancies at gestational ages 70 to 76 days and 90 percent of those at 77 to 83 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      64 to 91 days &mdash; Medical abortion has also been investigated at later gestational ages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/82,85\">",
"       82,85",
"      </a>",
"      ]. In another study, investigators administered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      (200 mg) first and then administered up to five doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (800 mcg per vaginam initially and then 400 mcg either intravaginally or orally every three hours) to 483 women at 64 to 91 days of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/82\">",
"       82",
"      </a>",
"      ]. Successful medical termination was achieved in 95 percent of pregnancies, with efficacy declining and the ongoing pregnancy rate increasing with advancing gestational age. Surgical evacuation was required in one woman",
"      <span class=\"nowrap\">",
"       (1/106)",
"      </span>",
"      at 9 to 10 weeks, but nine",
"      <span class=\"nowrap\">",
"       (9/114)",
"      </span>",
"      of those at 12 to 13 weeks. There were no major complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The higher rate of surgical intervention with advancing gestational age in the first trimester may be acceptable to some women. Therefore, several countries (eg, United Kingdom, Sweden, and Russia) and some abortion sites in the United States have extended the time period for using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    to up to 63 days after the first day of the last menstrual period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Failure of medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of failure of medical termination are incomplete abortion (5 percent), excessive bleeding (3 percent), and ongoing pregnancy (1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. The incidence of ongoing pregnancy increases progressively with the duration of gestation when oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is the prostaglandin (",
"    <a class=\"graphic graphic_figure graphicRef65526 \" href=\"mobipreview.htm?10/7/10367\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/8,9,12,17\">",
"     8,9,12,17",
"    </a>",
"    ], but not with gemeprost or vaginal misoprostol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failures can be treated with an additional dose of prostaglandin or surgical evacuation, at any time from 4 hours to 12 days after administration of the prostaglandin. As an example, in a large case series, more than half of women expelled a retained gestational sac after receiving an additional vaginal dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ; the few patients with persistent cardiac activity had a lower expulsion rate (5 of 14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On occasion, surgical intervention may be required for other medical reasons (eg, severe pain or vomiting) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of successful abortion is lower with increasing parity and in women who have had a previous abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. It is possible that pregnancy is better established at an earlier gestational stage in parous women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/33,87,88\">",
"     33,87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Implications for future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that medical termination of pregnancy is associated with any increased risk of adverse outcome in subsequent pregnancies. Two studies from China did not find an increased risk of low birth weight in nulliparous women in the pregnancy after a medically induced abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. A well-designed study from Denmark compared the outcome of a subsequent pregnancy in women with a history of medical or surgical first trimester pregnancy termination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/91\">",
"     91",
"    </a>",
"    ]. Both groups had similar rates of miscarriage, ectopic pregnancy, preterm birth, and low birth weight in the first pregnancy after their abortion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COMPARISON WITH SURGICAL ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First trimester vacuum aspiration is 98 to 99 percent effective in terminating pregnancy, with an overall complication rate of nine events per 1000 procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/92\">",
"     92",
"    </a>",
"    ]. The surgical procedure is quick and takes place in a health care facility or office. The major surgical complications are uterine perforation, problems related to anesthesia, and endometritis. Failures invariably occur at very early gestational ages; some physicians will not perform vacuum aspiration until at least seven weeks of gestation for this reason [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/93\">",
"     93",
"    </a>",
"    ]. In contrast, the efficacy of medical termination is high in very early pregnancies; this represents a distinct advantage and provides an effective option at this gestational age. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4453?source=see_link\">",
"     \"Surgical termination of pregnancy: First trimester\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is critical that women understand the need to follow up and complete the abortion process, whether a medical or surgical procedure is chosen. However, the teratogenic risk to an ongoing pregnancy is higher with medical than surgical abortion.",
"   </p>",
"   <p>",
"    The overall success rate of medical abortion is not quite as high as its surgical counterpart, and surgical aspiration may still be required in 2 to 10 percent of women, but the medical procedure appears to be as safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Other advantages of medical abortion are that anesthesia is not required, there is higher acceptability (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Acceptability'",
"    </a>",
"    below), and more privacy. Some women prefer the control of aborting at home, while others find this experience lonely and frightening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medical methods require greater involvement from the women, such as more clinic visits and a longer time commitment, since the procedure can extend over several days. In addition, women having a medical abortion had more bleeding, nausea, vomiting, and pain than those who underwent vacuum extraction when these two procedures were compared in the same study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A further disadvantage of medical abortion is that in many European countries where this method is available, a three-hour clinic stay after administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is required. This is often prolonged to six hours when gemeprost is used. A clinic stay is not required in the United States.",
"   </p>",
"   <p>",
"    There are data showing that a clinic stay after prostaglandin administration might be unnecessary in women with duration of gestation &lt;49 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/98\">",
"     98",
"    </a>",
"    ]. In one multicenter study using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (600 mg) and oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (400 mcg), the incidence of serious adverse events requiring emergency department visits or hospitalization was not greater on the day of prostaglandin administration in those women with duration of gestation of less than 49 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"     12",
"    </a>",
"    ]. However, women with gestations of greater than 49 days had the majority of their major complications on the day of prostaglandin administration. In contrast, another US-conducted study reported that home administration of vaginal misoprostol following mifepristone was safe and acceptable to women with gestations up to 63 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Acceptability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient satisfaction is a complicated, difficult to measure outcome and is likely affected by personal circumstances, general coping strategies, and preprocedure counseling and expectations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/99\">",
"     99",
"    </a>",
"    ]. Women who refuse the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"      mifepristone",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"      misoprostol",
"     </a>",
"    </span>",
"    medical method usually do so because it requires too many visits and drags on too long.",
"   </p>",
"   <p>",
"    An acceptability study found that women who underwent medical abortion reported greater satisfaction than those who had surgical abortion at the same clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/100\">",
"     100",
"    </a>",
"    ]. If a future abortion was required, 42 percent of patients who underwent a surgical abortion would opt for a medical abortion; in contrast, only 9 percent of women who received medical abortion would prefer a surgical abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/100\">",
"     100",
"    </a>",
"    ]. However, others have reported greater satisfaction with surgical abortion.",
"   </p>",
"   <p>",
"    Medical abortion becomes more painful and less effective in women with gestations over 50 days, particularly in those using oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . Therefore, these women are likely to find vacuum extraction more acceptable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     CLINICAL PROTOCOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Details describing the provision of abortion services are reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Three clinic visits are suggested.",
"   </p>",
"   <p>",
"    There are basically two protocols in clinical use:",
"   </p>",
"   <p>",
"    (1) FDA",
"    <span class=\"nowrap\">",
"     approved/manufacturer",
"    </span>",
"    recommended regimen, which is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (600 mg orally), followed by 48 hours later by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (400 mcg orally) administered by a health care provider.",
"   </p>",
"   <p>",
"    (2) Alternative regimen (also called the evidence-based regimen), which is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (200 mg orally), followed 48 hours later by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (800 mcg vaginally) administered either by a health care provider or self-administered in the home.",
"   </p>",
"   <p>",
"    The alternative protocol and FDA",
"    <span class=\"nowrap\">",
"     approved/manufacturer",
"    </span>",
"    recommended protocols are equally effective. The alternative protocol had been endorsed by Planned Parenthood Federation of America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/71\">",
"     71",
"    </a>",
"    ], and has probably been more widely used than the FDA",
"    <span class=\"nowrap\">",
"     approved/manufacturer",
"    </span>",
"    recommended regimen. The advantage of the alternative regimen is a lower frequency of side effects and fewer ongoing pregnancies. In this alternative evidence-based regimen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was administered vaginally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, due to several deaths due to clostridial sepsis in the United States in patients who received vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    , some organizations, such as Planned Parenthood (the largest abortion provider in the United States), are now using either oral or buccal misoprostol and have introduced the use of prophylactic antibiotics (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Infection'",
"    </a>",
"    above). This protocol change was described in an observational study conducted by Planned Parenthood of over 227,000 women with gestational ages up to 63 days who underwent",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"      mifepristone",
"     </a>",
"     /misoprostol",
"    </span>",
"    abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/25\">",
"     25",
"    </a>",
"    ]; the risk of serious infection decreased from 0.93 to 0.06 per 1000 women with use of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg orally twice a day for seven days, starting on the day of mifepristone administration) versus no antimicrobial prophylaxis. Doxycycline provides coverage for chlamydia, most gonorrhea strains, and has in vitro efficacy against Clostridium sordellii (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Infection'",
"    </a>",
"    above). During the time period of the study, the route of administration was also changed from vaginal to buccal; therefore, it is possible that this is also partially responsible for the decrease in infection rate.",
"   </p>",
"   <p>",
"    In view of these encouraging results, Planned Parenthood currently recommends the following protocol for all women having medical abortion at their clinics throughout the United States:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    200 mg orally followed 24 to 48 hours later by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . Women can choose between oral misoprostol (400 mcg) if they have amenorrhea of 49 days or less or buccal misoprostol (800 mcg) if they have amenorrhea up to 63 days. Misoprostol is self-administered by the women at home. All women are routinely given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg oral twice a day for seven days, beginning on the day the woman receives mifepristone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     First clinic visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first clinic visit is used to assess a woman's eligibility for medical abortion and to dispense",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirmation of pregnancy &mdash; Pregnancy should be confirmed by urinary or serum human chorionic gonadotropin measurement (hCG) or vaginal ultrasonography. Contraindications to medical termination of pregnancy are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef54726 \" href=\"mobipreview.htm?10/54/11115\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Counseling and consent &mdash; The nature of the procedure is fully explained to the woman and she is given the Patient Agreement and Medication Guide to review and discuss with her provider. These forms are available on-line from the manufacturer (www.earlyoptionpill.com, or telephone 1-877-432-7596).",
"     </li>",
"     <li>",
"      Patient preparation &mdash; Rh typing should be performed. An intrauterine device, if present, should be removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Planned Parenthood now routinely administers prophylactic antibiotics, as noted in the preceding section. According to some experts, there is still insufficient information to recommend the use of prophylactic antibiotics in women undergoing medical abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/104\">",
"     104",
"    </a>",
"    ]. The reasons include the fact that the risk of fatal sepsis in these women is rare (estimated as about 1 in 100,000) and endometritis is uncommon (less than 1 percent). Prophylactic antibiotic use carries its own risk and may also stimulate the growth of antibiotic resistant bacteria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of gestational age &mdash; The duration of gestation is defined as the number of days from the first day of the last menstrual period (LMP). Gestational age must be carefully determined since the duration of gestation is critical to deciding whether a woman is a candidate for medical termination of pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaginal ultrasonography is the most reliable method for estimation of gestational age and in the US, this is almost always used. The duration of pregnancy may also be determined from menstrual history and clinical examination in women with regular cyclic menses, known LMP, and uterine size consistent with menstrual dates. The LMP may not be reliable for gestational age estimation of the woman who has used estrogen-progestin contraceptives within three months of conception. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If vaginal ultrasonography is not routinely available or is cost prohibitive, it should still be performed to verify the gestational age is no more than 63 days gestation whenever the history and examination are not concordant. If no gestational sac is apparent at the initial ultrasound, it should be repeated after a few days.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclusion of ectopic pregnancy &mdash; The overall risk of undiagnosed ectopic pregnancy during medical abortion treatment is low (0.02 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/105\">",
"       105",
"      </a>",
"      ]. Unless there is a strong suspicion because of clinical findings or the patient's history, there is no indication for a work-up for an ectopic pregnancy (Creinin, personal communication). However, vaginal sonography should be performed in women at high risk for or suspected of an ectopic pregnancy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       Mifepristone",
"      </a>",
"      is NOT an effective treatment for extrauterine gestations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=see_link\">",
"       \"Incidence, risk factors, and pathology of ectopic pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      &mdash; The woman is given mifepristone if she meets eligibility criteria (",
"      <a class=\"graphic graphic_table graphicRef60393 \" href=\"mobipreview.htm?3/5/3163\">",
"       table 3",
"      </a>",
"      ) and after she consents to the procedure. She is then sent home with instructions to return to the clinic two days later. Approximately 1 to 6 percent of patients will expel the conceptus prior to the second clinic visit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Second clinic visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient returns to the clinic on day three of the protocol.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is administered unless abortion has occurred and been confirmed. At many sites, the patient self-administers at home the misoprostol that she was given on the day of the first visit, so this clinic visit is omitted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately two-thirds of women will pass the products of conception within four hours of receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef79736 \" href=\"mobipreview.htm?10/53/11102\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Analgesic, antiemetic, and antidiarrheal medicines can be taken, as required. The woman should be given instructions regarding side effects and what to do if significant pain, bleeding, or other adverse reactions develop. As an example, she should call if she soaks two pads per hour for two hours and is still bleeding. She should also be given a telephone number to call with questions or in case of an emergency.",
"   </p>",
"   <p>",
"    For pain, a NSAID can be given initially. If pain is unrelieved, 30 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    can be taken every 30 to 60 minutes for a maximum of 150 mg over two hours. A cumulative total dose of 300 mg in 24 hours may be prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rh negative women should receive Rh immune globulin, which may be given on the visit that the patient is given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .) As discussed above, there appears to be no difference in efficacy if vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    is given 24 or 48 hours after mifepristone. A slight decrease in efficacy is seen if the vaginal prostaglandin is given eight hours after the antiprogestin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/43,48\">",
"     43,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Third clinic visit",
"    </span>",
"    &nbsp;&mdash;&nbsp;A final visit is conducted in approximately two weeks to ensure that the pregnancy was terminated and absence of complications. Clinical examination (uterine size and consistency) alone can be used for confirmation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/108\">",
"     108",
"    </a>",
"    ]. Ultrasound assessment to confirm absence of a gestational sac is obtained if there is uncertainty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Debris in the uterus without a gestational sac, pain, fever, or excessive vaginal bleeding does not usually require intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/110\">",
"     110",
"    </a>",
"    ]. Vaginal bleeding and cramping are not sufficient evidence that the pregnancy has been terminated, but lack of bleeding following medical treatment can be a sign of ongoing pregnancy.",
"   </p>",
"   <p>",
"    Determination of a single hCG concentration is not useful as it may remain elevated for weeks after complete abortion. However, an hCG measurement that falls to less than 20 percent of its preprocedure value generally indicates successful pregnancy termination (absence of an ongoing intrauterine or ectopic pregnancy or gestational trophoblastic disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometrial thickness on transvaginal ultrasound is not a clinically useful predictor for the subsequent need for surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/112-116\">",
"     112-116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have had a failure of medical abortion are offered surgical evacuation. The procedure is performed using mini-suction and a 3 to 7 mm cannula, usually without further cervical dilation.",
"   </p>",
"   <p>",
"    Another pregnancy can occur after successful medical termination of pregnancy, even before resumption of normal menses. Therefore, contraception should be initiated as soon as the pregnancy termination has been confirmed or before the woman resumes sexual intercourse. A full discussion of post-termination contraception can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=see_link\">",
"     \"Postpartum and postabortion contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     ALTERNATIVE MEDICAL METHODS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by vaginal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (800 mcg) three to seven days later also terminates pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/71\">",
"     71",
"    </a>",
"    ], but the process can be prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14,117-119\">",
"     14,117-119",
"    </a>",
"    ]. In one study, 23 percent of women who aborted did so after a mean delay of 24 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/119\">",
"     119",
"    </a>",
"    ]. It is not recommended for pregnancies over 49 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    given alone is less effective than when given in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/120\">",
"     120",
"    </a>",
"    ]; however, the use of misoprostol alone is a reasonable option in settings where mifepristone is not available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28330?source=see_link\">",
"     \"Misoprostol as a single agent for medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     CURRENT STATUS OF METHODS FOR MEDICAL ABORTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This medical approach to pregnancy termination has been approved in over 35 countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/38/33386/abstract/121\">",
"     121",
"    </a>",
"    ]. In most,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    is approved for use at gestational ages up to 49 days; in the United Kingdom, Sweden, and Russia, the method is approved for use in pregnancies up to 63 days. Contrary to expectation, the legalization of medical interruption of pregnancy has not been associated with an increase in the demand for abortion.",
"   </p>",
"   <p>",
"    In developed countries, medical abortion offers women an alternative to surgical abortion. In developing countries, surgical abortion may not be an option because physicians may not have adequate facilities or training to perform even minor elective surgical procedures. For these women, medical termination of pregnancy may be the only practical alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/11/29874?source=see_link\">",
"       \"Patient information: Abortion (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/47/42739?source=see_link\">",
"       \"Patient information: Abortion (pregnancy termination) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       Mifepristone",
"      </a>",
"      is indicated for medical termination of intrauterine pregnancy. It is most effective through day 49 after the first day of the last menstrual period. Use of the drug from day 50 to 63 after the last menstrual period is associated with acceptable, but lower clinical efficacy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Clinical efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful completion of medical abortion in pregnancies up to 49 days of gestation ranges from 92 to 98 percent. Failures are treated by surgical termination. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Clinical efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two clinical protocols are in use worldwide. The regimen approved by the US Food and Drug Administration and recommended by the manufacturer comprises",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      (600 mg orally) followed 48 hours later by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (400 mcg orally). An alternative regimen consists of mifepristone (200 mg orally) followed 48 hours later by misoprostol (800 mcg buccally).",
"     </li>",
"     <li>",
"      Oral administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      is less effective and results in more side effects than vaginal. It is not recommended with amenorrhea of beyond 49 days. Vaginal dosing appears to be associated with an increased risk of serious postabortal infection. Buccal dosing is as effective up to 63 days of gestation as vaginal, and is well-tolerated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Route of administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing medical abortion:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend the 200 mg dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest buccal administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      if the amenorrhea is up to 63 days and oral misoprostol if the amenorrhea is 49 days or less (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest against the use of vaginal misoprostol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Route of administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Side effects following administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      primarily consist of pain, excessive bleeding, and gastrointestinal discomfort. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There has been a small number of deaths from septic shock related to Clostridium sordellii after",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?1/45/1753?source=see_link\">",
"        mifepristone",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"        misoprostol",
"       </a>",
"      </span>",
"      induced abortion. Routine administration of prophylactic antibiotics, however, still remains controversial. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Clinical protocol'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/1\">",
"      Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med 1993; 329:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/2\">",
"      Couzinet B, Le Strat N, Ulmann A, et al. Termination of early pregnancy by the progesterone antagonist RU 486 (Mifepristone). N Engl J Med 1986; 315:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/3\">",
"      Spitz IM, Bardin CW. Clinical pharmacology of RU 486--an antiprogestin and antiglucocorticoid. Contraception 1993; 48:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/4\">",
"      el-Refaey H, Rajasekar D, Abdalla M, et al. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N Engl J Med 1995; 332:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/5\">",
"      Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone. World Health Organization. Fertil Steril 1991; 56:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/6\">",
"      Schaff EA, Fielding SL, Eisinger SH, et al. Low-dose mifepristone followed by vaginal misoprostol at 48 hours for abortion up to 63 days. Contraception 2000; 61:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/7\">",
"      Silvestre L, Dubois C, Renault M, et al. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. A large-scale French experience. N Engl J Med 1990; 322:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/8\">",
"      Aub&eacute;ny E, Peyron R, Turpin CL, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol [corrected]. Int J Fertil Menopausal Stud 1995; 40 Suppl 2:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/9\">",
"      Baird DT, Sukcharoen N, Thong KJ. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Hum Reprod 1995; 10:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/10\">",
"      Peyron R, Aub&eacute;ny E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/11\">",
"      Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998; 13:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/12\">",
"      Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998; 338:1241.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Mifepristone for medical pregnancy termination. ACOG Committee Opinion No 245. American College of Obstetricians and Gynecologists, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/14\">",
"      Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med 2000; 342:946.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/16\">",
"      Termination of pregnancy with reduced doses of mifepristone. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BMJ 1993; 307:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/17\">",
"      Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial. World Health Organisation Task Force on Post-ovulatory Methods of Fertility Regulation. BJOG 2000; 107:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/18\">",
"      Creinin MD, Pymar HC, Schwartz JL. Mifepristone 100 mg in abortion regimens. Obstet Gynecol 2001; 98:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/19\">",
"      Shannon CS, Winikoff B, Hausknecht R, et al. Multicenter trial of a simplified mifepristone medical abortion regimen. Obstet Gynecol 2005; 105:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/20\">",
"      Li&egrave;vre M, Sitruk-Ware R. Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception 2009; 80:95.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Task Force on Post-ovulatory Methods for Fertility Regulation, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/22\">",
"      Prasad RN, Choolani M. Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost. Aust N Z J Obstet Gynaecol 1996; 36:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/23\">",
"      Rodger MW, Baird DT. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analogue (gemeprost). Contraception 1989; 40:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/24\">",
"      Kulier R, G&uuml;lmezoglu AM, Hofmeyr GJ, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev 2004; :CD002855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/25\">",
"      Fjerstad M, Trussell J, Sivin I, et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009; 361:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/26\">",
"      Darney PD. Deaths associated with medication abortion. Contraception 2005; 72:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/27\">",
"      Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracept Reprod Health Care 2000; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/28\">",
"      Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception 2001; 64:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/29\">",
"      Winikoff B, Dzuba IG, Creinin MD, et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstet Gynecol 2008; 112:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/30\">",
"      ACOG. ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion. Obstet Gynecol 2005; 106:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/31\">",
"      Tang OS, Xu J, Cheng L, et al. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum Reprod 2002; 17:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/32\">",
"      Wagaarachchi PT, Ashok PW, Smith NC, Templeton A. Medical management of early fetal demise using sublingual misoprostol. BJOG 2002; 109:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/33\">",
"      Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. BJOG 2002; 109:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/34\">",
"      Honkanen H, Piaggio G, Hertzen H, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. BJOG 2004; 111:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/35\">",
"      von Hertzen H, Honkanen H, Piaggio G, et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: Efficacy. BJOG 2003; 110:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/36\">",
"      Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002; 66:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/37\">",
"      Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 1997; 90:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/38\">",
"      Fjerstad M, Sivin I, Lichtenberg ES, et al. Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days. Contraception 2009; 80:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/39\">",
"      Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception 2005; 72:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/40\">",
"      Raghavan S, Comendant R, Digol I, et al. Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol. Contraception 2009; 79:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/41\">",
"      Coyaji K, Krishna U, Ambardekar S, et al. Are two doses of misoprostol after mifepristone for early abortion better than one? BJOG 2007; 114:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/42\">",
"      Schaff EA, Fielding SL, Westhoff C, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA 2000; 284:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/43\">",
"      Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. Contraception 2006; 74:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/44\">",
"      Creinin MD, Schreiber CA, Bednarek P, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol 2007; 109:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/45\">",
"      Guest J, Chien PF, Thomson MA, Kosseim ML. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG 2007; 114:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/46\">",
"      Creinin MD, Fox MC, Teal S, et al. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 2004; 103:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/47\">",
"      Creinin MD, Schwartz JL, Pymar HC, Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG 2001; 108:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/48\">",
"      Wedisinghe L, Elsandabesee D. Flexible mifepristone and misoprostol administration interval for first-trimester medical termination. Contraception 2010; 81:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/49\">",
"      Sandstr&oslash;m O, Brooks L, Schantz A, et al. Interruption of early pregnancy with mifepristone in combination with gemeprost. Acta Obstet Gynecol Scand 1999; 78:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/50\">",
"      Greene MF. Fatal infections associated with mifepristone-induced abortion. N Engl J Med 2005; 353:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/51\">",
"      The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study--final results. Contraception 1997; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/52\">",
"      Creinin MD, Shulman T. Effect of nonsteroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion. Contraception 1997; 56:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/53\">",
"      Fiala C, Swahn ML, Stephansson O, Gemzell-Danielsson K. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifepristone and misoprostol at 13-22 weeks gestation. Hum Reprod 2005; 20:3072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/54\">",
"      Livshits A, Machtinger R, David LB, et al. Ibuprofen and paracetamol for pain relief during medical abortion: a double-blind randomized controlled study. Fertil Steril 2009; 91:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/55\">",
"      Thonneau P, Poirel H, Fougeyrollas B, et al. A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Hum Reprod 1995; 10:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/56\">",
"      Chan YF, Ho PC, Ma HK. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception 1993; 47:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/57\">",
"      Martin CW, Brown AH, Baird DT. A pilot study of the effect of methotrexate or combined oral contraceptive on bleeding patterns after induction of abortion with mifepristone and a prostaglandin pessary. Contraception 1998; 58:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/58\">",
"      Tang OS, Gao PP, Cheng L, et al. A randomized double-blind placebo-controlled study to assess the effect of oral contraceptive pills on the outcome of medical abortion with mifepristone and misoprostol. Hum Reprod 1999; 14:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/59\">",
"      Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005; 353:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/60\">",
"      Meites E, Zane S, Gould C, C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med 2010; 363:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/61\">",
"      Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol 2007; 110:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/62\">",
"      Sinave C, Le Templier G, Blouin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002; 35:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/63\">",
"      Wiebe E, Guilbert E, Jacot F, et al. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. Obstet Gynecol 2004; 104:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/64\">",
"      Ho CS, Bhatnagar J, Cohen AL, et al. Undiagnosed cases of fatal Clostridium-associated toxic shock in Californian women of childbearing age. Am J Obstet Gynecol 2009; 201:459.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/65\">",
"      Miech RP. Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii. Ann Pharmacother 2005; 39:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/66\">",
"      Fiala C, Gemzel-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception 2006; 74:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/67\">",
"      van der Schoot P. Treatment with mifepristone (RU486) and oestradiol facilitates the development of genital septic disease after copulation in female rats. Hum Reprod 1992; 7:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/68\">",
"      Tait AS, Dalton M, Geny B, et al. The large clostridial toxins from Clostridium sordellii and C. difficile repress glucocorticoid receptor activity. Infect Immun 2007; 75:3935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/69\">",
"      Waiser J, B&ouml;hler T, Stoll J, et al. The immunosuppressive potential of misoprostol--efficacy and variability. Clin Immunol 2003; 109:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/70\">",
"      Aronoff DM, Hao Y, Chung J, et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J Immunol 2008; 180:8222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/71\">",
"      Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol 2004; 104:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/72\">",
"      Elam-Evans LD, Strauss LT, Herndon J, et al. Abortion surveillance--United States, 2000. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/73\">",
"      Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet 1998; 352:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/74\">",
"      Orioli IM, Castilla EE. Epidemiological assessment of misoprostol teratogenicity. BJOG 2000; 107:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/75\">",
"      Fonseca W, Alencar AJ, Mota FS, Coelho HL. Misoprostol and congenital malformations. Lancet 1991; 338:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/76\">",
"      Gonzalez CH, Vargas FR, Perez AB, et al. Limb deficiency with or without M&ouml;bius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet 1993; 47:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/77\">",
"      Gonzalez CH, Marques-Dias MJ, Kim CA, et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998; 351:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/78\">",
"      Pastuszak AL, Sch&uuml;ler L, Speck-Martins CE, et al. Use of misoprostol during pregnancy and M&ouml;bius' syndrome in infants. N Engl J Med 1998; 338:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/79\">",
"      Broome, M. Using mifepristone in a family planning clinic. Br J Fam Plan 1994; 20:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/80\">",
"      Bartley J, Brown A, Elton R, Baird DT. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Hum Reprod 2001; 16:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/81\">",
"      Gouk EV, Lincoln K, Khair A, et al. Medical termination of pregnancy at 63 to 83 days gestation. Br J Obstet Gynaecol 1999; 106:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/82\">",
"      Hamoda H, Ashok PW, Flett GM, Templeton A. Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. Am J Obstet Gynecol 2003; 188:1315.",
"     </a>",
"    </li>",
"    <li>",
"     www.plannedparenthood.org/library/ABORTION/Mif_fact.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/84\">",
"      Bracken H, Ngoc NT, Schaff E, et al. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion. Obstet Gynecol 2007; 109:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/85\">",
"      L&oslash;keland M, Iversen OE, Dahle GS, et al. Medical abortion at 63 to 90 days of gestation. Obstet Gynecol 2010; 115:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/86\">",
"      Schwarz EB, Smith R, Steinauer J, et al. Measuring the effects of unintended pregnancy on women's quality of life. Contraception 2008; 78:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/87\">",
"      Child TJ, Thomas J, Rees M, MacKenzie IZ. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. Hum Reprod 2001; 16:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/88\">",
"      Bartley J, Tong S, Everington D, Baird DT. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception 2000; 62:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/89\">",
"      Yimin C, Wei Y, Weidong C, et al. Mifepristone-induced abortion and birth weight in the first subsequent pregnancy. Int J Gynaecol Obstet 2004; 84:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/90\">",
"      Sun Y, Che Y, Gao E, et al. Induced abortion and risk of subsequent miscarriage. Int J Epidemiol 2003; 32:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/91\">",
"      Virk J, Zhang J, Olsen J. Medical abortion and the risk of subsequent adverse pregnancy outcomes. N Engl J Med 2007; 357:648.",
"     </a>",
"    </li>",
"    <li>",
"     Burnhill, M. Artificial termination of a pregnancy--first trimester abortion by suction curettage. In: Sciarra JJ,(ed) Gynecology and Obstetrics. Harper and Row, Hagerstown, Maryland 1977, p1-26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/93\">",
"      Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil Steril 1986; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/94\">",
"      Henshaw RC, Naji SA, Russell IT, Templeton AA. A comparison of medical abortion (using mifepristone and gemeprost) with surgical vacuum aspiration: efficacy and early medical sequelae. Hum Reprod 1994; 9:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/95\">",
"      Jensen JT, Astley SJ, Morgan E, Nichols MD. Outcomes of suction curettage and mifepristone abortion in the United States. A prospective comparison study. Contraception 1999; 59:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/96\">",
"      Hamoda H, Critchley HO, Paterson K, et al. The acceptability of home medical abortion to women in UK settings. BJOG 2005; 112:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/97\">",
"      Winikoff B, Sivin I, Coyaji KJ, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion. Am J Obstet Gynecol 1997; 176:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/98\">",
"      Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days. Hum Reprod 2010; 25:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/99\">",
"      R&oslash;rbye C, N&oslash;rgaard M, Nilas L. Medical versus surgical abortion: comparing satisfaction and potential confounders in a partly randomized study. Hum Reprod 2005; 20:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/100\">",
"      Jensen JT, Harvey SM, Beckman LJ. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. Am J Obstet Gynecol 2000; 182:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/101\">",
"      Breitbart V, Rogers MK, Vanderhei D. Medical abortion service delivery. Am J Obstet Gynecol 2000; 183:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/102\">",
"      Breitbart V. Counseling for medical abortion. Am J Obstet Gynecol 2000; 183:S26.",
"     </a>",
"    </li>",
"    <li>",
"     Cullins, V, Fjerstad, M. Planned Parenthood Federation, 2009. Personal communication.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Medical management of abortion. ACOG Practice Bulletin #26, American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/105\">",
"      Shannon C, Brothers LP, Philip NM, Winikoff B. Ectopic pregnancy and medical abortion. Obstet Gynecol 2004; 104:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/106\">",
"      Clark WH, Gold M, Grossman D, Winikoff B. Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research. Contraception 2007; 75:245.",
"     </a>",
"    </li>",
"    <li>",
"     Creinin, M, University of Pittsburgh, 2011, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/108\">",
"      Clark W, Bracken H, Tanenhaus J, et al. Alternatives to a routine follow-up visit for early medical abortion. Obstet Gynecol 2010; 115:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/109\">",
"      Cowett AA, Cohen LS, Lichtenberg ES, Stika CS. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstet Gynecol 2004; 103:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/110\">",
"      Bar-Hava I, Aschkenazi S, Orvieto R, et al. Spectrum of normal intrauterine cavity sonographic findings after first-trimester abortion. J Ultrasound Med 2001; 20:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/111\">",
"      Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003; 109:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/112\">",
"      Harwood B, Meckstroth KR, Mishell DR, Jain JK. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 2001; 63:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/113\">",
"      Luise C, Jermy K, Collons WP, Bourne TH. Expectant management of incomplete, spontaneous first-trimester miscarriage: outcome according to initial ultrasound criteria and value of follow-up visits. Ultrasound Obstet Gynecol 2002; 19:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/114\">",
"      Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 2004; 86:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/115\">",
"      Reynolds A, Ayres-de-Campos D, Costa MA, Montenegro N. How should success be defined when attempting medical resolution of first-trimester missed abortion? Eur J Obstet Gynecol Reprod Biol 2005; 118:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/116\">",
"      Reeves MF, Fox MC, Lohr PA, Creinin MD. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol 2009; 34:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/117\">",
"      Wiebe E, Dunn S, Guilbert E, et al. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol 2002; 99:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/118\">",
"      Borgatta L, Burnhill MS, Tyson J, et al. Early medical abortion with methotrexate and misoprostol. Obstet Gynecol 2001; 97:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/119\">",
"      Creinin MD, Vittinghoff E, Keder L, et al. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception 1996; 53:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/120\">",
"      Jain JK, Dutton C, Harwood B, et al. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 2002; 17:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/38/33386/abstract/121\">",
"      Bartz D, Goldberg A. Medication abortion. Clin Obstet Gynecol 2009; 52:140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3296 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33386=[""].join("\n");
var outline_f32_38_33386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BIOLOGY AND PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PROVIDER REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DRUG ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mifepristone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prostaglandin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Misoprostol or gemeprost",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Route of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Provider versus self administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Excessive or prolonged bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal discomfort",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CLINICAL EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Up to 49 days gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      After 49 days gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Failure of medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Implications for future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COMPARISON WITH SURGICAL ABORTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Acceptability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CLINICAL PROTOCOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      First clinic visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Second clinic visit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Third clinic visit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      ALTERNATIVE MEDICAL METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      CURRENT STATUS OF METHODS FOR MEDICAL ABORTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3296|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/8/1166\" title=\"figure 1\">",
"      Gemeprost and misoprostol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/3/36926\" title=\"figure 2\">",
"      Bleeding after medical abortion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/7/10367\" title=\"figure 3\">",
"      Outcome from medical terminatio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/53/11102\" title=\"figure 4\">",
"      Time of abortus expulsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3296|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/60/37835\" title=\"table 1\">",
"      Patient agreement mifepristone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/54/11115\" title=\"table 2\">",
"      Contraindications medication abortion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/5/3163\" title=\"table 3\">",
"      Eligibility med abortion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/15/21752?source=related_link\">",
"      Incidence, risk factors, and pathology of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/42/28330?source=related_link\">",
"      Misoprostol as a single agent for medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40888?source=related_link\">",
"      Overview of maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/11/29874?source=related_link\">",
"      Patient information: Abortion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/47/42739?source=related_link\">",
"      Patient information: Abortion (pregnancy termination) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/47/8952?source=related_link\">",
"      Pharmacology and mechanism of action of progesterone receptor modulators (PRMs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/8/24713?source=related_link\">",
"      Postpartum and postabortion contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4453?source=related_link\">",
"      Surgical termination of pregnancy: First trimester",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25866?source=related_link\">",
"      Therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=related_link\">",
"      Toxic shock syndrome due to Clostridium sordellii",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_38_33387="Features of HIDS";
var content_f32_38_33387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F79149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F79149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of hyperimmunoglobulin D syndrome (HIDS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       General",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       High IgD (&gt;14 mg/dL), measured on two occasions, at least one month apart",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Elevated IgA (&gt;260 mg/dL)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Recurrent attacks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mutations in MVK gene (",
"       <strong>",
"        classic",
"       </strong>",
"       HIDS)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased MVK activity (",
"       <strong>",
"        classic",
"       </strong>",
"       HIDS)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       During Attacks",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Elevated inflammatory markers (ESR, CRP, SAA, and leukocytosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abrupt onset of fever (&gt;38.5&deg;C or 101.3&deg;F)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphadenopathy (predominantly cervical)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abdominal distress (vomiting, diarrhea, pain)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skin manifestations (varying erythematous macules, papules, petichiae, and purpura)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arthralgias/Arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Splenomegaly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mildly elevated urinary mevalonic acid concentration (",
"       <strong>",
"        classic",
"       </strong>",
"       HIDS)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Drenth, JP, Haagsma, CJ, van der Meer, JW. Medicine (Baltimore) 1994; 73:133 and Drenth, JP, van Deuren, M, van der Ven-Jongekrijg, J, et al. Blood 1995; 85:3586.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33387=[""].join("\n");
var outline_f32_38_33387=null;
var title_f32_38_33388="Lactose content of different foods PI";
var content_f32_38_33388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lactose content of different foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Product",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactose content (grams)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Milk (1 cup)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Whole, 2 percent, 1 percent, skim",
"       </td>",
"       <td>",
"        9-14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Buttermilk",
"       </td>",
"       <td>",
"        9-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Evaporated milk",
"       </td>",
"       <td>",
"        24-28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sweetened condensed milk",
"       </td>",
"       <td>",
"        31-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactaid&reg; milk (lactose-reduced)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Goat's milk",
"       </td>",
"       <td>",
"        11-12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acidophilus, skim",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Yogurt, low fat, 1 cup",
"        </strong>",
"       </td>",
"       <td>",
"        4-17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Cheese, 1 ounce",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cottage cheese (1/2 cup)",
"       </td>",
"       <td>",
"        0.7-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cheddar (sharp)",
"       </td>",
"       <td>",
"        0.4-0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mozzarella (part skim, low moisture)",
"       </td>",
"       <td>",
"        0.08-0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American (pasteurized, processed)",
"       </td>",
"       <td>",
"        0.5-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ricotta (1/2 cup)",
"       </td>",
"       <td>",
"        0.3-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cream cheese",
"       </td>",
"       <td>",
"        0.1-0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Butter (1 pat)",
"        </strong>",
"       </td>",
"       <td>",
"        0.04-0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Cream (1 tablespoon)",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Light, whipping, sour",
"       </td>",
"       <td>",
"        0.4-0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ice cream (1/2 cup)",
"        </strong>",
"       </td>",
"       <td>",
"        2-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ice milk (1/2 cup)",
"        </strong>",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sherbet (1/2 cup)",
"        </strong>",
"       </td>",
"       <td>",
"        0.6-2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988; 48:1079. Copyright &copy; 1988 American Society for Clinical Nutrition.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33388=[""].join("\n");
var outline_f32_38_33388=null;
var title_f32_38_33389="Cumulative two year mortality rates in CKD pts";
var content_f32_38_33389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Cumulative two year mortality rates in chronic kidney disease patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long-term mortality of patients with different stages of CKD is displayed. Thus, the cumulative mortality rates at two years after stroke and transitory ischemic attacks (TIA) in patients with CKD or with hemodialysis were dramatically higher than in the control cohort without CKD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705. Copyright &copy; 2009 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33389=[""].join("\n");
var outline_f32_38_33389=null;
var title_f32_38_33390="Nomogram DSS resect gastric CA";
var content_f32_38_33390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Nomogram for disease-specific survival (DSS) in patients with resected gastric cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 546px; background-image: url(data:image/gif;base64,R0lGODlhZAIiAsQAAP///wAAAIiIiCIiIhEREURERLu7uzMzM5mZme7u7szMzFVVVd3d3WZmZnd3d6qqqj8/P8/PzwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAiICAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztKUGBAEEBj4PASQCAQEHDDwIA8EFCSIFyDkMzAEDuwDAwsQ9wNfVwzrB3iLb1zsKB8HT0AU60N8A6DwOwdLgwdzO5QELI+46Dun6zcsA1tpCQAA1Aj2O+RKhIIACAAvy7WhgkEFBagMSJBhg8IaBZAAaHADQ8GHEHg9w/xErCVEijgDTGDpsycOig18ZN3acmE9ATo46EBAg5gAhy5M5CjQAwACoT41AbzAQ+FQnRqg7B15pOGImDwMLqfm7BaQAAogdBbhMelPAWITjAvQi5lYE2Rwwf719txYtuL5SAxBbkBYwDWPKHgwQaxfuy2l1Cf/VUVeEZGr5LqvVmsXYiAEPeoAd0WAp0wDKeijoOOAsAAQjczSIpqy0iKmpcTR9MJWY7dO5bXiT9xv3jgMKBzxsLQI2jwWmmb+OLTuAyIfFUecYYNrBYunOc1QGAH5kec5YPIsALTps9uDOTJN3HV5Hg3TvdRyoKDikaeMTIZSfDgPcFJJ59FGHA/9Y15yXgwEDMABbPgPeoEByCDanoA3jnecgelVwBUACXu0wGjj+pCSaP5Z15IBhNYxWmYrdeBMMAjM6poOMKeqIQwEdjXbZizsoNcKQMMpwWW85+rDATUhSxmKUUYJoxUUC+PhgWEclOcNTOGGFgwCmFZBOlz70RtJMSN2AgERmrmmSlzL4NFg6VUW14FAj5JmVDd7RRUACaL7Dp59S9vmTQYhaWcUtucREoDf+hMPDOtEEFACLNhhwTz2W9qAmNfSIYwM5pc5jTQ8LpNqOQDjoqSmnNyTQajSQubogPQ/N6oyNHe3z6qaOFmvsscgmq+yyzDbr7LPQRivttNRWa+3/tdhmq+0SYQnRrbdGfBuEuECQ+4O5PqDbg7o8sNvutkq4i1e49BYh77z21kvEvS8dwW8a9yBj6i/4pAAPnXz8W4PCC+s7BMM0QDyDxDJQHIPFMGCcMR7lhAYPrS8cfIi45JJ8Qsknp1wCyiawvHLLKr8M88wkuFxzzDfLrHPOO3dFM89A+/yzCDYL3TPRQyOdNABFM42z0UErHbXTT8/RMQC9LKYANAc8BEw+5SxQzgEJVBPMA1t786ceJifdNNVHww313FJP3Xbcb99td9Vy1013334Hnjffev89ON6EV3044owvHcfVszmQAC4KWDTo1wCUc1M5BolMnlyCQGDj/+ikl2766ainrvrqrLfu+uuwxy777LTXbvvtuOf+OgQc27gUAplmHgCOBXMOUQA3ea4QRfA27zwQV48A/GLCEw92AAa1mnzBTDlwj3zPhy/+DNGLMLlDlpddPPbHt0UsCbOBP/789KdQPkNce71+9sgzdU8v3lgAfOpHwAIa8IAITKACF8jABjrwgRCMoAQnSMEKWvCCGMygBjfIwQ568IMgDKEIR0jCEprwhChMoQpXyMIWuvCFMIyhDGdIwxra8IY4ZARYXAMpXXChGm+JFAqAqCp55PCIMkiAa5hCAAK4BktaqoL3eiUCKJ5giiO4hdcGhcQuskABrXKNTpgjIv+mUdEKJDpjGUtkPjaOx4dejGMJBHCA/ZCgADdhjnrIExosZC0Yv6MeH0vwR+u8hgAPscgS5RhHZiwSAP1Yz1n2yJ708EkBBHgAJR8AFnMIZSWZDEk8QMdIRtLRjpryRgNElMYs3KUdAmAlGwHwSiCRoCEDLGUXwTi8EkjHilmYnEEasgtgkkCYa4oJOQykS10q0Zc8xAUcXamQIElTUlmspqbW1sxuevOb4AynOMdJznKa85zoTKc616kCjXHBnexcgzRBBE8t1DOeZwDejdBzTyz0E59kYAYuphQMXOTDVmpLxT+tsFCAgmEqMAkGUYglMmbs4hjYHEVDqbBRh3b/ARjpMF45znIwiALLEbpLqUpXytKW2sijMlDIcKoHSXxAdGCN6CjfUKHTb3aSGBA1QPyOdz2JLKCPjOhp3HgKUxjMhkXMaEACuGbIBMxGYChNglIVsdV0Gq8SXQ2cQpuKg4Yk1BJhBdxYycrWtrr1rXCNq1wLyM25jmKHjREiCvBKKlyxAFO76GFGh2WOvhpREsBgpl1GZxDB2pUSlnsio6LIRCfSEpEHyeUd/2TMzZJAi5mFrPZOMJWHdPaxjhjjWdZ4RvNxhDlvHKxnR8BaE9iyTyya5iSsyj74LaW2qH0EHufzGkFW8o55nCRmFbmCdRhkk7ZNqFASadlK8DYr/w0hBnSD24hIEneTnYSJd6Vz1WMgdQXAUwB4vSGp9IoyGqSUBANGWwIjFfcz5+VuIjBlHVm2lr/gw+ULYOLfdkpKwIjtnwkYJJM2tla/i/jlZFUgHYYcQLGk5UaWlHFa/wkqN8ukRF3bodgOQ1gR0nFsCqQDjRGPYKrxmIaKjwkNI7a4Evz1h1CCM+MT+/jHQA6ykIdM5CIb+chITrKSl8zkJjv5yVCOspSnTOUqW/nKWM6ylrfM5S57+ctgDrOYS7nHMY8TePI5BgrKbOZwCqU/AFyzINvs5gEMVykLGc5D1AMPYTyYzl40xi1SciLS5MMzlfEuoBnpmQIU5ERFaf9Go20050UHejE7lpE86tJoDFtajmUejfdGdIB0IBqzCJDfp48Yal8woBwEKPV933uRVdv61rjOta53zete+/rXwA62sJuQ1mEnYb7xcMCflVVsYx/BvCO6zLOa7WwiNASzJDCGwLI2oiYuWxbUrvYQZGpLsOCJWMAQADweOZBwizsICfCO2q7qDbg0YAC1foRLUffuOMwGOoas7wEI4OlFuLvfaNhaH5khgF5g9gE9Gd66IXFwhJsh3jXuCGzUxu3JYTunFmdkxUP+wJGTvIEROLnKV87yljtV1S6fYHiDgYPfxNyChZYNzG8OwZzX1M/kuUcBbtURPftnROjQLM//DzhzASQ6HXZOAFgOrR1DH/22qFw6A3OOqe+4Ji9qijSxbDO6nWu9gFzHsHTALhif7KIuZM/v2ReY8yzteSlr30VvRp0AWdumAGSjhovnPj+fX/UieT8NA16dC78v5Rn0kC3hJ0/5ylv+8pjPvOY3z/nOe/7zoA+96EdP+tKb/vSoT73qV8/61sthVLSocC1OdJ8z9HZXkr9Wn4FuAtiXYvddQ4HsV2HRBS/U5s20E1MWwG7Fn0L5820+cVsxlQsb/wfI16WiP+Oa1lQ/GPz53j12oR4+lwpC+4SxMKTujcDjYfuSjP8AhC6CPivnkLk4S2mAgQD09xJVhmQ2ZucH/25BI32FC5+zFOEVeAD4XNKkf8gRDQwQXrRyK4G3f8NTDQjINPGAHREYIdB0IMcQIUIxAk4kgPXXgWpSDfcnEiOIU8yCSdzRAA3SfQgwFQYxF1PhPgYhErOGaCB4VBcxFz6BdKYiK3Ugg6VRg/KXDoqUXZDUfyCYElZ1AGeBTHMBHSSxFqVlCHYUSmCxC70gAtnHEcgkVBBCDFR4HeRxE9mHEcRwAEshEmcRhljzLQ1AIcFXICHIhnxoWQZ4GgoAhQ5wg4Jhh95xIMtRcM1CJq0SGtLhff0xH2pyIp5RfotxW7QUFvsBFqWhDAxAb4MHB44IOpF4FuQlVQSgFPpjI/+haBqFth9Zwjy0tA65twcCloeMsYlk+HiiWHej84q9eHT11REq8huVAWm4MHamUYb614xLEUnD9RHsNTmsqHiVkUa/8YbREkmnOCqZVIkLcYnU02g7EYsGYVWzAUbcoIl74I02OH1PAg4NUBB0VAK/gY4kcR8ZQQASkReEsHu5UDZjsRC2ITbEACR1tyHbOIeqdlvHaBrJ6AtuxxgN2YfQeBoM5o9EAxn1KABM4g/amJHR8on+YxDWJxSGuGeDIo7NsRgpwQBTtRjKJ4TPJRjMMzkPYH0XMoptYJKvhpI3oZLkMUy68CbKgEd4RQ7EiEzA8wx1iBqgAzy3qAcV1hr/KYEdBrkUPGmGF4GG/zcSFwl/cNh3DikCMSlKkDQSfYcfJMl9xPgbjpYOJBIaVImUJNYbdnhvcTmAyLJxgLRYwuBEU3FNzmeJ1IMO1GOBE6gQk6QQ+QApyOGTbACYAddJA4eKyzhMnyIogWlz/ncWZsMoyACQgnALuRFJV1UOwyiZQOF/k/WZGYlJ73Mk9FAb8rGaCMF4seaWw0gCzHGRr0FKQERgnbmCHdiXrqcHwxUFZLmcsMAM9+cEChF80Hmd2Jmd2rmdiEAis/RXZ9MJJicI4wkL5UkEAWMdMKgCxuOd33YCwEMrmMMqtzcH5/kH99kK+RkExjM9SncC7RkM/+9pAvDAiJewnwmTQAj6A18FD79VY6FRDu5wK8HgnZEGGNq2KQkAQLlAMEU1NuwHF460e9VlNgjRKsOUPzVVarkwoO9ECwu6VnbwVcBDNgOQEdcmPDfBcMKTjmdzPpLCbTVaU32BOZrTo8LDG8EjmAwADAqCoudTOU0Ub8JQUyATBjGaB1l6Clt6HL1Vo/pkI6hCmiHFPu4JALhwXkPlnQzgOX2yP+1DKhTRP7zkDepFD8p2PAIwPSIwUiLjpDWyb4I6qIRaqIZ6qIiaqITaOy6CPHxKAsYDUkh6pmkKP1UlUW46D9fDPzfhccxgWthzpmTiDci2p8HjpwUDqPhiB/9dWgetqi39SRvnUxHJIFLsw6OUGl93iGlVmqmksqlxejxV6p0G0ElUdFNQSjnp86dVuqquOguvmi3pKVX4E0DCoxAGkhIVKqBoqqvFhQzK4KtGyj70BUBpQQ8CunvMgaIkoaLMuiENcwfRKgfzWkBfRXF4UK9woK/1c6/6lq/Qyp0CO7AEW7DeNHwG+wRTIUizUZVSsA4IQwUIuwfqhw//WW2FeYWF1QW21BSUGQUTqwcLMBb1cHJT4YOjelHx2ICGxZL7tA7SdwO3VRrG0BA0+D3rsQ9vZlkYuEjzhwxE94Nag7PqB3WrdQ8GKgdZR1tIW1w2y3hVxTXsd5uLVlr/mYRIeXGKZ9gAiLgYloUAilWCPmBLmIQAQhEsTmhZdsZEUqiGg0KHJhB1UzecSlSOi6GFYNQOToggk6N3umUHNdoABtK3TGQAZ7sMaYsjizFVR/ixWcYkq8g0KitJdSeSDgF4DeAadMQOPbAOQylIAEkkqWg2EsWNidcbmHgQtGia8zFzvfSOIjEUrmu2oDsNL+KJ1BqKZ0VnvTEVu5C1Nli5DvYaIrEADdFYC+WOexS6+SAdT3KPvnUCpysYqbuPBZARrNsaYHGxHCMA25tttVt/B1UaDoGQsFS1k9iRmTOUTrS1exkhwUdHaTkbP6C8ghQnZVuUJKELSymWMDe9/wwQkzPZDlE5VXs7H5OzFLbisG1wW7dgAAkcbYZ7v2fiRDmZSV3puFjme3mBmZYFmy2LUH6FDsmbFXsEtdGxmeCwjGcZt1+nd/2hmH3FPlBrtLQkdOspB1lSUEGCwyeMsxkambgwmQnrwkVMQCF7xEq8xEzcxE78xFAcxVI8xVRcxVZ8xVicxVq8xVzcxV78xWAcxmI8xmRsfJLic5xWaWUsCmj2GeaCxqamxmsMCm+mhjR3AnA8a3M8CsZwZ/SLnLmwELcSuebHe3u8CYJ2taOhl3kxhsoXSYjmD895yJXQaI/mam1XkOfLGJM2U5SsCZc4KIucyYu1yWlMYp/sCf+tpnhZqZbeoxGydmp3l8qZsMpqspq+0Hf0EMdkyMO0/MvAHMzCPMzEXMzGfMzmxK+f56814DnsOgnK7HnMTAO+SgnR3Hn+mja8t8MdGjBdQ7oQxz7aHHzwwKIfR57AfK9Rmj6SagLAsBjOHKrKOqXlbKWFcM2cd6+POlIjlW3rgBDxbKrUg6oRB69soKiro8T6fKrD08+LhUgOR6SWgT37LHGp2qz7egX4/GvqPM+XU5sRDQwI0c7Jij70fNEGvQb5udG+lp6oMc69ws0IQVW7+T/sCtMSraoZzVDIDLA83dOsqtFAPdREXdRGfdTHwrpRMCq+i9RqoNRQwNRQ7dT/Y8C6LPgQdrRhaOoxvDIfrZLDLSDVBjAVN0bW4JeCQNcaX03VTmCaXQtJ+cAMaIMaT0ceBeCiLCDWOHiHi8c+RCjJUHfXbP0EppmNDkGFBEcYI9F10xcY11BaoyKJNcjYSTzY4RIThm1aL4JJttSccKkbXtG7kxiOo/0Anh1/lk1sMfG+Ex2hM2F3xNvYN7C27bAYXbhjt305qIZ3MZva+2IjBnDVK6wMWUIavlzZMACAwVeYQsTccHR4BoHcvg0Ivud70z0J1Z2+173d3N3d3v3d4B3e4j3e5F3e5n3e6J3e6r3e7N3e7r0CFjFYIlxdxsJfKKBoM3elrHdVg/Vq/w8BD8yiiyUAUSzic9o51Z8lx45i3biVRSx9awhOGmCNHlo4RAXefhOuegAZXpiN1wPBYMPCIuPxYgcQsagX4QUgd/U9gCPe4Afe30uLLLcA1uPBPEGZnfQmLrOLLEhIAibFPm/GPe895ERe5EZ+5Eie5PGqLQ9OLdKkDOcDI2fqAhFtP71FOSvgr7BG3AoWCE0+MnG0jG4YDFLOrVTeoVbuuFreDIk1CF9uCG8eLUOcSYF8UBRqEMu4fjYCEhnqEDbiABzaPxSKGli+k3YKqfUJaxlIp86VoNsS59CCC29WIAVTfBg15f+wSgM5AlX+YsdwFl9FOWABgiaw5u/c5v/Q5geQ7uZhLhfwoG42RToCMOU+EUAQRXBnUeVUmlCh7hAOigJrzku4kEeApME7gNDInuzKvuzM3ux3vAqVmoILcFPHxK1OSqX58ABihwBVzgzA2usK8OsAmugOcT7906Y4Gy+rsOqSwO5aEO0SHTaWERq4sAsf8ypr8elgARecsxG3euUOMeowGOx9pVhDpe6q4O74ygrwLjK8hVXh8Cn4EOjBEgyAjgs36tfLGKXTcegj4NK63Cua451kzr3nsu4KpPD1o/JVwPIg51AuPwUxb3BKXvM2f/OUZ+zn1GOdIIpDBCvW0ua9p1tERE4mpgnBBzwDhEXwgmwGv7Fr6eH/cgRcoQC91S710XJdNTMNrWRO2/UJ+vRgheSX0qL1XTENY09OX0/Hosxen7S/Kj4tTt8y0/D2mBT3ulRgGoVNtaTzxiL0dN8Y+uD3N3T0mPARH1YCyERM2eJiALn4Ea5LPL8JkOdXC6ZN2ZJjvcwOIIzznv/5oB/6oj/6pF/6pn/6qJ/6qr/6rN/6rv/6sB/7sj/7tF/7tn/7uJ/7ur/7vA9Xnd77wmMjJt8COToDvy/RI9BnodEQKV360/wEx5+p9kcoGK36/sqjB0PyGkpUx5Di3b8mAC0MAvUQIvyl0oTmyS/kNYULms6WFGriSZ6ebIkcFrEhURWnx0DsBpCj//UMAk5QAEVgAMOpBEPyBAQwz+JCA6JABEJwABYBB65oPCKTyiWz6XxCo9IptWq9YrPaLbfr/YKPh16RQTi4ZgJVIHATCgDj+JwlswF8B0a73xM1AMDI4ODR6PjwADW0FTgkhDn5TVJWWl5iZmpucnZ6dkaGio6SlpqeRs4VGfwMMOT9JODByZHVxeS4we61vR4GBA4WGdbYtgHlmLSgFgUYOSNBPydJH1VPL11HP2lnY3Uzh4uPk5ebF6nSJAy4nOWSmLwZ0/XY5d7o1d4EPcAMACDAVUjXrzgsfuAI+G+cNnAAwDl0+FCJxBkVLXKLcpHJxnMeP4IMKdLIGD8JTP/EscGg5Bh59F7aw5MvAaNGr2qOIfTLzwMdxYCUHKGAXENq244itcaxSceJUJoaHSl1KtWqVq+CLJoUR0SKXr0tlaTxG9ayZs+iTau2GTalbt/CbRsVLNOxV6Cuzat3L9++fv8CDix4MOHChg8jTqx4MePGjh9Djix5MuXKli9jBmkGBYAEQmIgmGGABwHOSFa22VeiURJlfWYoI7GEVR/ZsaUYYOnrdhEEbApAWj3iiQPZsFlnTq58eaSanFcOFTGDQJwdSgoEYjCguot1cZY0wNd9++xraxJ4jyKASIIDRM6nx9Egjhnu6Mkv4TNczfjvzP8DGKAUJxhhwD8s0BD/wFDRcCYACQt8J4BqpwXwCoRqTHgEK0VcmEeGT2j3QBARfkhDAaF1KKETDtKQYokCwhijgAQW0cArvtEwgIhIDBBIDv8MEBpAyCSxgI9BzoAAkUjQ9sMrSA45hQr7QKkkEgp8V+WSSrA4g5YyghkmgDTSIMCCOHq54xEKsDEAEF8mwYovcDLR3g10RtFeHHjSwICPKQhpZRNdAprklmIimmhkZJagJoKdKdjEAkR06MCLsP1Z6aVGsKhpFZ1+Z2mBxo1Yw6Y4EOqpoquyyhiNK/k3XXU6KeEAAa/Ah5+Gt5bZH3j0HWBffE9cqJ2wuvIXXLLDLkForrG2Gq20ftXU/wYATbYR2mgxmKbhMQsKR6oRyIbLBAI8EFSueuiqxhsOri2jbn5+fOfutPfim6+++/Lbr7//AhywwAMTXLDBByOcsMILM9ywww9DHLHEE1NcscUXY5yxxhtz3LHHH4Mcssgjk1yyySejnLLKK7PcsssvwxyzzDPTXLPNN+Ocs84789yzzz8DHbTQQxNdtNFHI5200ksz3bTTT0MdtdRTU1211VdjzTEtWXOdrwiTECEGGUhsLQUP4BaRQBtod932YmoHoKzY0OJQNhdws+223obBrawPbVBqUlAHDGX3IMrs+PcQ0yk4SE1xoIuQ4rTuXTlffRdzAyNEpFPmMobHkP8AK3fosjkAZw/yAi5472K5639hnkIAoflTy3cIuCYD6ITwYODsgiyDOi4Hobc2QMc4kLdInzDfvPPPQx+99NNTX73112OfffZvtxGcCrQvo8roCgizO+O+g/+P8DIQz3oe1foyVUUX0R8WXVvFhT9b98+l//78y8V//xNggurylQMiMH8BJKBTEsjABiImdngwHUqAJ4NEBGFsMxCGQu4BANOtDwDEOx2j9BM/qczPfv17IAQVOMAVLjCGMiwgAF1IQwfaECM1nKEOccjDFubwhg/cSP0UEztYAG6D6DrJMXCxOxUQTg19CFsIR/g39/QBSlRJ4Q65okIYvjCIPRz/ogHBGMYgFrGLY2QhF314Ri+qUYhiJOIXxSSMRcURiD/U4w/T6MY1ipGPcgxkG834xkHuUZCATGQh2ZhHOuYxQHeETCPnWEc0XrKPmTzkIjmJSDj+8ZOiHCUp/WjIToIylKYk4+ta6cpXwjKWspwlLWtpSy1sqzQjwZZtkFOOzdAgl5wRJjmAeZw+oICY4vBMGwggJGUqExXMBM0x25BM0nSLGdX6DjSxqTTq5IFyHtkQqnxFDufQAJzWOd2sxoFO2EBLneI0BXRyIatw3nOdqKindEoQz3aOI4oBgYQ88zlPoT3qIcorBzlbRKJz0CihCpLoQktBpgLEiqLmMJAI/6UxUY9WlBQc9ScONFoOAQCBoiY1GppSoKaPNGkPhYqSOWjUUh3d9KXMuGgf4pBTc9gIIAtx6U/duZueCjVHOkVFQCKV06KydKg6moqdZiqocthUqg+AajgYlSQFcTUcZkqSVsN6irH2BqxaNce5EvDUtR7tUWoLqTlAZSqIckauH53BXImSTYsYQK90FUUBHAWNuQpWHIVlUGJrGtjD7hVSg+1ZQUUyHwDAKg/mxKppKltZhjxHpjsgKEDDkVkceLa0pzjtDFaCKwKQFp/iMEABXhvbdX72aNEEyblSYyJfutMPovHmtYgbjmo5g4ktGKZxmYGt33WTW+F4LgKUO/8A5kpXHAxQxnWHm93d3jK84h0vectr3vOiN73qXS972+ve98I3vvKdL33ra9/74je/+t0vf/vr3/8COMACHjCBC2zgAyM4wQpeMIMb7OAHQzjCEp4whSts4QtjOMMa3rDF7MZhpX2mD5P1yNmIpcEPg3hxh/Ewio8mhLAdwQf74AEDpkkGGEzRgox4qW9ELBOEiKAAKNkPjc9WQVb8Y3CFO3GLXdwHcKaNALANyA1MgAIVmGYds8NxGwwL21/gA8gmkbJbdSG8RZzYB/9gcZPj2jvFucQED9APvWRBr0n2qZkOCM2PgUAMISBACCIqsQq082XcPTmDdCuL9hrt6Ef/QzrSkp50Ji42BiHhAMnLMOG7dDEHPNOgJ+hCQJ89uMEREGAhJQ6yLsZXPiabBS9dkLUXaH1KsQwo1xnRdRVsfZeJLVYBZD4CG77Tkhks4AFz0LIAQF2E73VQBH5Ol+xUXOKDBEBEwsAgm7Hi6yx8Wwvh9mQZn8Lrcu+61zudWIgLsFAM8rVatX0AD9jRA2dzmQxMHIAQpj2hry2oxLUYqjJyoui1jNsKCf/1FsZNa1lD5eEMP8XCD2Y6hFV8ChmnQsYdrvFzbzKUIQ/DxgeWAIEfrOTmJgoXPA5ydEcykSL/gsrbbPOb4zznOt85z3XbXCkut5petYK9WluSU12h/+idKfgJWwNcoTtE6SIsSbeUzksqWF03XJB6MnD58+JmF7O6jHBuizuU0ZK0C88qAnYwS64trF0+yDgA0uN+hPAgwe6tJQCMe3UfaDWUCnrPA3vcA/fNtvbpVSg7O2X7zgevNA/G0SVGveCiZjRIXFu4vHz24YA/FemhR+BD0x2KoWGUiPPBDLfqyzBVLbS+TJqfQuRXOvQFc/VcQzFDaFyzaCrwqUc1GGoX+NQeAjQAOEzgU4tA/+xAbQkNbRgAuPgU09I3gfmyQzoUtE8oK+Qerg/5K+7FP4OaqIDHkcoCn9g0/UNpgU8sWsPvcaB9OSUh+GFrAJG03xm6Swn0If+BnmyB982eFISfUiUI+SlYYxkBC8jN+MFeqFzKpICBqqQTZ7RU6N2VEbQdB+ZAhlTetUgDBnLKAS6BCRbB912BCqoBCkKBA3YUX62fBJIdQAlZSRmea4VTBH6Kr7BCt9gK9mXB2gWhHNgGDC4LeRxhcRHhEsbBEa6BhRiHERLIZbEWFFghChTL2/3g35GgabDg4uGgbOTW7S2YMuWgcHyHdTEg1iHHEdJGFIUBbxyhAmgdE9ghjXgh28UhjXyGTP3Wfhxhb1FbFOwhCuyAb23dH6IAncEabhDXGioTcvXcJWJiJmriJnJiJ3riJ4JiKIriKJJiKZriKaJiKqriKrL/Yiu64ivCYizK4izSYi3a4i3iYi7q4i7yYi/64i8CYzAK4zASYzEa4zEKDcoho8FU0AzgoU2UhT08gTIuo8AoThsOwK3AAPz5BTVWo8BsTUAgA41xCBkgmQhxl4h8DTU5TrYlBBsoSKmNQQO4yZG1gD30Diw0ANw0AkHV4DcOzNbI2PkUwTZ+UA+sgwtIo2j0Qr55mbLIYx8cgEEygpnggggQgQqgjQkEgjcC5L8IJEH0TojtiYKQWVP5gQIoQIg1jkDggH7wHZ/pQj50TqFlYwLYAwtQH0JoVh/cgEdGAqUJ5VASZVEaJaWpTDjyJDmuYAsAw/EQHwkJAN44myDY/0q2RKR/sNoNSOMYVJAe2NlP/uMo1ByuMUStKdzHrdxamqVarlvKlI2UMYA4jp6IdQYP0AdwWBNtkI9LEtvsRBtCdA62iYg0/s2XBdlqiOWINdxZstyspeXLxVwqwRxbUhzKKE73TB00HoEQGIcCuEaY/cDa4Bu9LF0L9Jvt4MAYLIQ0nhxBoMZoLuZlikNZpltjqptkzhy58eatBaXPpF+Y2ObIkSVa5qZd3GZbVmZymsJwakztCKdjSiducpxbKudy+uZu0txHcmd3eud3gmd4ggl4IVF3CYc1bYHSxSb3VYHSKZcgNoHSwUs3SN0zMorV+YESXofi5cYxPCEUcP9dcXABeUaTMUFY2Y3G2X3ZCHLB4LWdsYDB4PHfDADgoCBejXzI4JlB30HhKozb4K3H/3HoFGio4lkB41XW4zlY5BEK5dVfFcQejYzhBJ5e59WA84GgitRl6cWeqBhB7AUeFcRen7yeFQyp5G1B7YHUAkZY7hHA7jnTeb5oFASfjzhAVBagAOLA8SWfD/KIlv4ojlpV9LVJ9YEpQ/on8J1pjhyimhpKjOnnEyRgmjAphIUV+rkjDQQEYy5B+7UJN2KB/JEA/TnB/VUIsa3pAOxf/62pOlSoFPgfAV6BAW7BnLpUnUIeZC0UBGIejYZgkYyop/poBpKVE7hgCYhpqXy+6rtwUwlSYBLMqKS8at7FaQrO6grWahPIoAOioYJV1ho64w6K1pcVIRAyyhBGqLGiwAEk4Yoo63AR4RZqFhX6XXocIRYGi+A9axdOqYWCYRMi6Rb8qhmqVq8mmBr20ti4YSMSIoHMIZ9KQSJuppM8gbymwIvaayCekLwaInsigbwuYpvCYbs+omlmAbp619hZongybMM67MNCbMRK7MRSbMVa7MVibMZq7MZybMd67MeCbMiK7MiSbMmaLKuEAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nomogram predicting 5- and 10- year overall survival after D2 gastrectomy for gastric cancer. The nomogram is used by adding up the points identified on the points scale for each variable. The total points projected on the bottom scales indicate the probability of 5- and 10-year survival.",
"    <div class=\"footnotes\">",
"     LN: lymph nodes.",
"    </div>",
"    <div class=\"reference\">",
"     From: Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after D2 gastrectomy for gastric cancer. J Clin Oncol 2012; 30:3834. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33390=[""].join("\n");
var outline_f32_38_33390=null;
var title_f32_38_33391="Binocular vision loss";
var content_f32_38_33391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Binocular vision loss algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 580px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IIH: idiopathic intracranial hypertension, ICP: intracranial pressure, CNS: central nervous system, ICI: intracranial injury.",
"     <br>",
"      * Etiologies are the same as for unilateral eye trauma.&nbsp;Go to algorithm \"Monocular vision loss\".",
"      <br>",
"       &bull; Causes include cerebral ischemia, cerebral stroke, meningoencephalitis, and uremia.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_38_33391=[""].join("\n");
var outline_f32_38_33391=null;
